CN101265285A - 免疫刺激性核酸分子 - Google Patents
免疫刺激性核酸分子 Download PDFInfo
- Publication number
- CN101265285A CN101265285A CNA2007101300520A CN200710130052A CN101265285A CN 101265285 A CN101265285 A CN 101265285A CN A2007101300520 A CNA2007101300520 A CN A2007101300520A CN 200710130052 A CN200710130052 A CN 200710130052A CN 101265285 A CN101265285 A CN 101265285A
- Authority
- CN
- China
- Prior art keywords
- application
- immunostimulatory oligonucleotide
- cpg
- cell
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 105
- 230000003308 immunostimulating effect Effects 0.000 title claims description 113
- 102000039446 nucleic acids Human genes 0.000 title claims description 108
- 108020004707 nucleic acids Proteins 0.000 title claims description 108
- 210000004027 cell Anatomy 0.000 claims abstract description 194
- 239000002671 adjuvant Substances 0.000 claims abstract description 27
- 108091034117 Oligonucleotide Proteins 0.000 claims description 454
- 239000002773 nucleotide Substances 0.000 claims description 71
- 125000003729 nucleotide group Chemical group 0.000 claims description 71
- 230000000638 stimulation Effects 0.000 claims description 45
- 238000002347 injection Methods 0.000 claims description 42
- 239000007924 injection Substances 0.000 claims description 42
- 210000001541 thymus gland Anatomy 0.000 claims description 39
- 210000004698 lymphocyte Anatomy 0.000 claims description 37
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 35
- 241000282414 Homo sapiens Species 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 32
- 210000004072 lung Anatomy 0.000 claims description 31
- 239000000427 antigen Substances 0.000 claims description 25
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- -1 cation lipid Chemical class 0.000 claims description 24
- 230000014509 gene expression Effects 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 150000004713 phosphodiesters Chemical class 0.000 claims description 21
- 208000006673 asthma Diseases 0.000 claims description 20
- 241000700605 Viruses Species 0.000 claims description 19
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 238000010253 intravenous injection Methods 0.000 claims description 15
- 230000005934 immune activation Effects 0.000 claims description 14
- 229960005486 vaccine Drugs 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 13
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 12
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 12
- 206010020751 Hypersensitivity Diseases 0.000 claims description 9
- 229940104302 cytosine Drugs 0.000 claims description 9
- 230000006641 stabilisation Effects 0.000 claims description 9
- 238000011105 stabilization Methods 0.000 claims description 9
- 238000002512 chemotherapy Methods 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 208000026935 allergic disease Diseases 0.000 claims description 7
- 230000007815 allergy Effects 0.000 claims description 7
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims description 7
- 230000036039 immunity Effects 0.000 claims description 7
- 238000009169 immunotherapy Methods 0.000 claims description 7
- 239000002502 liposome Substances 0.000 claims description 7
- 150000003230 pyrimidines Chemical class 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 229930182558 Sterol Natural products 0.000 claims description 3
- 231100000433 cytotoxic Toxicity 0.000 claims description 3
- 150000003432 sterols Chemical class 0.000 claims description 3
- 235000003702 sterols Nutrition 0.000 claims description 3
- 238000005728 strengthening Methods 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 239000000277 virosome Substances 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 108091028664 Ribonucleotide Proteins 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 229940084434 fungoid Drugs 0.000 claims description 2
- 210000005075 mammary gland Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 239000002336 ribonucleotide Substances 0.000 claims description 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 2
- 201000005404 rubella Diseases 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims 8
- 239000007929 subcutaneous injection Substances 0.000 claims 8
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 claims 2
- 239000001685 glycyrrhizic acid Substances 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 239000005547 deoxyribonucleotide Substances 0.000 claims 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims 1
- 238000000465 moulding Methods 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 104
- 230000000694 effects Effects 0.000 abstract description 78
- 108090000623 proteins and genes Proteins 0.000 abstract description 48
- 230000004936 stimulating effect Effects 0.000 abstract description 17
- 238000005336 cracking Methods 0.000 abstract description 8
- 230000028993 immune response Effects 0.000 abstract description 6
- 238000003786 synthesis reaction Methods 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 230000005965 immune activity Effects 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 335
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 333
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 205
- 241000699666 Mus <mouse, genus> Species 0.000 description 83
- 108090001005 Interleukin-6 Proteins 0.000 description 79
- 102000004889 Interleukin-6 Human genes 0.000 description 79
- 230000004913 activation Effects 0.000 description 71
- 238000001994 activation Methods 0.000 description 71
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 70
- 210000000822 natural killer cell Anatomy 0.000 description 61
- 230000001939 inductive effect Effects 0.000 description 57
- 239000002585 base Substances 0.000 description 56
- 102000004127 Cytokines Human genes 0.000 description 48
- 108090000695 Cytokines Proteins 0.000 description 48
- 238000002474 experimental method Methods 0.000 description 42
- 241000894006 Bacteria Species 0.000 description 40
- 102000004169 proteins and genes Human genes 0.000 description 38
- 230000004044 response Effects 0.000 description 38
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 36
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 36
- 239000002158 endotoxin Substances 0.000 description 35
- 230000005764 inhibitory process Effects 0.000 description 35
- 229920006008 lipopolysaccharide Polymers 0.000 description 35
- 238000000034 method Methods 0.000 description 35
- 108010065805 Interleukin-12 Proteins 0.000 description 33
- 102000013462 Interleukin-12 Human genes 0.000 description 33
- 230000028327 secretion Effects 0.000 description 33
- 241000588724 Escherichia coli Species 0.000 description 30
- 210000004681 ovum Anatomy 0.000 description 30
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 29
- 108010000912 Egg Proteins Proteins 0.000 description 28
- 102000002322 Egg Proteins Human genes 0.000 description 28
- 238000004519 manufacturing process Methods 0.000 description 25
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 24
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 24
- 229960003677 chloroquine Drugs 0.000 description 24
- 238000012986 modification Methods 0.000 description 24
- 210000001616 monocyte Anatomy 0.000 description 24
- 235000019633 pungent taste Nutrition 0.000 description 24
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 22
- 230000004048 modification Effects 0.000 description 22
- 244000309466 calf Species 0.000 description 21
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 20
- 108010074328 Interferon-gamma Proteins 0.000 description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 20
- 210000004988 splenocyte Anatomy 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 19
- 238000011160 research Methods 0.000 description 19
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 18
- 238000002965 ELISA Methods 0.000 description 18
- 102100037850 Interferon gamma Human genes 0.000 description 18
- 101710163270 Nuclease Proteins 0.000 description 18
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 18
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 18
- 210000001163 endosome Anatomy 0.000 description 18
- 230000007246 mechanism Effects 0.000 description 18
- 229910052760 oxygen Inorganic materials 0.000 description 18
- 239000001301 oxygen Substances 0.000 description 18
- 210000000952 spleen Anatomy 0.000 description 18
- 230000004663 cell proliferation Effects 0.000 description 17
- 238000001514 detection method Methods 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 14
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 14
- 210000003979 eosinophil Anatomy 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 229940104230 thymidine Drugs 0.000 description 14
- 230000000692 anti-sense effect Effects 0.000 description 13
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 108091081548 Palindromic sequence Proteins 0.000 description 12
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 238000004113 cell culture Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 11
- 241000242678 Schistosoma Species 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 230000003844 B-cell-activation Effects 0.000 description 10
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 10
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 206010025135 lupus erythematosus Diseases 0.000 description 10
- 230000002101 lytic effect Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 208000023275 Autoimmune disease Diseases 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 210000004969 inflammatory cell Anatomy 0.000 description 9
- 210000002345 respiratory system Anatomy 0.000 description 9
- 238000011765 DBA/2 mouse Methods 0.000 description 8
- 102000004388 Interleukin-4 Human genes 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000001900 immune effect Effects 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 231100000344 non-irritating Toxicity 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 230000002103 transcriptional effect Effects 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 7
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 230000000527 lymphocytic effect Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- 229940045145 uridine Drugs 0.000 description 7
- 102000006306 Antigen Receptors Human genes 0.000 description 6
- 108010083359 Antigen Receptors Proteins 0.000 description 6
- 238000011725 BALB/c mouse Methods 0.000 description 6
- 108010063593 DNA modification methylase SssI Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 230000004992 fission Effects 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 229940028885 interleukin-4 Drugs 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000003226 mitogen Substances 0.000 description 6
- 150000003014 phosphoric acid esters Chemical class 0.000 description 6
- 239000012266 salt solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 6
- 101150013553 CD40 gene Proteins 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 229930191564 Monensin Natural products 0.000 description 5
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 241000194017 Streptococcus Species 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 description 5
- XDHNQDDQEHDUTM-UHFFFAOYSA-N bafliomycin A1 Natural products COC1C=CC=C(C)CC(C)C(O)C(C)C=C(C)C=C(OC)C(=O)OC1C(C)C(O)C(C)C1(O)OC(C(C)C)C(C)C(O)C1 XDHNQDDQEHDUTM-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000022131 cell cycle Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- FIVPIPIDMRVLAY-RBJBARPLSA-N gliotoxin Chemical compound C1C2=CC=C[C@H](O)[C@H]2N2[C@]1(SS1)C(=O)N(C)[C@@]1(CO)C2=O FIVPIPIDMRVLAY-RBJBARPLSA-N 0.000 description 5
- 229940103893 gliotoxin Drugs 0.000 description 5
- 229930190252 gliotoxin Natural products 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 5
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 5
- 239000013010 irrigating solution Substances 0.000 description 5
- 230000000622 irritating effect Effects 0.000 description 5
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 description 5
- 230000001035 methylating effect Effects 0.000 description 5
- 229960005358 monensin Drugs 0.000 description 5
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 5
- 239000002777 nucleoside Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- 102000004533 Endonucleases Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108060002716 Exonuclease Proteins 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- VSWDORGPIHIGNW-UHFFFAOYSA-N Pyrrolidine dithiocarbamic acid Chemical compound SC(=S)N1CCCC1 VSWDORGPIHIGNW-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 230000000078 anti-malarial effect Effects 0.000 description 4
- 239000000074 antisense oligonucleotide Substances 0.000 description 4
- 238000012230 antisense oligonucleotides Methods 0.000 description 4
- 230000020411 cell activation Effects 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 102000013165 exonuclease Human genes 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002516 radical scavenger Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000012827 research and development Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- XDHNQDDQEHDUTM-XJKSCTEHSA-N (3z,5e,7r,8s,9r,11e,13e,15s,16r)-16-[(2s,3r,4s)-4-[(2r,4r,5s,6r)-2,4-dihydroxy-5-methyl-6-propan-2-yloxan-2-yl]-3-hydroxypentan-2-yl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one Chemical compound CO[C@H]1\C=C\C=C(C)\C[C@@H](C)[C@H](O)[C@H](C)\C=C(/C)\C=C(OC)\C(=O)O[C@@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](C(C)C)[C@@H](C)[C@H](O)C1 XDHNQDDQEHDUTM-XJKSCTEHSA-N 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- QOSATKMQPHFEIW-UHFFFAOYSA-N COP(O)=S Chemical compound COP(O)=S QOSATKMQPHFEIW-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 3
- 244000301850 Cupressus sempervirens Species 0.000 description 3
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 3
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 3
- 241000186359 Mycobacterium Species 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108091027981 Response element Proteins 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 241000242680 Schistosoma mansoni Species 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007599 discharging Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229940029575 guanosine Drugs 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 3
- KDWFDOFTPHDNJL-TUBOTVQJSA-N odn-2006 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 KDWFDOFTPHDNJL-TUBOTVQJSA-N 0.000 description 3
- 230000020477 pH reduction Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- AVWQQPYHYQKEIZ-UHFFFAOYSA-K trisodium;2-dodecylbenzenesulfonate;3-dodecylbenzenesulfonate;4-dodecylbenzenesulfonate Chemical compound [Na+].[Na+].[Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1.CCCCCCCCCCCCC1=CC=CC(S([O-])(=O)=O)=C1.CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O AVWQQPYHYQKEIZ-UHFFFAOYSA-K 0.000 description 3
- 230000007923 virulence factor Effects 0.000 description 3
- 239000000304 virulence factor Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- DVOOXRTYGGLORL-VKHMYHEASA-N (2r)-2-(methylamino)-3-sulfanylpropanoic acid Chemical compound CN[C@@H](CS)C(O)=O DVOOXRTYGGLORL-VKHMYHEASA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000701242 Adenoviridae Species 0.000 description 2
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 2
- 108020004491 Antisense DNA Proteins 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 241000508786 Arrhenatherum elatius Species 0.000 description 2
- 240000006891 Artemisia vulgaris Species 0.000 description 2
- 244000075850 Avena orientalis Species 0.000 description 2
- 235000007319 Avena orientalis Nutrition 0.000 description 2
- 230000024704 B cell apoptotic process Effects 0.000 description 2
- 241000219495 Betulaceae Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241001529572 Chaceon affinis Species 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 102000001327 Chemokine CCL5 Human genes 0.000 description 2
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- 241000193468 Clostridium perfringens Species 0.000 description 2
- 241000193449 Clostridium tetani Species 0.000 description 2
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 2
- 240000005109 Cryptomeria japonica Species 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 240000004585 Dactylis glomerata Species 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 241000150562 Hantaan orthohantavirus Species 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 241000175212 Herpesvirales Species 0.000 description 2
- 241000228404 Histoplasma capsulatum Species 0.000 description 2
- 240000003857 Holcus lanatus Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AJMOLNFDYWTVQW-QWRGUYRKSA-N L-leucyl-l-leucine methyl ester Chemical compound COC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C AJMOLNFDYWTVQW-QWRGUYRKSA-N 0.000 description 2
- 241000589248 Legionella Species 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- 241000589902 Leptospira Species 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 240000000233 Melia azedarach Species 0.000 description 2
- 241000186367 Mycobacterium avium Species 0.000 description 2
- 241000187484 Mycobacterium gordonae Species 0.000 description 2
- 241000186364 Mycobacterium intracellulare Species 0.000 description 2
- 241000186363 Mycobacterium kansasii Species 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 241000702259 Orbivirus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 241000721464 Parietaria officinalis Species 0.000 description 2
- 241000746983 Phleum pratense Species 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 102100023715 Poly(A)-specific ribonuclease PARN Human genes 0.000 description 2
- 241001505332 Polyomavirus sp. Species 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 241000702263 Reovirus sp. Species 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241000831652 Salinivibrio sharmensis Species 0.000 description 2
- 244000082988 Secale cereale Species 0.000 description 2
- 235000007238 Secale cereale Nutrition 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241001478880 Streptobacillus moniliformis Species 0.000 description 2
- 241000193985 Streptococcus agalactiae Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 241000218636 Thuja Species 0.000 description 2
- 241000223997 Toxoplasma gondii Species 0.000 description 2
- 241000589886 Treponema Species 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 102000000160 Tumor Necrosis Factor Receptor-Associated Peptides and Proteins Human genes 0.000 description 2
- 108010080432 Tumor Necrosis Factor Receptor-Associated Peptides and Proteins Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000010398 acute inflammatory response Effects 0.000 description 2
- 108700010877 adenoviridae proteins Proteins 0.000 description 2
- 230000000240 adjuvant effect Effects 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 230000002052 anaphylactic effect Effects 0.000 description 2
- 230000003172 anti-dna Effects 0.000 description 2
- 239000003816 antisense DNA Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 229930192649 bafilomycin Natural products 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940038705 chlamydia trachomatis Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 231100000652 hormesis Toxicity 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000017306 interleukin-6 production Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 210000000088 lip Anatomy 0.000 description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000005868 ontogenesis Effects 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 235000021110 pickles Nutrition 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000004911 positive regulation of CREB transcription factor activity Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940030998 streptococcus agalactiae Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Substances CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 1
- KZELNMSPWPFAEB-UMMCILCDSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-8-sulfanylidene-3,7-dihydropurin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2NC(=S)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O KZELNMSPWPFAEB-UMMCILCDSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical class OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 102000039549 ATF family Human genes 0.000 description 1
- 108091067350 ATF family Proteins 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000186041 Actinomyces israelii Species 0.000 description 1
- 241000701386 African swine fever virus Species 0.000 description 1
- 241000743339 Agrostis Species 0.000 description 1
- 240000005611 Agrostis gigantea Species 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 241000219496 Alnus Species 0.000 description 1
- 241000223602 Alternaria alternata Species 0.000 description 1
- 240000004178 Anthoxanthum odoratum Species 0.000 description 1
- 235000014251 Anthoxanthum odoratum Nutrition 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000256836 Apis Species 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 235000004355 Artemisia lactiflora Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 241000219430 Betula pendula Species 0.000 description 1
- 241000702628 Birnaviridae Species 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 241000238657 Blattella germanica Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000743756 Bromus inermis Species 0.000 description 1
- 241000209202 Bromus secalinus Species 0.000 description 1
- 102000001764 CREB-Binding Protein Human genes 0.000 description 1
- 108010040163 CREB-Binding Protein Proteins 0.000 description 1
- 101100026251 Caenorhabditis elegans atf-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589994 Campylobacter sp. Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000723436 Chamaecyparis obtusa Species 0.000 description 1
- 235000000509 Chenopodium ambrosioides Nutrition 0.000 description 1
- 244000098897 Chenopodium botrys Species 0.000 description 1
- 235000005490 Chenopodium botrys Nutrition 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186249 Corynebacterium sp. Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- QMNFFXRFOJIOKZ-UHFFFAOYSA-N Cycloguanyl Natural products CC1(C)N=C(N)N=C(N)N1C1=CC=C(Cl)C=C1 QMNFFXRFOJIOKZ-UHFFFAOYSA-N 0.000 description 1
- 230000030933 DNA methylation on cytosine Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 241000238713 Dermatophagoides farinae Species 0.000 description 1
- 239000012988 Dithioester Substances 0.000 description 1
- 102000052526 E1A-Associated p300 Human genes 0.000 description 1
- 108700039043 E1A-Associated p300 Proteins 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000508725 Elymus repens Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101100379079 Emericella variicolor andA gene Proteins 0.000 description 1
- 101100001670 Emericella variicolor andE gene Proteins 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241001495410 Enterococcus sp. Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000186811 Erysipelothrix Species 0.000 description 1
- 241000186810 Erysipelothrix rhusiopathiae Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000234642 Festuca Species 0.000 description 1
- 241000234645 Festuca pratensis Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 108010061414 Hepatocyte Nuclear Factor 1-beta Proteins 0.000 description 1
- 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 241000226709 Hesperocyparis arizonica Species 0.000 description 1
- 241001290232 Hesperocyparis macrocarpa Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000666730 Homo sapiens T-complex protein 1 subunit alpha Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108700040486 I kappa B beta Proteins 0.000 description 1
- 230000004950 I-kappaB phosphorylation Effects 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 241000701377 Iridoviridae Species 0.000 description 1
- 241000701372 Iridovirus Species 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 241000721668 Juniperus ashei Species 0.000 description 1
- 240000005308 Juniperus chinensis Species 0.000 description 1
- 241000592238 Juniperus communis Species 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000209082 Lolium Species 0.000 description 1
- 244000100545 Lolium multiflorum Species 0.000 description 1
- 240000004296 Lolium perenne Species 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 241001036794 Microsorum maximum Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 1
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 1
- 102100033457 NF-kappa-B inhibitor beta Human genes 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 241000795633 Olea <sea slug> Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 241000150218 Orthonairovirus Species 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- OYCDTPQIKJZGBS-UHFFFAOYSA-N P(O)(O)(O)=O.[O] Chemical compound P(O)(O)(O)=O.[O] OYCDTPQIKJZGBS-UHFFFAOYSA-N 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 241001465379 Parietaria judaica Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 241001668545 Pascopyrum Species 0.000 description 1
- 235000002748 Paspalum commersonii Nutrition 0.000 description 1
- 241001330451 Paspalum notatum Species 0.000 description 1
- 240000004928 Paspalum scrobiculatum Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000238675 Periplaneta americana Species 0.000 description 1
- 241000745991 Phalaris Species 0.000 description 1
- 244000081757 Phalaris arundinacea Species 0.000 description 1
- 241000713137 Phlebovirus Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 244000239204 Plantago lanceolata Species 0.000 description 1
- 235000010503 Plantago lanceolata Nutrition 0.000 description 1
- 244000292693 Poa annua Species 0.000 description 1
- 241000136254 Poa compressa Species 0.000 description 1
- 241000209049 Poa pratensis Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 244000274906 Quercus alba Species 0.000 description 1
- 235000009137 Quercus alba Nutrition 0.000 description 1
- 101150002130 Rb1 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 244000004774 Sabina virginiana Species 0.000 description 1
- 235000008691 Sabina virginiana Nutrition 0.000 description 1
- 241000235343 Saccharomycetales Species 0.000 description 1
- 206010039361 Sacroiliitis Diseases 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 241000545593 Scolytinae Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000701033 Simian cytomegalovirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 244000046109 Sorghum vulgare var. nervosum Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000605008 Spirillum Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 102100038410 T-complex protein 1 subunit alpha Human genes 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000006290 Transcription Factor TFIID Human genes 0.000 description 1
- 108010083268 Transcription Factor TFIID Proteins 0.000 description 1
- 108090000941 Transcription factor TFIIB Proteins 0.000 description 1
- 102000004408 Transcription factor TFIIB Human genes 0.000 description 1
- 241000589904 Treponema pallidum subsp. pertenue Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000120645 Yellow fever virus group Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N anhydrous methyl chloride Natural products ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000309743 astrovirus Species 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 101150093710 clec-87 gene Proteins 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013502 data validation Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 125000005022 dithioester group Chemical group 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003181 encephalopathic effect Effects 0.000 description 1
- 229940092559 enterobacter aerogenes Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 230000013764 eosinophil chemotaxis Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940116886 human interleukin-6 Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- VQWNELVFHZRFIB-UHFFFAOYSA-N odn 1826 Chemical compound O=C1NC(=O)C(C)=CN1C(O1)CC(O)C1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C3=NC=NC(N)=C3N=C2)OC1COP(O)(=O)OC1CC(N2C3=C(C(NC(N)=N3)=O)N=C2)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(N=C(N)C=C2)=O)OC1COP(O)(=O)OC1CC(N2C(NC(=O)C(C)=C2)=O)OC1COP(O)(=O)OC(C(O1)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)CC1N1C=C(C)C(=O)NC1=O VQWNELVFHZRFIB-UHFFFAOYSA-N 0.000 description 1
- DHYWDEXXBWTTEH-UHFFFAOYSA-N odn 2007 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)C(O)C1 DHYWDEXXBWTTEH-UHFFFAOYSA-N 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049547 paraxin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000009304 pastoral farming Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- WIFGCZCFSNIILK-UHFFFAOYSA-N platinum;pyrimidine Chemical class [Pt].C1=CN=CN=C1 WIFGCZCFSNIILK-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 230000018491 positive regulation of cytokine secretion Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 108700004030 rev Genes Proteins 0.000 description 1
- 101150098213 rev gene Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 239000004577 thatch Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960002203 tilactase Drugs 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000000207 volumetry Methods 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明涉及含有未甲基化的CpG二核苷酸的核酸序列,其可调节免疫反应,包括刺激Th1类型的免疫活化、细胞因子的产生、NK裂解活性、以及B细胞的增殖。这些序列也可以用作合成佐剂。
Description
本申请是中国发明专利申请No.971993521的分案申请,其申请日为1997年10月30日,发明创造名称为“免疫刺激性核酸分子”。
本发明的研究部分地得到了美国国家卫生研究院的第R29-AR42556-01拨款的资助。美国政府有本发明的部分权利。
技术领域
本发明一般地涉及寡核苷酸,具体地讲,涉及那些免疫刺激性的、在序列中包括至少一个未甲基化CpG二核苷酸的寡核苷酸。
背景技术
在二十世纪七十年代,一些研究人员报道了高分子量DNA与细胞膜的结合(Lerner,R.A.et al.,1971.“Membran-associated DNA in the cytoplasm of diploid humanlymphocytes”.Proc.Natl.Acad.Sci.USA 68:1212;Agrawal,S.K.,R.W.Wagner,P.K.McAllister,and B.Rosenberg.1975.“Cell-surface-associated nucleic acid in tumorigenic cells madevisible with platinum-pyrimidine complexes by electronmicroscopy”.Proc.Natl.Acad.Sci.USA 72:928)。在1985年,Bennett等人首次提出证据证明了DNA与淋巴细胞的结合相似于配体与受体的相互作用,即结合是可饱和的、竞争性的、并导致DNA细胞内吞作用和降解为寡核苷酸(Bennett,R.M.,G.T.Gabor,and M.M.Merritt.1985.“DNA binding to humanleukocytes.Evidence for receptor-mediated association,internalization,and degradation of DNA”.J.Clin.Invest.76:2182)。类似于DNA,寡脱氧核糖核苷酸(ODN)也能以可饱和、不依赖序列、但依赖温度和能量的形式进入到细胞中(见Jaroszewski,J.W.,and J.S.Cohen.1991.“Cellular uptake ofantisense oligodeoxynucleotides”.Advanced Drug DeliveryReviews 6:235;Akhtar,S.,Y.Shoji,and R.L.Juliano.1992.“Pharmaceutical aspects of the biological stability andmembrane transport characteristics of antisenseoligonucleotides”.In:Gene Regulation:Biology of Antisense RNA and DNA.R.P.Erickson,and J.G.Izant,eds.RavenPress,Ltd.New York,pp.133:and Zhao,Q.T.Waldschmidt,E.Fisher,C.J.Herrera,and A.M.Krieg.,1994.“Stage specificoligonucleotide uptake in murine bone marrow B cellprecursors”.Blood,84:3660)。但是,还没有克隆化到负责DNA或ODN摄入的受体,而且,还不清楚ODN结合及细胞摄入是采取与高分子量的DNA相同或不同的机制。
淋巴细胞的ODN吸收已经被证明可由细胞活化来调节。用B细胞促分裂原LPS刺激的脾细胞在B细胞群体中显示了ODN吸收的显著提高,而用T细胞促分裂原Con A处理的脾细胞显示在T细胞中有ODN吸收的提高而在B细胞中没有(Krieg,A.M.,F.Gmelig-Meyling,M.F.Gourley,W.J.Kisch,L.A.Chrisey,and A.D.Steinberg.1991.“Uptake ofoligodeoxyribonucleotides by lymphoid cells is heterogeneousand inducible”.Antisense Research and Development 1:161)。
已经对一些多核苷酸作为生物反应修饰剂进行了广泛的研究。也许最好的例子是多聚(I,C),这是一种IFN生产的强力诱导物,也是巨噬细胞活化子和NK活性诱导物(Talmadge,J.E.,J.Adams,H.Phillips,M.Collins,B.Lenz,M.Schneider,E.Schlick,R.Ruffmann,R.H.Wiltrout,and M.A.Chirigos.1985.“Immunomodulatory effects in mice ofpolyinosinic-polycytidylic acid comlexed with poly-L-lysineand carboxymethylcellulose”.Cancer Res.45:1058;Wiltrout,R.H.,R.R.Salup,T.A.Twilley,and J.E.Talmadge.1985.“Immunomodulation of natural killer activity bypolyribonucleotides”.J.Biol.Resp.Mod.4:512;Krown,S.E.1986.“Interferons and interferon inducers in cancertreatment”.Sem.Oncol.13:207;and Ewel,C.H.,S.J.Urba,W.C.Kopp,J.W.Smith II,R.G.Steis,J.L.Rossio,D.L.Longo,M.J.Jones,W.G.Alvord,C.M.Pinsky,J.M.Beveridge,K.L.McNitt,and S.P.Creekmore.1992.“Polyinosinic-polycytidylicacid complexed with poly-L-lysine and carboxymethylcellulosein combination with interleukin-2 in patients with cancer:clinical and immunological effects”.Canc.Res.52:3005)。看起来,这种鼠NK活化可能仅仅是由于IFN-β分泌的诱导(Ishikawa,R.,and C.A.Biron.1993.“IFN induction andassociated changes in splenic leukocyte distribution”.J.Immunol.150:3713)。这种活化是对核糖为特异的,因为脱氧核糖没有效力。其强有力的体外抗肿瘤活性导致多种采用与多聚-L-赖氨酸和羧甲基纤维素复合的(用以减少由RNAse引起的降解)进行的临床研究(Talmadge,J.E.,et al.,1985.出处同上;Wiltrout,R.H.,et al.,1985.出处同上);Krown,S.E.,1986.出处同上);以及Ewel.C.H.,et al.,1992.出处同上)。不幸的是,毒性副作用由此大大妨碍了多聚(I,C)成为有用的治疗药剂。
在C8位发生溴或硫醇基取代的鸟嘌呤核糖核苷酸是B细胞促分裂原,并且可以代替“B细胞分化因子”(Feldbush,T.L.,and Z.K.Ballas.1985.“Lymphokine-like activity of8-mercaptoguanosine:indnction of T and B celldifferentiation”.J.Immunol.134:3204;and Goodman,M.G.1986.“Mechnism of snyergy between T cell signals andC8-substituted guanine nucleosides in humoral immunity:Blymphotropic cytokines induce responsiveness to8-mercaptoguanosine”.J.Immunol.136:3335)。8-巯基鸟苷和8-溴鸟苷还可以取代MHC限制型CTL产生的细胞因子需求(Feldbush,T.L.,1985.出处同上),增加大鼠NK活性(Koo,G.C.,M.E.Jewell,C.L.Manyak,N.H.Sigal,and L.S.Wicker.1988.“Activation of murine natural killer cells and macrophages by8-bromoguanosine”.J.Immunol.140:3249),以及与IL-2协同诱导鼠LAK产生(Thompson,R.A.,and Z.K.Ballas.1990.“Lymphokine-activated killer (LAK)cells.V.8-Mercaptoguanosine as an IL-2-sparing agent in LAKgeneration”.J.Immunol.145:3524)。这些C8取代的鸟苷的NK和LAK活性的增大看起来归因于它们对IFN的诱导(Thompson,R.A.,et al.,1990.出处同上)。近来,由分枝杆菌产生的5’三磷酸化胸苷被发现对人γδT细胞亚类有促细胞分裂作用(Constant,P.,F.Davodeau,M.A.Peyrat,Y.Poquet,G.Puzo,M.Bonneville,and J.-J.Fournie.1994.“Stimulation ofhuman γδT cells by nonpeptidic mycobacterial ligands”Science 264:267)。该篇报道指明有可能免疫系统已经进化出了对微生物核酸优先反应的方式。
一些观察结果暗示,某些DNA结构可能也具有活化淋巴细胞的潜力。例如,Bell等人曾经报道,在脾细胞上清液中的核小体蛋白质-DNA复合物(不是裸露的DNA)引起了B细胞的增殖和免疫球蛋白的分泌(Bell,D.A.,B.Morrison,and P.VanderBygaart.1990.“Immunogenic DNA-related factors”.J.Clin.Invest.85:1487)。在其它的情况下,裸露的DNA已经被报道具有免疫效应。例如,Messina等人最近曾报道说,多聚(dG)·(dC)和多聚(dG·dC)的260至800bp的片段对B细胞有促细胞分裂作用(Messina,J.P.,G.S.Gilkeson,and D.S.Pisetsky.1993.“The influence of DNA structure on the in vitrostimulation of murine lymphocytes by natural and syntheticpolynucleotide antigens”.Cell.Immunol.147:148)。Tokunaga等人已经报道了dG·dC可诱导γ-IFN和NK活性(Tokunaga,S.Yamamoto,and K.Namba.1988.“A synthetic single-strandedDNA,poly(dG,dC),induces interferon-α/b and-g,augmentsnatural killer activity,and suppresses tumor growth”Jpn.J.Cancer Res.79:682)。除了这些人造的均聚体序列之外,Pisetsky等人报道了纯的哺乳动物DNA没有可检测的免疫效应,但是,从某些细菌来的DNA则诱导了B细胞的活化和免疫球蛋白的分泌(Messina,J.P.,G.S.Gilkeson,and D.S.Pisetsky.1991.“Stimulation of in vitro murine lymphocyteproliferation by bacterial DNA”.J.Immunol.147:1759)。假设这些数据不是由一些罕见污染物所引起的,那么,这些研究则暗示,细菌DNA的特定结构或其它性质使其能够触发B细胞的活化。对分枝杆菌DNA序列的研究显示,含有某种回文序列的ODN可以活化NK细胞(Yamamoto,S.,T.Yamamoto,T.Kataoka,E.Kuramoto,O.Yano,and T.Tokunaga.1992.“Unique palindromic sequences in synthetic oligonucleotidesare required to induce INF and agument INF-meidatednatural killer activity”.J.Immunol.148:4072;Kuramoto,E.,O.Yano,Y.Kimura,M.Baba,T.Makino,S.Yamamoto,T.Yamamoto,T.Kataoka,and T.Tokunaga.1991.“Oligonucleotide sequences required fro natural killer cellactivation”.Jpn.J.Cancer Res.83:1128)。
还报道了其它一些硫代磷酸酯修饰的ODN诱导了体外或体内B细胞刺激(Tanaka,T.,C.C.Chu,and W.E.Paul.1992.“An antisense oligonucleotide complementary to a sequence inIg2b increases g2b germline transcripts,stimulates B cell DNAsynthesis,and inhibits immunoglobulin secretion”.J.Exp.Med.175:597;Branda,R.F.,A.L.Moore,L.Mathews,J.J.McCormack,and G.Zon.1993.“Immune stimulaiton by anantisense oligomer complementary to the rev gene of HIV-1”.Biochem.Pharmacol.45:2037;McIntyre,K.W.,K.Lombard-Gillooly,J.R.Perez,C.Kunsch,U.M.Sarmiento,J.D.Larigan,K.T.Landreth,and R.Narayanan.1993.“A sensephosphorothioate oligonucleotide directed to the initiationcodon of transcription factor NF-κB T65 causessequence-specific immune stimulation”.Antisense Res.Develop.3:309;and Pisetsky,D.S.,and C.F.Reich.1993.“Stimulation of murine lymphocyte proliferation by aphosphorothioate oligonucleotide with antisense activity forherpes simplex virus”.Life Sciences 54:101)。这些报道没有暗示在这些ODN中有可以解释这些效果的共同结构基元或序列因素。
cAMP效应元件结合蛋白质(CREB)和活化转录因子(ATF)或转录因子的CREB/ATF家族是普遍被表达的一类转录因子,其11个成员已经被克隆化了(reviewed in de Groot,R.P.,and P.Sassone-Corsi:“Hormonal control of gene expression:Multiplicity and versatility of cyclic adenosine3’,5’-monophosphate-responsive nucler regulators”.Mol.Endocrin.7:145,1993;Lee,K.A.W.,and N.Masson:“Transcriptional regulation by CREB and its relatives”.Biochim.Biophys.Acta 1174:221,1993)。它们都属于蛋白质的碱性区/亮氨酸拉链结构(bZip)类。所有的细胞似乎都表达一种或多种CREB/ATF蛋白质,但是,所表达的成员和对mRNA剪接的调节则似乎是组织特异性的。活化域的差异剪接可以确定某一具体的CREB/ATF蛋白质是转录抑制子还是活化子。许多的CREB/ATF蛋白质活化病毒转录,但是,有些缺少活化域的剪接变体则是抑制性的。CREB/ATF蛋白质可以作为均二聚体或异二聚体通过cAMP效应元件,即CRE来结合DNA,其中CRE的共有形式是未甲基化序列TGACGTC(如果CpG是甲基化的,则没有结合)(Iguchi-Ariga,S.M.M.,andW.Schaffner:″CpG methylation of the cAMP responsiveenhancer/promoter sequence TGACGTCA abolishes specificefactor binding as well as transcriptional activation″.Genes &Develop.3:612,1989.)。
CRE的转录活性在B细胞活化期间有提高(Xie,H.T.C.Chiles,and T.L.Rothstein:″Induction of CREB activity viathe surface Ig receptor of B cells″.J.Immunol.151:880,1993)。CREB/ATF蛋白质似乎通过CRE来对多种基因的表达进行调节,包括免疫学上重要的基因,例如fos、jun B、Rb-1、IL-6、IL-1(Tsukada,J.,K.Saito,W.R.Waterman,A.C.Webb,and P.E.Auron:″Transcription factors NF-IL-6 andCREB recognize a common essential site in the humanprointerleukin 1 gene″.Mol.Cell.Biol.14:7285,1994;Gray,G.D.,O.M.Hernadez,D.Hebel.M.Root,J.M.Pow-Sang,andE.Wickstrom:″antisense DNA inhibition of tumor growthinduced by c-Ha-ras oncogene in nude mice″.Cancer Res.53:577,1993),IFN-(Du,W.,and T.Maniatis:″AnATF/CREB binding site protein is required for virus inductionof human interferon B gene″.Proc.Natl.Acad.Sci.USA89:2150,1992),TGF-1(Asiedu,C.K.,L.Scott,R.K.Assoian,M.Ehrlich:″Binding of AP-1/CREB proteins and of MDBP tocontiguous sites downstream of the human TGF-B1 gene″.Biochim.Biophys.Acta 1219:55,1994),TGF-2,II类MHC(Cox,P.M.,and C.R.Goding:″An ATF/CREB bindingmotif is required for aberrant constitutive expression of theMHC class II DRa promoter and activation by SV40T-antigen″.Nucl.Acids Res.20:4881,1992),E-选择素,GM-CSF,CD-8,种系Ig恒定区基因,TCR V基因,以及增殖细胞核抗原(Huang,D.,P.M.Shipman-Appasamy,D.J.Orten,S.H.Hinrichs,and M.B.Prystowsky:″Promoteractivity of the proliferating-cell nuclear antigen gene isassociated with inducible CRE-binding proteins in interleukin2-stimulated T lymphocytes:.Mol.Cell.Biol.14:4233,1994)。除了通过cAMP途径的活化,CREB还可以介导对细胞内Ca++浓度变化的转录应答(Sheng,M.,G.McFadden,and M.E.Greenberg:″Membrane depolarization and calcium inducec-fos transcription via phosphorylation of transcription factorCREB″.Neuron 4:571,1990)。
在CREB/ATF蛋白质的转录活化中,蛋白质-蛋白质之间的相互作用似乎极其重要。已经有一些发表的研究报道了在NFKB蛋白质和CREB/ATF蛋白质之间的直接性或间接性相互作用[Whitley,et al.,(1994)Mol.& Cell.Biol.14:6464;Cogswell,et al.,(1994)J.Immun.153:712;Hines,et al.,(1993)Oncogene 8:3189;and Du,et al.,(1993)Cell 74:887]。通过环AMP途径对CREB的活化需要蛋白质激酶A(PKA),其将CREB341在ser133磷酸化,并允许其与近来克隆的蛋白质CBP结合(Kwok,R.P.S.,J.R.Lundblad,J.C.Chrivia,J.P.Richards,H.P.Bachinger,R.G.Brennan,S.G.E.Roberts,M.R.Green,and R.H.Goodman:″Nuclear protein CBP is a coactivator forthe transcription factor CREB″.Nature 370:223,1994;Arias,J.,A.S.Alberts,P.Brindle,F.X.Claret,T.Smea,M.Karin,J.Feranmisco,and M.Montminy:″Activation of cAMP andmitogen responsive genes relies on a common nuclear factor″.Nature 370:226,1994.)。CBP继而再与碱性转录因子TFIIB相互作用,导致转录提高。CREB还被报道与dTAFII 110相互作用,该dTAFII 110是一种TATA结合蛋白质相关因子,其结合可以调节转录(Ferreri,K.,G.Gill,and M.Montminy:″The cAMP-regulated transcription factor CREB interactswith a component of the TFIID complex″.Proc.Natl.Acad.Sci.USA 91:1210,1994)。除了这些相互作用之外,CREB/ATF蛋白质还可以特异性结合多种其它的核因子(Hoeffler,J.P.,J.W.Lustbader,and C.-Y.Chen:″Identification of multiplenuclear factors that interact with cyclic adenosine3′,5′-monohosphate response element-binding protein andactivating transcription factor-2 by protein-proteininteractions″.Mol.Endocrinol.5:256,1991),但是,这些相互作用中的大多数的生物学重要性还都是未知的。一般认为CREB作为均二聚体或与其它一些蛋白质的异二聚体形式与DNA结合。另人惊奇的是,CREB单体组成性地激活转录(Krajewski,Wl,and K.A.W.Lee:″A monomeric derivative ofthe cellular transcription factor CREB functions asconstitutive activator″.Mol.Cell.Biol.14:7204,1994)。
除了在调节细胞转录中的重要作用之外,最近还证实了CREB/ATF蛋白质被某些感染性病毒和逆病毒所破坏,所述病毒需要该CREB/ATF蛋白进行病毒复制。例如,已知的最为强烈的哺乳动物启动子之一,即巨细胞病毒立即早期启动子,其含有对启动子功能必需的CRE 11个拷贝(Chang,Y.-N.,S.Crawford,J.Stall,D.R.Rawlins,K.-T.Jeang,and G.S.Hayward:″The palindromic series I repeats in the simiancytomegalovirus major immediate-early promoter behave asboth strong basal enhancers and cyclic AMP responseelements″.J.Virol.64:264,1990)。诱导众多启动子的腺病毒E1A蛋白质的至少一部分转录活化效应归因于其与CREB/ATF蛋白质的DNA结合域即ATF-2的结合,该结合域介导E1A可诱导转录活化(Liu,F.,and M.R.Green:″Promoter targeting by adenovirus E1a through interactionwith different cellular DNA-bin ding domains″.Nature 368:520,1994)。还已经暗示,E1A与CREB结合蛋白质CBP相结合(Arany,Z.,W.R.Sellers,D.M.Livingston,and R.Eckner:″E1A-associated p300 and CREB-associated CBP belong to aconserved family of coactivators″.Cell 77:799,1994)。人T嗜淋巴细胞病毒-I(HTLV-1),即造成人T细胞白血病和热带痉挛轻瘫的逆转录病毒,也需要CREB/ATF蛋白质来复制。在这种情况下,逆转录病毒产生蛋白质Tax,其与CREB/ATF蛋白质结合,将它们从其正常的细胞结合位点重导向存在于HTLV转录增强子中的不同DNA序列(侧翼为富含G和C的序列)(Paca-Uccaralertkun,S.,L.-J.Zhao,N.Adya,J.V.Cross,B.R.Cullen,I.M.Boros,and C.-Z.Giam:″In vitro selection ofDNA elements highly responsive to the human T-celllymphotropic virus type I transcriptional activator,Tax″.Mol.Cell.Biol.14:456,1994;Adya,N.,L.-J.Zhao,W.Huang,I.Boros,and C.-Z.Giam:″Expansion of CREB′s DNArecognition specificity by Tax results from interaction withAla-Ala-Arg at positions 282-284 near the conservedDNA-binding domain of CREB″.Proc.Natl.Acad.Sci.USA91:5642,1994)。
本发明的概述
本发明基于的是如下发现,即某些含有未甲基化胞嘧啶-鸟嘌呤(CpG)二核苷酸的核酸能在受试者中活化淋巴细胞,并使受试者的免疫反应由Th2转变为Th1(例如通过诱导单核细胞以及其它细胞产生Th1细胞因子,包括IL-12、IFN-γ和GM-CSF)。依据这个发现,本发明在一方面涉及新的免疫刺激性核酸组合物。
在一个实施方案中,本发明提供了分离的免疫刺激性的含有CpG基元的核酸序列,其表达式为:
5′N1X1CGX2N23′
其中,至少一个核苷酸将连续的CpGs间隔开来;X1是腺嘌呤,鸟嘌呤,或胸腺嘧啶;X2是胞嘧啶或胸腺嘧啶;N是任何的核苷酸,且N1+N2是约0-26个碱基,条件是N1和N2不含有CCGG四元体或多于一个的CCG或CGG三元体;并且该核酸序列的长度为约8-30个碱基。
在另一个实施方案中,本发明提供了分离的免疫刺激性的含有CpG基元的核酸序列,其表达式为:
5′N1X1X2CGX3X4N23′
其中,至少一个核苷酸将连续的CpGs间隔开来;X1 X2选自GpT、GpG、GpA、ApT和ApA;X3X4选自TpT或CpT;N是任何的核苷酸,且N1+N2是约0-26个碱基,条件是N1和N2不含有CCGG四元体或多于一个的CCG或CGG三元体;并且该核酸序列的长度为约8-30个碱对。
在另一个实施方案中,本发明提供了刺激免疫活化的方法,其中将本发明的核酸序列提供给受试者,优选人。在优选的实施方案中,免疫活化产生主要是Th1形式的免疫活化。
在另一个实施方案中,本发明的核酸序列刺激细胞因子的生产。具体地讲,通过用本文中所述的核酸序列刺激免疫系统来产生细胞因子如IL-6、IL-12、IFN-γ、TNF-α和GM-CSF。在另一方面,本发明的核酸序列刺激天然杀伤细胞(NK)的裂解活性和B细胞的增殖。
在另一个实施方案中,本发明的核酸序列可用作人工佐剂用于哺乳动物如小鼠或人中抗体的产生。
在另一个实施方案中,通过抑制受试者对CpG介导的淋巴细胞活化的应答来治疗自身免疫紊乱。本发明提供了用内体酸化的抑制物如bafilomycin a,氯喹和莫能星来缓解自身免疫紊乱。具体地讲,用这种方式治疗系统性红斑狼疮。
本发明的核酸序列还可以用于治疗、预防或缓解其它的紊乱(例如,肿瘤或癌症,或者病毒性、真菌性、细菌性或寄生性感染)。此外,可以施用本发明的核酸序列刺激对疫苗的应答。进一步,通过将受试者的免疫反应从Th2改变为Th1,本发明的核酸序列可以用于治疗或预防气喘疾病。此外,本发明的核酸序列可以与特定的变应原一起施用给受试者,作为一种类型的脱敏疗法,用于治疗或预防与气喘相关的过敏反应的发生。
进一步,本发明所述核酸序列的诱导白血病细胞进入细胞循环的能力支持了其治疗白血病的应用,该治疗可通过提高慢性白血病细胞的敏感性随后进行常规消除性化疗,或者通过将所述核酸序列与其它的免疫治疗一起组合使用来实现。
本发明的其它的特点和优点将可以从下面的描述和权利要求书中更为明显地看出。
附图的简要说明
图1A-C用制图说明在消除了T细胞的脾细胞培养物中对各种DNA序列应答的剂量依赖性IL-6生产。
图1A是大肠杆菌DNA(l)和小牛胸腺DNA(n)序列和LPS(大肠杆菌和小牛胸腺DNA浓度的10×)(u)。
图1B是对照磷酸二酯寡脱氧核苷酸(ODN)5′ATGGAAGGTCCAGTGTTCTC3′(SEQ ID No:1)(n)和两种磷酸二酯CpG ODN5′ATCGACCTACGTGCGTTCTC3′(SEQ ID No:2)(u)和5′TCCATAACGTTCCTGATGCT3′(SEQ ID No:3)(l)。
图1C是对照硫代磷酸酯ODN5′GCTAGATGTTAGCGT3′(SEQ ID No:4)(n)和两种硫代磷酸酯CpG ODN 5′GAGAACGTCGACCTTCGAT3′(SEQ IDNo:5)(u)和5′GCATGACGTTGAGCT3′(SEQ ID No:6)(l)。数据代表一式三份实验的平均值±标准偏差。
图2图示由注射后1-8小时所确定的体内CpG DNA诱导的IL-6生产。数据代表从两只小鼠的血清的一式两份分析得到的平均值。对BALB/c小鼠(每组两只)静脉内注射100微升的PBS(o)或200微克的CpG硫代磷酸酯ODN5′TCCATGACGTTCCTGATGCT3′(SEQ ID No:7)(n)或非-CpG硫代磷酸酯ODN 5′TCCATGAGCTTCCTGAGTCT3′(SEQ IDNo:8)(u)。
图3是放射性自显影图,其中显示了由反转录聚合酶链反应确定的肝、脾和胸腺中在进行如下处理后各个时期的IL-6mRNA表达情况:对BALB/c小鼠(每组两只)静脉内注射100微升的PBS,200微克的CpG硫代磷酸酯ODN5′TCCATGACGTTCCTGATGCT3′(SEQ ID No:7)或非-CpG硫代磷酸酯ODN 5′TCCATGAGCTTCCTGAGTCT3′(SEQ IDNo:8)进行体内刺激。
图4A是图示抗IL-6对CpG诱导的IgM生产的剂量依赖性抑制。在如ELISA所测定培养物上清液中油指示浓度的中和性抗-IL-6(u)或同种型对照Ab(l)和IgM存在的情形下用CpG ODN 5′TCCAAGACGTTCCTGATGCT3′(SEQ ID No:9)刺激来自DBA/2小鼠的脾B细胞,有给出,在培养物上清液中的IgM水平有ELISA确定。在没有CpG ODN存在的情况下,抗-IL-6抗体对IgM分泌没有影响(n)。图4B图示用抗-IL-6和CpG S-ODN 5′TCCATGACGTTCCTGATGCT3′(SEQ IDNo:7)(u)培养或仅用抗-IL-6抗体培养(n)的脾B细胞中CpG-诱导的刺激指数。数据代表一式三份试验的平均值±标准偏差。
图5是条块图,说明在被不含启动子的CAT构建体(pCAT)、阳性对照质粒(RSV)、IL-6启动子-CAT构建体转染的WEHI-231细胞单独或者用所示浓度的CpG5′TCCATGACGTTCCTGATGCT3′(SEQ ID No:7)或非-CpG5′TCCATGAGCTTCCTGAGTCT3′(SEQ ID No:8)硫代磷酸酯ODN培养后细胞中的氯霉素、乙酰转移酶(CAT)的活性。数据代表一式三份试验的平均值。
图6是免疫刺激性的含有未甲基化CpG的核酸的免疫效果的总体图示,该核酸可以直接活化B细胞和单核细胞(包括巨噬细胞和树状细胞)。该免疫刺激性寡核苷酸不直接活化纯化的NK细胞,但可以使它们有能力应答IL-12,并且其IFN-γ生产有明显提高。通过诱导IL-12的产生以及随后NK细胞的IFN-γ分泌提高,该免疫刺激性核酸促进了Th1类型的免疫应答。没有发现高度纯化的T细胞的增殖或细胞因子分泌的直接激活。然而,由免疫刺激性寡核苷酸对Th1细胞因子分泌的诱导促进了细胞毒性淋巴细胞应答的产生。
图7是显示用大肠杆菌DNA处理的单核细胞中NFkB活化的时间的自显影图,显示被大肠杆菌(EC)DNA(含有未甲基化CpG基元)、对照(CT)DNA(不含未甲基化CpG基元)和脂多糖(LPS)所处理的单核细胞在不同的测量时间在接触后15分钟、30分钟的NFKB mRNA诱导。
图8A显示流式细胞仪的测定结果,其中使用小鼠B细胞,采用二氢若丹明123染料来确定反应性氧种类的水平。在该图的A图中仅用了染料的样品显示染料阳性细胞的背景值为28.6%。这个水平的反应性氧种类在用PMA和离子霉素即阳性对照(B图)处理20分钟的细胞中被大大提高到了80%。用CpG寡核苷酸(TCCATGACGTTCCTGACGTT,SEQ ID No.10)处理的细胞也显示了反应性氧种类水平的提高,即50%以上的细胞变为阳性(D图)。然而,用具有同样序列但CpGs交换(TCCATGAGCTTCCTGAGTGCT,SEQ ID No.11)的寡核苷酸处理的细胞则没有显示反应性氧种类水平的这种显著提高(E图)。
图8B显示流式细胞术研究的结果,其中使用小鼠B细胞,有氯喹存在,采用二氢若丹明123染料,以确定反应性氧种类的水平。氯喹将细胞中反应性氧种类的背景水平稍微降低了一些,使在A图中的未处理细胞仅有4.3%为阳性。氯喹完全消除了用CpG DNA处理的细胞中反应性氧种类的诱导(B图),但不降低用PMA和离子霉素处理的细胞中反应性氧种类的水平(E图)。
图9说明肺灌洗细胞计数对时间的作图,显示CpG和呼吸道暴露对肺部灌洗液的细胞计数效应。该图显示,当小鼠开始被注射了诱导Th2免疫应答的Schistosoma mansoni卵,“卵”、并且随后吸入Schistosoma mansoni卵抗原“SEA”后(空心环),则在肺部内有众多的炎性细胞。然而,当小鼠开始接受的是CpG寡核苷酸(SEQ ID No.10)以及卵时,则肺部内的炎性细胞并不因后续吸入SEA而增加(空心三角形)。
图10说明肺部灌洗嗜伊红粒细胞计数对时间的作图,显示CpG和呼吸道暴露对肺部灌洗液嗜伊红粒细胞数的效应。该图显示,当小鼠开始注射卵、并随后吸入SEA(空心环),则在肺部内有众多的嗜伊红粒细胞存在。然而,当小鼠开始接受的是CpG寡核苷酸(SEQ ID No.10)和卵时,则肺部内的炎性细胞就不因后来吸入SEA而增高(空心三角形)。
图11是显示CpG和呼吸道暴露肺部灌洗液中各成分的效应的条块图,说明分别暴露于仅仅盐水;卵,然后SEA;卵加SEQ ID No.11,然后SEA;卵加对照寡核苷酸(SEQ IDNo.11),然后SEA后,所诱导的对巨噬细胞、淋巴细胞、嗜中性细胞、嗜伊红粒细胞百分数的影响。当小鼠在初始暴露于卵之时给予对照寡核苷酸,则吸入SEA后对嗜伊红粒细胞向肺部的随后流入几乎没有影响。因此,当小鼠在第14天或第21天吸入卵时,它们在肺部内产生急性炎性反应。然而,如果在第0天和第7天开始接触抗原的时候将CpG寡核苷酸同卵一起提供给小鼠,则就完全消除了小鼠在第14天吸入卵抗原时嗜伊红粒细胞的增加。
图12是显示寡核苷酸剂量对总细胞数和嗜伊红粒细胞数的效应的一个条块图,说明对注射不同量的保护性寡核苷酸SEQ ID No.10响应的嗜伊红粒细胞计数。
图13显示CpG和呼吸道暴露对肺部灌洗中的IL-4的效应,其是响应于注射卵和随后的SEA(空心菱形);卵加SEQID No.10和随后的SEA(空心环);或盐水加随后的盐水(空心矩形)小鼠中白细胞介素-4(IL-4)的生成(pg/ml)随时间的作图。该图显示,所产生的炎性反应与肺部Th2细胞因子IL-4的水平相关。
图14是显示CpG和呼吸道暴露对肺部灌洗中的IL-12的效应的条块图,说明响应于注射盐水;卵和随后的SEA;或卵加SEQ ID No.10和随后的SEA,小鼠中白细胞介素-12(IL-12)的生成(pg/ml)随时间的作图。该图的结果显示,施用含有未甲基化CpG基元的寡核苷酸确实可以使肺的细胞因子应答重导向为产生IL-12,表明是Th1型的免疫应答。
图15是显示CpG和呼吸道暴露对肺部灌洗中的IFN-γ的效应的条块图,说明响应于注射盐水;卵和随后的SEA;或卵加SEQ ID No.10和随后的SEA小鼠中伽玛干扰素(IFN-γ)的生成(pg/ml)随时间的变化。该图的结果显示,施用含有未甲基化CpG基元的寡核苷酸也可以将肺的细胞因子应答重导向为IFN-γ产生,表明是Th1型的免疫应答。
本发明的详细描述
定义
在本文中,下面各个术语和词组所表达的意思定义如下:
术语“过敏原”指的是可以在易感受试者中产生过敏反应或气喘反应的物质。过敏原的名单是非常巨大的,可以包括花粉、昆虫毒物、动物皮、真菌孢子和药物(青霉素)等。天然的、动物的和植物的过敏原的实例包括下面各属特异性的蛋白质:犬(Canis familiaris),螨(Dermatophagoides farinae),Felis(Felisdomesticus),豚草(Ambrosia artemiisfolia),黑麦草(Loliumperenne或Lolium multiflorum),柳杉(Cryptomeria japonica),链格孢(Alternaria alternata),小蠹甲(Alder),桤木(Alnusgultinosa),桦木(Betula verrucosa),栎(Quercus alba),木犀榄(Olea europa),蒿(Artemisia vulgaris),车前(Plantago lanceolata),墙草(Parietaria officinalis或Parietaria judaica),小蠊(Blattellagermanica),蜂(Apis multiflorum),柏木(Cupressus sempervirens,Cupressus arizonica和Cupressus macrocarpa),刺柏(Juniperussabinoides,Juniperus virginiana,Juniperus communis和Juniperus ashei),Thuya(Thuya orientalis),扁柏(Chamaecyparisobtusa),大蠊(Periplaneta americana),冰草(Agropyron repens),黑麦(Secale cereale),小麦(Triticum aestivum),鸭茅(Dactylisglomerata),羊茅(Festuca elatior),早熟禾(Poa pratensis或Poacompressa),燕麦(Avena sativa),绒毛草(Holcus lanatus),黄花茅(Anthoxanthum odoratum),燕麦草(Arrhenatherum elatius),剪股颖(Agrostis alba),梯牧草(Phleum pratense),Phalaris(Phalaris arundinacea),雀稗(Paspalum notatum),高粱(Sorghum halepensis),以及雀麦(Bromus inermis)。
术语“过敏”指的是对某种物质(过敏原)所获得的过度敏感。过敏状况包括湿疹、过敏性鼻炎或鼻炎、枯草热、支气管气喘、荨麻疹、风疹、食物过敏,以及其它的特应性疾病。
术语“气喘”(asthma)指的是呼吸系统的疾病,其特征是发炎,气管变窄,以及气管对吸入物质的反应增加。气喘虽然不是必然的但也是经常地伴随着特应性或过敏性症状。
术语“免疫系统缺陷”指的是这样的疾病或紊乱,其中,个体的免疫系统不能正常发挥功能,或者其中增强个体的免疫应答可能比较有用,从而消除例如受试者中的肿瘤或癌症[例如脑、肺(包括小细胞和非小细胞)、卵巢、乳腺、前列腺、结肠肿瘤,以及其它的恶性瘤和肉瘤]或其它的感染。
感染性病毒的实例包括:Retroviridae[例如,人免疫缺陷病毒,如HIV-1(也称为HTLV-III,LAV或HTLV-III/LAV,或HIV-III;以及其它的分离物,例如HIV-LP)];小RNA病毒科(Picornaviridae)(例如,脊髓灰质炎病毒,甲肝病毒,肠病毒,人柯萨奇病毒,鼻病毒,艾柯病毒),嵌杯样病毒(Caliciviridae)(例如,造成肠胃炎的株系),披膜病毒(例如马脑炎病毒,风疹病毒),黄色病毒(Flaviridae)(例如,登革病毒(dengue viruses),脑炎病毒(encephalitis viruses),黄热病毒(yellow fever viruses)],冠形病毒[Coronaviridae,例如冠形病毒(coronaviruses)],棒状病毒[Rhabdoviridae,例如,疱疹性口腔炎病毒(vesicularstomatitis viruses),狂犬病毒(rabies viruses)],线状病毒(Filoviridae)(例如,依波拉病毒(ebola viruses)),副粘病毒(Paramyxoviridae),例如副流感病毒,腮腺炎病毒,麻疹病毒,呼吸道合胞病毒],正粘病毒(Orthomyxoviridae](例如流感病毒),Bungaviridae[例如,汉坦病毒(Hantaan viruses),bungaviruses,白蛉病毒(phleboviruses)和纳依罗病毒(Nairoviruses)],沙粒病毒病毒(Arena viridae)(例如,出血热病毒),呼吸道肠道病毒(Reoviridae)[例如,呼肠病毒(reoviruses),环状病毒(orbiviruses)和轮状病毒(rotaviruses)],双RNA病毒(Birnaviridae),嗜肝DNA病毒(Hepadnaviridae)[例如,乙肝病毒(Hepatitis B virus)],细小病毒(Parvoviridae](细小病毒属),乳多空病毒(Papovaviridae)(例如,乳头瘤病毒(papilloma viruses),多瘤病毒(polyoma viruses)),腺病毒科(Adenoviridae)(大部分腺病毒)],疱疹病毒(Herpesviridae)(例如单纯疱疹病毒(HSV)1和2,水痘带状疱疹病毒(varicellazoster virus),巨细胞病毒(CMV),疱疹病毒],痘病毒[天花病毒,痘苗病毒,痘病毒],和虹彩病毒(Iridoviridae)(例如,African swine fever virus],以及一些未分类的病毒[例如,海绵脑病的致病因子,丁型肝炎致病因子(被认为是乙型肝炎病毒的缺陷型变体),非甲非乙肝炎的致病因子(1类=内部传染,2类=肠胃外传染(如丙型肝炎),Norwalk病毒以及相关的病毒,和星状病毒)]。
感染性细菌的实例包括:幽门螺杆菌(Helicobacterpyloris),布氏疏螺旋体(Borelia burgdorferi),侵肺军团菌(Legionella pneumophilia),分枝杆菌(Mycobacteria sps.)(例如,结核分枝杆菌(M.Tuberculosis),鸟分枝杆菌(M.avium),胞内分枝杆菌(M.intracellulare),堪萨斯分枝杆菌(M.kansaii),戈登分枝杆菌(M.gordonae)),金黄色葡萄球菌(Staphylococcus aureus),淋病奈瑟氏球菌(Neisseriagonorrhoeae),脑膜炎奈瑟氏球菌(Neisseria meningitidis),单核细胞增多性李斯特氏菌(Listeria monocytogenes),酿脓链球菌[Streptococcus pyogenes(A组链球菌)],无乳链球菌[Streptococcus agalactiae(B组链球菌)],链球菌属(viridans组),粪链球菌(Streptococcus faecalis),牛链球菌(Streptococcus bovis),链球菌属(厌氧菌),肺炎链球菌(Streptococcus pneumoniae),致病性弯曲杆菌(Campylobactersp.,),肠球菌(Enterococcus sp.,),流感嗜血杆菌(Haemophilusinfluenzae),炭疽芽孢杆菌(Bacillus antracis),白喉棒杆菌(Corynebacterium diphtheriae),棒杆菌属(Corynebacteriumsp.,),红斑丹毒丝菌(Erysipelothrix rhusiopathiae),产气荚膜梭菌(Clostridium perfringers),破伤风梭菌(Clostridiumtetani),产气肠杆菌(Enterobacter aerogenes),肺炎克雷伯氏菌(Klebsiella pneumoniae),多杀巴斯德氏菌(Pasturellamultocida),拟杆菌(Bacteroides sp.,),具核梭杆菌(Fusobacterium nucleatum),念珠状链杆菌(Streptobacillusmoniliformis),梅毒螺旋菌(Treponema pallidium),极细密螺旋体(Treponema pertenue),钩端螺旋体(Leptospira)和伊氏放线菌(Actinomyces israelli)。
感染性真菌的实例包括:新型隐球酵母(Cryptococcusneoformans),荚膜组织胞浆菌(Histoplasma capsulatum),粗球孢子菌(Coccidioides immitis),皮炎芽酵母(Blastomycesdermatitidis),沙眼衣原体(Chlamydia trachomatis),白假丝酵母(Candida albicans)。其它的感染性有机体(例如,原生动物)包括:恶性疟原虫(Plasmodium falciparum)和鼠弓形虫(Toxoplasma gondii)。
术语“免疫刺激性核酸分子”指的是这样的核酸分子,它们含有未甲基化的胞嘧啶、鸟嘌呤二核苷酸序列(即,“CpG DNA”或含有胞嘧啶并接着鸟苷且由磷酸酯键所连接的DNA)并刺激脊椎动物淋巴细胞(例如,对所述细胞具有促分裂效应,或者诱导或提高其细胞因子表达)。免疫刺激性核酸分子可以是双链的或单链的。一般地,双链分子在体内更为稳定,而单链分子则具有提高的免疫活性。
本发明一方面提供了一种分离的核酸序列,其含有至少一个未甲基化CpG二核苷酸,其通式如下:
5′N1X1CGX2N23′
其中至少一个核苷酸将连续的CpGs间隔开来;X1是腺嘌呤,鸟嘌呤,或胸腺嘧啶;X2是胞嘧啶或胸腺嘧啶;N是任何核苷酸,并且N1+N2是约0-26个碱基,条件是N1和N2不含有CCGG四元体或多于一个的CCG或CGG三元体;并且所述核酸序列的长度为约8-30个碱基。
在一个实施方案中,其中的X1是胸腺嘧啶。
在另一个实施方案中,其中所述的X2是胸腺嘧啶。
在又一个实施方案中,所述的核酸序列是GTCG(T/C)T或是TGACGTT。
在又一个实施方案中,所述的核酸序列是TGTCG(T/C)T。
在又一个实施方案中,所述的核酸序列是TCCATGTCGTTCCTGTCGTT。
在又一个实施方案中,所述的核酸序列是TCCTGACGTTCCTGACGTT。
在又一个实施方案中,所述的核酸序列是TCGTCGTTTTGTCGTTTTGTCGTT。
本发明另一方面提供了一种分离的核酸序列,其含有至少一个未甲基化CpG二核苷酸,其通式如下:
5′N X1X2CGX3X4N3′
其中至少一个核苷酸将连续的CpGs分开;X1X2选自GpT、GpG、GpA、ApT和ApA;X3X4选自TpT或CpT;N是任何核苷酸,并且N1+N2是约0-26个碱基,条件是N1和N2不含有CCGG四元体或多于一个的CCG或CGG三元体;并且所述核酸序列的长度为约8-30个碱基。
在一个实施方案中,其中所述的分隔至少两个连续CpGs的核苷酸是胸腺嘧啶。
在又一个实施方案中,其中所述的X3和X4是胸腺嘧啶。
在又一个实施方案中,其中至少一个核苷酸具有磷酸主链修饰。
在又一个实施方案中,其中所述的磷酸主链修饰是硫代磷酸酯修饰或二硫代磷酸酯修饰。
在又一个实施方案中,其中所述的磷酸主链修饰发生在核酸的5′端。
在又一个实施方案中,其中所述的修饰发生在该核酸5′端的前两个核苷酸间连键(linkage)。
在又一个实施方案中,其中所述的磷酸主链修饰发生在该核酸的3′端。
在又一个实施方案中,其中所述的修饰发生在该核酸3′端的最后5个核苷酸间连键。
本发明还提供了一种刺激受试者的免疫活化的方法,其中所述的刺激主要是Th1类型的免疫活化,该方法包括向受试者施用前述的核酸序列。在一个实施方案中,其中所述的受试者是人。
本发明提供了一种刺激受试者的细胞因子生产的方法,该方法包括给受试者施用前述的核酸序列。
在一个实施方案中,其中所述的细胞因子选自包括IL-6、IL-12、IFN-γ、TNF-α和GM-CSF的一组。
在又一个实施方案中,其中所述的受试者是人。
在又一个实施方案中,其中所述的核酸序列选自包括下述序列的组中:
TCCATGTCGCTCCTGATGCT,
TCCATAACGTTCCTGATGCT,
TCCATGACGATCCTGATGCT
TCCATGGCGGTCCTGATGCT
TCCATGTCGGTCCTGATGCT
TCCATAACGTCCCTGATGCT
TCCATGTCGTTCCTGATGCT,以及
TCGTCGTTTTGTCGTTTTGTCGTT。
本发明还提供了一种刺激受试者的NK裂解活性的方法,该方法包括向受试者施用上述通式的核酸序列。
在一个实施方案中,其中所述的受试者是人。
在又一个实施方案中,其中所述的核酸序列选自包括下述序列的组中:
TCGTCGTTGTCGTTGTCGTT,
TCCATGACGGTCCTGATGCT,
TCCATGACGATCCTGATGCT,
TCCATGACGCTCCTGATGCT,
TCCATGACGTTCCTGATGCT,
TCCATAACGTTCCTGATGCT,
TCCATCACGTGCCTGATGCT,
GGGGTCAACGTTGAGGGGGG,
TCGTCGTTTTGTCGTTTTGTCGTT,
TCGTCGTTGTCGTTTTGTCGTT,
GCGTGCGTTGTCGTTGTCGTT,
TGTCGTTTGTCGTTTGTCGTT,
TGTCGTTGTCGTTGTCGTT,以及
TCGTCGTCGTCGTT。
本发明还提供了一种刺激受试者的B细胞增殖的方法,该方法包括向受试者施用具有上述通式的核酸序列。
在一个实施方案中,其中所述的受试者是人。
在又一个实施方案中,其中所述的核酸序列选自包括下述序列的一组:
TCCTGTCGTTCCTTGTCGTT,
TCCTGTCGTTTTTTGTCGTT,
TCGTCGCTGTCTGCCCTTCTT,
TCGTCGCTGTTGTCGTTTCTT,
TCGTCGTTTTGTCGTTTTGTCGTT,
TCGTCGTTGTCGTTTTGTCGTT,以及
TGTCGTTGTCGTTGTCGTT。
本发明还提供了一种刺激受试者的免疫活化的方法,该方法包括向受试者施用具有上述通式的核酸序列,其中所述的核酸序列起佐剂的作用。
在一个实施方案中,其中所述的受试者是哺乳动物。
在另一个实施方案中,其中所述的核酸序列选自包括下述序列的组中:
TCCATGACGTTCCTGACGTT,
GTCG(T/C)T,以及
TGTCG(T/C)T。
本发明还提供了一种治疗患有气喘疾病的受试者的方法,该方法包括向该受试者施用处于药学可接受载体中的具有上文所示通式的核酸序列。在一个实施方案中,其中所述的受试者是人。在另一个实施方案中,其中所述的核酸序列是TCCATGACGTTCCTGACGTT。
本发明还提供了一种通过抑制CpG介导的淋巴细胞活化来治疗患有自身免疫疾病或其它的与CpG相关的疾病的受试者的方法,该方法包括向该受试者施用处于药学可接受载体中的内体酸化抑制物。在一个实施方案中,其中所述的受试者是人。在另一个实施方案中,其中所述的抑制物选自包括bafilomycin A、氯喹、和莫能菌素的组中。在又一个实施方案中,其中所述的抑制物的提供剂量小于约10μM。在又一个实施方案中,其中所述的疾病选自包括系统性红斑狼疮、脓毒症、炎性肠疾病、牛皮癣、龈炎、关节炎、克罗恩氏病(Crohn′sdisease)、格雷夫斯氏病(Grave′s disease)和气喘的组中。优选地,其中所述的疾病是系统性红斑狼疮。
在本发明的一个优选的实施方案中,提供了分离的免疫刺激性核酸序列,其含有如下所示的CpG基元:
5′N1X1CGX2N23′
其中,至少有一个核苷酸将连续的CpGs间隔开来;X1是腺嘌呤,鸟嘌呤,或胸腺嘧啶;X2是胞嘧啶或胸腺嘧啶;N是任何的核苷酸,且N1+N2是约0-26个碱基,条件是N1和N2不含有CCGG四元体或多于一个的CCG或CGG三元体;并且该核酸序列的长度为约8-30个碱基。
在另一个实施方案中,本发明提供了分离的免疫刺激性核酸序列,其中含有下式所示的CpG基元:
5′N1X1X2CGX3X4N23′
其中,至少有一个核苷酸将连续的CpGs间隔开来;X1X2是选自GpT、GpG、GpA、ApT和ApA;X3X4是选自TpT或CpT;N是任何的核苷酸,且N1+N2是约0-26个碱基,条件是N1和N2不含有CCGG四元体或多于一个的CCG或CGG三元体;并且该核酸序列的长度为约8-30个碱基。
优选的是,本发明的免疫刺激性核酸序列包括X1X2,它们选自GpT、GpG、GpA和ApA,且X3X4选自TpT、CpT和GpT(例如参见表5)。为了促进被摄入细胞中,含有CpG的免疫刺激性核酸分子优选为8-30个碱基的长度。然而,如果有足够的免疫刺激性基元存在,则任何长度的核酸(甚至数千个碱基对长)都可以是免疫刺激性的,因为这样的更大型的核酸在细胞内被降解为寡核苷酸。优选的合成寡核苷酸在其5′和/或3′端或附近不含有CCGG四元体或者多于一个的CCG或CGG三元体,和/或共有的促细胞分裂性CpG基元不是回文结构。用稳定化的寡核苷酸可以获得长久的免疫刺激,其中寡核苷酸中整合有磷酸酯主链的修饰。例如,当修饰为硫代磷酸酯或二硫代磷酸酯类的修饰时即是如此。另外,更具体地讲,磷酸酯主链修饰发生在核酸的5′端,例如在核酸5′端的最初两个核苷酸上。进而言之,磷酸酯主链修饰可以发生在核酸的3′端,例如在核酸3′端的最后5个核苷酸上。
优选地,所述免疫刺激性CpG DNA是寡核苷酸时,其长度为8-30个碱基。可选择地,CpG二核苷酸可以在质粒中大规模生产,当其被给予个体后,被降解为寡核苷酸。优选的免疫刺激性核酸分子[例如,用于提高疫苗的有效性,或在个体内通过刺激抗体(例如体液)应答来治疗免疫系统缺陷]具有相对高的针对B细胞、单核细胞和/或天然杀伤细胞反应的刺激指数(例如,细胞因子、增殖性、裂解性或其它的反应)。
本发明的核酸序列例如刺激受试者中的细胞因子产生。细胞因子包括但不限于IL-6、IL-12、IFN-γ、TNF-α、GM-CSF。这些序列的实例包括:TCCATGTCGCTCCTGATGCT(SEQID NO:42),TCCATGTCGTTCCTGATGCT(SEQ ID NO:43),和TCGTCGTTTTGTCGTTTTGTCGTT(SEQ ID NO:56)。
本发明的核酸序列还可以用于刺激受试者例如人内天然杀伤细胞(NK)的裂解活性。这些序列的具体但非限制性的实例包括:
TCGTCGTTGTCGTTGTCGTT(SEQ ID NO:57),
TCGTCGTTTTGTCGTTTTGTCGTT(SEQ ID NO:58),
TCGTCGTTGTCGTTTTGTCGTT(SEQ ID NO:59),
GCGTGCGTTGTCGTTGTCGTT(SEQ ID NO:),
TGTCGTTTGTCGTTTGTCGTT(SEQ ID NO:),
TGTCGTTGTCGTTGTCGTT(SEQ ID NO:60)和
TCGTCGTCGTCGTT(SEQ ID NO:61)。
本发明的核酸序列还可以刺激受试者例如人中B细胞增殖。具体的但非限制性的实例包括:
TCCTGTCGTTCCTTGTCGTT(SEQ ID NO:62),
TCCTGTCGTTTTTTGTCGTT(SEQ ID NO:63),
TCGTCGCTGTCTGCCCTTCTT(SEQ ID NO:64),
TCGTCGCTGTTGTCGTTTCTT(SEQ ID NO:65),
TCGTCGTTTTGTCGTTTTGTCGTT(SEQ ID NO:66),
TCGTCGTTGTCGTTTTGTCGTT(SEQ ID NO:67),和
TGTCGTTGTCGTTGTCGTT(SEQ ID NO:68)。
在另一个方面,本发明的核酸序列可以用作佐剂,在哺乳动物中抗体生产期间使用。这种序列的具体但非限制性的实例包括TCCATGACGTTCCTGACGTT(SEQ ID NO:10),GTCG(T/C)T和TGTCG(T/C)T。进而言之,可以施用这些核酸序列,从而通过将受试者的免疫应答从Th2型改变为Th1型,以用于治疗或预防气喘疾病症状。代表性的序列包括TCCATGACGTTCCTGACGTT(SEQ ID NO:10)。
具体的免疫刺激性CpG DNA的刺激指数可以用各种免疫细胞检测来测定。优选地,免疫刺激性CpG DNA针对B细胞增殖的刺激指数为至少约5,优选至少约10,更优选地至少约15,最优选地至少约20,该刺激指数是通过在鼠B细胞培养物中掺入3H-尿苷而测定的,该B细胞培养物已在37℃下与20μM的ODN接触20小时,并且用1μCi的3H尿苷进行脉冲标记,并按照实施例1所述在4小时后收获和计数。对于体内的应用,例如通过刺激受试者中细胞介导的(局部)免疫反应用于治疗免疫系统缺陷,重要的是该免疫刺激性CpG DNA能够有效地诱导单核细胞的细胞因子分泌和/或天然杀伤细胞(NK)的细胞裂解活性。
优选的免疫刺激性CpG核酸应该可以导致产生至少约500pg/ml的TNF-α、15pg/ml的IFN-γ、70pg/ml的GM-CSF、275pg/ml的IL-6、200pg/ml的IL-12,这取决于治疗适应症,如按照实施例12中所述的检测法所测定的。其它优选的免疫刺激性CpG DNAs应能够产生至少约10%,更优选至少约15%,最优选至少约20%的YAC-1细胞特异性裂解,或至少约30%,更优选至少约35%,最优选至少约40%的2C11细胞特异性裂解,如通过实施例4中描述的检测法所测定的。
术语“核酸”或“DNA”指的是多个核苷酸{即,含有糖(如核糖或脱氧核糖)且其与磷酸酯基团和可互换的有机碱(其或者是取代的嘧啶[例如,胞嘧啶(C)、胸腺嘧啶(T)或尿嘧啶(U)]、或者取代的嘌呤[例如,腺嘌呤(A),鸟嘌呤(G)])相连接。在本文中,该术语指的是核糖核苷酸以及寡脱氧核糖核苷酸。该术语还应该包括多核苷(即,多核苷酸减去磷酸)以及含有有机碱的任何其它聚合物。核酸分子可以从已经存在的核酸来源获得(例如,基因组或cDNA),但是,优选合成性的(例如,由寡核苷酸合成所产生的)。
术语“核酸递送复合物”指的是与靶向装置[例如,对靶细胞(如B细胞和天然杀伤(NK)细胞)表面有较高亲和结合性和/或提高靶细胞的细胞摄入的分子]结合在一起(通过离子键或共价键结合,或包裹在其内)的核酸分子。核酸递送复合物的实例包括与下列物质结合的核酸:固醇(例如,胆固醇)、脂类(例如,阳离子脂质、病毒体、或脂质体)、或靶细胞特异性结合剂(例如,由靶细胞特异性受体所识别的配体)。优选的复合物必须在体内足够稳定,可以防止在被靶细胞内化之前被显著解偶联。然而,这些复合物应能够在细胞内在适宜的条件下被剪切,使核酸以功能性的形式被释放。
术语“回文序列”指的是反向的重复(即,如ABCDEE′D′C′B′A′这样的序列,其中A和A′是能够形成常规的Watson-Crick碱基对的碱基。在体内,这样的序列可能形成双链结构。
术语“稳定化的核酸分子”指的是对体内降解(例如,通过外切核酸酶或内切核酸酶的降解)具有相对抵抗性的核酸分子。稳定可以是长度或二级结构的函数。长度为数十至数百kb的含有未甲基化CpG的核酸分子对体内降解有相对的抵抗性。对于较短的免疫刺激性核酸分子,二级结构可以稳定和提高其效果。例如,如果核酸分子的3′端具有对上游区的自我互补性,使它可以回折并形成某种茎-环结构,那么该核酸分子就变为稳定化的,并因而表现出更多活性。
优选的本发明的稳定化核酸分子具有被修饰的主链。用于免疫刺激时,特别优选的稳定化核酸分子是硫代磷酸酯(即,核酸分子的至少一个磷酸氧被硫所取代)或二硫代磷酸酯修饰的核酸分子。更具体地讲,磷酸酯主链修饰发生在核酸的5′端,例如在核酸5′端的最初两个核苷酸处。进而言之,磷酸酯主链修饰可以发生在核酸的3′端,例如发生在核酸3′端的最后5个核苷酸处。除了稳定核酸分子外,正如本文中进一步描述的那样,硫代磷酸酯-修饰(包括二硫代磷酸酯-修饰)的核酸分子可以提高如本文所示含有未甲基化CpG二核苷酸的核酸分子的免疫刺激程度。题目为“硫代磷酸酯寡核苷酸类似物的免疫刺激”的国际专利申请公开第WO95/26204号也报道了硫代磷酸酯修饰的寡核苷酸的非序列特异性免疫刺激效果。如本文所描述的,含有未甲基化CpG、并具有硫代磷酸酯主链的核酸分子已经被发现优先活化B细胞活性,而含有未甲基化CpG并具有磷酸二酯主链的核酸分子已经被发现优先活化单核细胞(巨噬细胞、树状细胞和单核细胞)和NK细胞。带有优选的人基元的硫代磷酸酯CpG寡核苷酸也是单核细胞和NK细胞的强活化子。
其它的稳定化核酸分子包括:非离子性DNA类似物,例如烷基和芳基膦酸酯(其中带电的膦酸氧被烷基或芳基所取代),磷酸二酯和烷基磷酸三酯,其中带电的氧部分被烷基化。在任一末端或两末端含带有二醇例如四乙二醇或六乙二醇的核酸分子,已经显示对核酸酶降解有实质性抗性。
术语“受试者”指的是人或脊椎动物,包括狗、猫、马、牛、猪、绵羊、山羊、鸡、猴子、大鼠,和小鼠。
在本文中,术语“载体”指的是能够运送与之相连的另一核酸的核酸分子。优选的载体是能够对与之相连的核酸进行自我复制和表达的载体(例如,附加体)。能够指导与之可操作性相连的基因的表达的载体在本文中被称为“表达载体”。总体来说,在重组DNA技术中有用的表达载体经常都是“质粒”形式,其一般指的是双链DNA环,其在载体形式时不与染色体结合。在本说明书中,术语“质粒”和“载体”是可以相互替换使用的,因为质粒是最常用形式的载体。然而,本发明也意图包括可发挥等同功能以及后来为本领域所知的这种其它形式的载体。
某些含有未甲基化CpG的核酸在体内和体外显示具有B细胞
刺激活性
在根据随后的实施例1和2中描述的方案进行的对内源逆转录病毒序列具有特异性的两种反义寡核苷酸的淋巴细胞刺激效应的研究中,令人惊奇地发现了在24个“对照”(对于“反义”ODN图,包括各种杂乱的、有义的、和错配的对照)中的2个也介导了B细胞活化和IgM分泌,而其它的“对照”则不具有这样的效果。
这两个研究的结果表明,这种“对照”ODN的B细胞活化机制可能不涉及反义效果,1)通过与基因库(GenBank)所列的脊椎动物DNA序列相比较,没有显示出比那些没有刺激性的ODN更高的同源性,以及2)这两个对照在使用10μg的脾poly A+RNA的Northen印迹中没有显示出杂交。在不同的合成器上重合成这些ODN,或用聚丙烯酰胺凝胶电泳或高压液相色谱来充分提纯,都得到相同的刺激,排除了杂质的可能性。采用来自C3H/HeJ小鼠的B细胞也见到了类似的刺激,这排除了脂多糖(LPS)污染可能导致这些结果的可能性。
两个“对照”ODN所造成的B细胞活化与两个“反义”ODN造成的活化相类似这一事实提出了这样的可能性,即所有四个ODN对B细胞的刺激通过某种非反义机制进行的,该机制涉及在所有的其它非刺激性对照ODN中都不存在的序列基元。比较这些序列时发现,所有四个刺激性ODN都含有处于与非刺激性对照不同的序列环境中的CpG二核苷酸。
为了确定存在于刺激性ODN中的CpG基元是否负责所观察到的刺激作用,合成了超过300种ODN,它们的长度范围是5-42个碱基,并含有处于不同序列环境下的甲基化或未甲基化的CpG二核苷酸,或者不含有CpG二核苷酸。对这些ODN,包括两个原始的“对照”(即ODN 1和2)以及两个原始合成的“反义”物[ODN 3D和3M;Krieg,A.M.J.Immunol.143:2448(1989)],检查它们对脾细胞的体外影响(代表性序列在表1中给出)。含有CpG二核苷酸的几种ODN诱导了B细胞的活化和IgM的分泌;这种刺激的程度一般可以由可通过增加更多的CpG二核苷酸来提高(表1;比较ODN 2与2a或3D与3Da和3Db)。看起来刺激不是反义机制或杂质所致。ODN没有造成可检测的γδ或其它T细胞群体的增殖。
如果CpG二核苷酸发生突变,或如果CpG二核苷酸的胞嘧啶被5-甲基胞嘧啶取代(表1;ODN 1b,2b,3Dd,和3Mb),则促细胞分裂性ODN序列都一致地变为非刺激性的(表1;比较ODN 1与1a;3D与3Dc;3M与3Ma;以及4与4a)。CpG基元的部分甲基化造成刺激效果的部分损失(比较2a与2c,表1)。相对照而言,对其它胞嘧啶的甲基化没有减少ODN活性(ODN 1c,2d,3De和3Mc)。这些数据确认了CpG基元是ODN中存在的活化B细胞的必需元件。
在这些研究的过程中,变得更为清楚的是,在CpG二核苷酸侧翼的碱基在由ODN诱导的小鼠B细胞活化的确定中起着重要的作用。已确定最佳的刺激基元包括有以两个5′嘌呤(优选为GpA二核苷酸)和两个3′嘧啶(优选TpT或TpC二核苷酸)为侧翼的CpG。将此CpG基元更类似这种理想形态的ODN突变改善了刺激性(例如,表1,比较ODN 2与2e;3M与3Md),而那些扰乱该基元的突变则减弱了刺激性(见表1,比较ODN3D与3Df;4与4b,4c和4d)。另一方面,在CpG基元以外的突变没有减弱刺激性(例如,表1,比较ODN 1与1d;3D与3Dg;3M与3Me)。对于活化人细胞,最佳的侧翼碱基是稍有不同的(见表5)。
在那些实验过的ODNs中,长度小于8个碱基的ODN都没有刺激性(例如,表1,ODN 4e)。在所测试过的48个长度为8个碱基的ODN中,确定了具有强刺激性的序列是TCAACGTT(ODN 4),其含有自我互补的“回文序列”AACGTT。在对该基元的进一步优化中,发现在两个末端都有G的ODN具有更强的刺激性,当ODN被硫代磷酸酯修饰了末端的核苷酸间连键而具有对核酸酶的抗性后更是如此。ODN1585[5′GGGGTCAACGTTCAGGGGGG3′(SEQ ID NO:12)]中,前两个和最后5个核苷酸间连键都被硫代磷酸酯所修饰,该ODN使得小鼠脾细胞增殖平均提高了25.4倍,而相比之下,由ODN 1638所造成的增殖只增加了平均3.2倍,该ODN 1638与ODN 1585具有相同的序列,只是在两末端的10个G被10个A所取代。富含G的末端的效果是顺式的,将具有polyG末端但不含CpG基元的ODN与1638一起加入细胞,也不会导致增殖增加。对于长度大于8个碱基对的核酸分子,含有未甲基化CpG的非回文序列基元被发现是更具有刺激性的。
含有6碱基回文序列并在5′端有TpC二核苷酸的八聚ODN也是活性的(见表1,ODN 4b,4c)。在5′端的其它二核苷酸也减弱刺激性(例如,ODN 4f,对所有可能的16种二核苷酸都进行了测试)。有3′端二核苷酸存在并不足以补偿5′端二核苷酸的缺失(见表1,ODN 4g)。对回文序列的破坏就消除了八聚ODN的刺激性(例如,表1,ODN 4h),但是,在更长的ODN中,回文序列不是必须的。
表1:寡核苷酸对小鼠B细胞的刺激
′刺激指数是由至少三个单独实验得到的平均值和标准偏差,并且与没有加入ODN进行培养的小孔进行比较。
ND=未进行。
CpG二核苷酸用下划线标出。
黑点表示相同,短线表示缺失。
Z代表5甲基胞嘧啶。
表2:鉴定小鼠IL-6生产和B细胞活化的最优CpG基元
黑点代表相同;CpG二核苷酸用下划线标出;ND=未进行
a该实验进行至少三次,得到相似结果。CH12.LX和脾B细胞的未受刺激的对照培养物的IL-6水平≤10pg/ml。未受刺激的培养物的IgM水平为547±82ng/ml。CpG二核苷酸用下划线标出,黑点代表相同。
b[3H]尿嘧啶吸收用对未受刺激的对照(2322.67±213.68cpm)而言的增加倍数表示(SI:刺激指数)。细胞用20μM各种CpG O-ODN刺激。数据代表一式三份的平均值±标准偏差。
c用ELISA测定。
对淋巴细胞活化的动力学的研究采用了小鼠脾细胞。在加入ODN的同时对细胞进行脉冲,4小时后立即收获,3H-鸟嘧啶掺入已经有2倍的增加。刺激在12-48小时达峰值,然后降低。24小时后,检测不到完整的ODN,这也许就是当纯化的B细胞在有或没有抗-IgM(亚促细胞分裂剂量)条件下与CpG ODN一起培养时发生随后刺激下降的原因,还发现在48小时后,这两种促细胞分裂原相组合造成增殖协同性地增加了约10倍。刺激的幅度是浓度依赖性的,并且在针对二者的优化条件下都一致地超过LPS的刺激幅度。含有抗核酸酶的硫代磷酸酯主链的寡核苷酸比未修饰的寡核苷酸强大约200倍。
采用细胞周期分析来确定由CpG-ODN活化的B细胞的比例。CpG-ODN在多于95%的B细胞中诱导了进入细胞周期。通过流式细胞术分拣成CD23-(边缘区)和CD23+(小泡区)亚群的脾B淋巴细胞对ODN诱导的刺激都有同样的反应,采用Percoll梯度通过分级分离的静息和活化B细胞群也是如此。这些研究表明,CpG-ODN诱导几乎所有的B细胞进入细胞周期。
免疫刺激性核酸分子阻断小鼠B细胞编程性细胞死亡
有些B细胞系,例如WEHI-231,应答于它们的抗原受体被抗-IgM的交联而被诱导经历生长停滞和/或编程性细胞死亡,[Jakway,J.P.et al.,″Growth regulation of the Blymphoma cell line WEHI-231 by anti-immunoglobulin,lipopolysaccharide and other bacterial products″J.Immunol.137:2225(1986);Tsubata,T.,J.Wu and T.Honjo:B-cellapoptosis indueced by antigen receptor corsslinking is blockedby a T-cell signal through CD40.″Nature 364:645(1993)]。用某些刺激物如LPS和CD40配体可以将WEHI-231细胞从这种生长停滞状态下恢复出来。含有CpG基元的ODN也被发现可以保护WEHI-231细胞不发生抗-IgM诱导的生长停滞,表明这种效果不需要辅助细胞群。随后的研究工作表明,CpG ODN诱导了Bcl-x和myc表达,它们可能对是免于编程性细胞死亡的保护作用的原因。再者,CpG核酸被发现可以阻断人细胞中的编程性细胞死亡。这种对编程性细胞死亡的抑制具有重要性,因为它将提高和延长CpG DNA的免疫活化。
鉴定诱导小鼠IL-6和IgM分泌以及B细胞增殖的为最优化
CpG基元
为了确定最优化的B细胞刺激性CpG基元是否与对IL-6分泌的最优化CpG基元相同,研究了一组ODN,它们的CpG二核苷酸侧翼的碱基被逐步取代。使用脾B细胞和CH12.LX细胞对该组ODN分析它们对B细胞增殖、Ig生产、IL-6分泌的影响。如表2所示,优化的刺激性基元含有未甲基化的CpG,侧翼为两个5′嘌呤和两个3′嘧啶。一般地说,5′嘌呤向3′嘧啶的突变或者3′嘧啶向嘌呤的突变都显著地降低这种效应。从5′嘌呤向C的变化是特别的有破坏性的,但是,从5′嘌呤向T的变化或3′嘧啶向嘌呤的变化所产生的影响就比较小。根据这些分析以及其它ODN的结果,确定了诱导IL-6分泌的优化CpG基元为TGACGTT,其与最佳的促细胞分裂和IgM诱导性CpG基元相同(表2)。该基元比任何所研究过的含有回文序列的序列都更具有刺激性(1639,1707和1708)。
细菌DNA中或寡核苷酸中的CpG基元对小鼠细胞因子分泌的
诱导
如在实施例9中所描述的那样,CpG DNA刺激后脾细胞分泌的IL-6的量用ELISA测定。在最初的研究发现T细胞对CpG DNA刺激的脾细胞生产的IL-6几乎没有或没有任何作用后没有任何作用后,不采用全脾细胞,而采用去除了T细胞的脾细胞培养物进行体外研究,如表3所示,在用大肠杆菌DNA培养的细胞中,IL-6的生产显著增加,而用小牛胸腺DNA培养的细胞则没有提高。为了确认用大肠杆菌DNA所观察到的IL-6生产的增加不是由于其它细菌产物的污染所造成的,在进行分析之前,对DNA用DNA酶进行消化。这种DNA酶的预处理消除了由大肠杆菌DNA诱导的IL-6的生产(表3)。此外,从LPS-非应答性C3H/HeJ小鼠来源的脾细胞响应于细菌DNA而产生相似水平的IL-6。为了研究由大肠杆菌DNA诱导的IL-6的分泌是否由细菌DNA中的未甲基化CpG二核苷酸所介导,检验了甲基化的大肠杆菌DNA和一组合成性ODN。如表3所示,CpG ODN显著地诱导了IL-6的分泌(ODN 5a,5b,5c),而CpG甲基化大肠杆菌DNA,或含有甲基化CpG的ODN(ODN 5f),或不含CpG的ODN(ODN 5d)则都没有发生诱导。在CpG二核苷酸以外位置的改变(ODN 5b),或者其它胞嘧啶的甲基化(ODN 5g)都没有减弱CpG ODN的效果。在含有三个CpG的ODN中单个CpG的甲基化导致了刺激性的部分降低(表3,比较ODN 5c和5e)。
表3:细菌DNA中或寡核苷酸中的CpG基元诱导小鼠IL-6分泌
处理 | IL-6(pg/ml) | |
小牛胸腺DNA | ≤10 | |
小牛胸腺DNA+DNase | ≤10 | |
大肠杆菌DNA | 1169.5±94.1 | |
大肠杆菌DNA+DNase | ≤10 | |
CpG甲基化大肠杆菌DNA | ≤10 | |
LPS | 280.1±17.1 | |
培养基(没有DNA) | ≤10 | |
ODN | ||
5a SEQ ID NO:1 | ATGGACTCTCCAGCGTTCTC | 1096.4±372.0 |
5b SEQ ID NO:2 | ■■■■■AGG■■■■A■■■■■■■ | 1124.5±126.2 |
5c SEQ ID NO:3 | ■■C■■■■■■■G■■■■■■■■■ | 1783.0±189.5 |
5d SEQ ID NO:4 | ■■■■AGG■■C■■T■■■■■■■ | ≤10 |
5e SEQ ID NO:5 | ■■C■■■■■■■G■■Z■■■■■■ | 851.1±114.4 |
5f SEQ ID NO:6 | ■■Z■■■■■■ZG■■Z■■■■■■ | ≤10 |
5g SEQ ID NO:7 | ■■C■■■■■■■G■■■■■■Z■■ | 1862.3±87.26 |
来自DBA/2小鼠的去除了T细胞的脾细胞用磷酸二酯修饰的寡核苷酸(O-ODN)(20μM)、小牛胸腺DNA(50μg/ml)、大肠杆菌DNA(50μg/ml)(经过或不经过酶处理)、或LPS(10μg/ml)分别刺激24小时。数据代表一式三份实验的平均值±SD。CpG二核苷酸用下划线标出,黑点代表相同。Z表示5-甲基胞嘧啶。
CpG基元可以被用作人工佐剂
免疫应答的非特异性刺激物已知是佐剂。使用佐剂对于诱导针对可溶性抗原的强抗体应答是必需的(Harlow and Lane,Antibodies:A Laboratory manual,Cold Spring harbor,N.Y.Current Edition;通过在此引述而合并于本文)。佐剂的总体效应是强烈的,但它们的重要性不能被过分强调。佐剂的作用允许用更小剂量的抗原并产生更为一致的抗体应答。免疫应答的非特异性活化经常可以解释成功或未成功获得免疫应答之间的区别。应该在第一次注射的时候使用佐剂,除非有非常特殊的理由要求避免这样做。大多数的佐剂含有两种成分。一种成分是用来保护抗原不被快速分解代谢[例如,脂质体或合成的表面活性剂(Hunter et al.,1981)]。脂质体仅仅在免疫原被整合到外脂层时有效,内埋的分子是免疫系统看不见的。另一成分则是非特异性刺激免疫应答的物质。这些物质的作用是提高淋巴因子的水平。淋巴因子直接刺激抗原加工细胞的活性,并引起注射位置的局部发炎反应。早期的工作完全依赖于热杀死细菌(Dienes 1936)或脂多糖(LPS)(Johnson et al.,1956)。LPS是相当有毒的,通过对它的结构成分的分析,已发现其作为佐剂的大多数的性质存在于称作脂质A的部分。脂质A可以以多种合成的和天然的形式获得,其毒性远远小于LPS,但仍然保留了其母体LPS分子的大多数良好的佐剂性质。脂质A化合物经常通过脂质体递送。
近来,寻找强有力的、副作用更可接受的佐剂的深入工作导致了新的合成佐剂的产生。在本发明中,我们提供了序列1826,即TCCATGACGTTCCTGACGTT(SEQ ID NO:10),它是包括含CpG的核酸的佐剂。该序列是强的免疫活化序列,并且是非常优秀的佐剂,其效力完全与弗氏佐剂相当或更为优越,但是又没有明显的毒性。
确定CpG基元对小鼠IL-6分泌的诱导水平
细菌DNA和CpG ODN以剂量依赖性方式诱导去除了T细胞的小鼠脾细胞中的IL-6生产,但是,脊椎动物DNA和非CpG ODN则不是(图1)。IL-6的生产在大约50μg/ml细菌DNA或40μM的CpG O-ODN达到平台。由细菌DNA和CpG ODN诱导的IL-6的最大水平分别是1-1.5ng/ml和2-4ng/ml。这些水平比在LPS刺激后所见到的(0.35ng/ml)要明显地高(图1A)。为了评价具有核酸酶抗性DNA主链的CpG ODN是否也可以诱导IL-6的生产,向去除了T细胞的小鼠脾细胞中加入S-ODN。CpG S-ODN也以剂量依赖型方式诱导IL-6的生产,水平类似于CpG O-ODN,而非CpG S-ODN则没有诱导IL-6的生产(图1C)。浓度为0.05μM的CpG S-ODN可以在这些细胞中诱导最大的IL-6生产。这个结果表明,核酸酶抗性的DNA主链修饰保留了CpG DNA对诱导IL-6分泌的序列特异性能力,并且在该检测系统中CpG S-ODN比CpG ODN的效力高出80倍以上。
CpG DNA在体内对小鼠IL-6分泌的诱导
为了评价细菌DNA和CpG S-ODN体内诱导IL-6分泌的能力,给BALB/c小鼠静脉注射内100μg大肠杆菌DNA、小牛胸腺DNA、CpG或非刺激性S-ODN,2小时后放血。在注射了大肠杆菌DNA的组中,血清内IL-6水平为约13ng/ml,而在注射了小牛胸腺DNA的组或注射了PBS的组中,血清内没有检测到IL-6(表4)。CpG S-ODN也诱导了体内IL-6分泌。在注射了CpG S-ODN的组中,血清内IL-6的水平为约20ng/ml。相比之下,在注射了非刺激性S-ODN的组中,在其血清内没有检测到IL-6(表4)。
表4.体内CpG DNA刺激诱导的小鼠IL-6分泌
刺激物 | IL-6(pg/ml) |
PBS | <50 |
大肠杆菌DNA | 13858±3143 |
小牛胸腺DNA | <50 |
CpG S-ODN | 20715±606 |
非-CpG S-ODN | <50 |
小鼠(每组2只)接受静脉内注射100μl的PBS、200μg的大肠杆菌DNA或小牛胸腺DNA、或500μg的CpG S-ODN或非-CpG对照S-ODN。注射后2小时对小鼠采血,按1∶10稀释,每种血清用ELISA测定IL-6。ELISA测定IL-6的灵敏度限度为5pg/ml。CpG S-ODN的序列是5′GCATGACGTTGAGCT3′(SEQ ID NO:48),非刺激性S-ODN的序列是5′TCTAGATGTTAGCGT3′(SEQ ID NO:49)。应该注意的是,虽然在序列48中有CpG,但如本文中所解释的,它太靠近3′端而不能引起刺激作用。数据代表一式两份实验的平均值±标准偏差。实验进行至少两次且结果类似。
体内CpG基元刺激后小鼠IL-6分泌的动力学
为了评价CpG DNA在体内诱导IL-6分泌的动力学,对BALB/c小鼠静脉注射CpG或对照非-CpG S-ODN。在注射了CpG S-ODN的组中,血清IL-6水平在1小时内就明显提高,并且在2小时达到峰值水平约9ng/ml(图2)。血清中IL-6蛋白质水平在4小时后快速下降,并在刺激后12小时时恢复到基础水平。与CpG DNA刺激的组相反,在注射了非刺激性S-ODN或PBS的组中,血清内IL-6没有明显提高(图2)。
CpG基元在体内诱导的IL-6mRNA表达的动力学和组织分布
如图2所示,在CpG DAN刺激后,血清IL-6水平迅速提高。为了调查这种血清IL-6的可能的组织起源以及CpGDNA刺激后体内IL-6基因表达的动力学,对BALB/c小鼠静脉内注射CpG或非CpG S-ODN,并在刺激后的不同时间点从肝、脾、胸腺和骨髓提取RNA。如图3A所示,注射CpG S-ODN后30分钟内,在肝、脾、和胸腺内的IL-6mRNA水平提高。肝内IL-6mRNA在注射后2小时达到峰值,随后迅速下降并在刺激后8小时回复到基础水平(图3A)。脾内IL-6 mRNA在刺激后2小时达到峰值,然后逐渐降低(图3A)。胸腺内IL-6mRNA在注射后1小时达到峰值,然后逐渐降低(图3A)。在注射CpG S-ODN后1小时内,骨髓内IL-6 mRAN明显提高,然后恢复到基础水平。作为对CpG S-ODN的应答,肝、脾和胸腺显示IL-6 mRNA表达的提高明显高于骨髓。
CpG DNA诱导的小鼠细胞因子表达的形式
在体内或在全脾细胞中,在最初的6个小时内,下列的白细胞介素IL-2、IL-3、IL-4、IL-5或IL-10都没有检测到其蛋白质水平的显著提高[Ilinman,D.M.et al.,(1996)Proc.Natl.Acad.Sci.USA 93:2879-2883]。然而,在注射CpG ODN的小鼠血清中,TNF-α的水平在30分钟内提高,IL-6的水平在2小时内显著地升高。在脾细胞中,在首先的2小时内也检测到IL-12和γ-干扰素(IFN-γ)mRNA的表达提高。
表5.CpG寡核苷酸诱导人PBMC细胞因子的分泌
ODN | 序列(5′-3′) | IL-61 | TNF-α1 | IFN-γ1 | GM-CSF | IL-12 |
512SEQ ID NO:31 | TCCATGTCGGTCCTGATGCT | 500 | 140 | 15.6 | 70 | 250 |
1637SEQ ID NO:38 | ■■■■■■C■■■■■■■■■■■■■ | 550 | 16 | 7.8 | 15.6 | 16 |
1615SEQ ID NO:39 | ■■■■■■G■■■■■■■■■■■■■ | 600 | 145 | 7.8 | 45 | 145 |
1614SEQ ID NO:40 | ■■■■■■A■■■■■■■■■■■■■ | 550 | 31 | 0 | 50 | 31 |
1636SEQ ID NO:41 | ■■■■■■■■■A■■■■■■■■■■ | 325 | 250 | 35 | 40 | 250 |
1634SEQ ID NO:42 | ■■■■■■■■■C■■■■■■■■■■ | 300 | 400 | 40 | 85 | 400 |
1619SEQ ID NO:43 | ■■■■■■■■■T■■■■■■■■■■ | 275 | 450 | 200 | 80 | 450 |
1618SEQ ID NO:44 | ■■■■■■A■■T■■■■■■■■■■ | 300 | 60 | 15.6 | 15.6 | 62 |
1639SEQ ID NO:45 | ■■■■■AA■■T■■■■■■■■■■ | 625 | 220 | 15.6 | 40 | 220 |
1707SEQ ID NO:46 | ■■■■■■A■■TC■■■■■■■■■ | 300 | 70 | 17 | 0 | 70 |
1708SEQ ID NO:47 | ■■■■■CA■■TG■■■■■■■■■ | 270 | 10 | 17 | ND | 10 |
黑点代表相同,CpG二核苷酸用下划线标出。
1由ELISA测定,采用了来自R&D System的Quantikine试剂盒(pg/ml)。在收集上清液和检测前,细胞培养在10%自身血清并加以给出剂量的寡脱氧核苷酸(12μg/ml),对TNF-α为4小时,对其它的细胞因子为24小时。数据代表相对于没有加入寡脱氧核苷酸的小孔而言细胞因子的提高水平。
CpG DNA诱导的人PBMC,特别是单核细胞的细胞因子分泌
采用了与研究小鼠细胞因子表达的同一组ODN,来确定人细胞是否也被CpG基元诱导表达细胞因子(或增殖),并确定有关的CpG基元。寡核苷酸1619(GTCGTT)是TNF-α和IFN-γ分泌的最好的诱导物,寡核苷酸1634中与其几乎相同的基元(GTCGCT)则紧随其后(表5)。在寡脱氧核苷酸1637和1614中的基元(GCCGGT和GACGGT)导致强烈的IL-6分泌,但对其它的细胞因子则相对没有诱导。因此,似乎人淋巴细胞同小鼠淋巴细胞一样,应答于CpG二核苷酸有差异地而分泌细胞因子,具体由其周围的碱基所决定。然而,对刺激小鼠细胞为最好的基元则不同于对人细胞最有效的基元。某些CpG寡脱氧核苷酸对活化人细胞是很差的(寡脱氧核苷酸1707、1708,它们分别含有形成回文的序列GACGTC和CACGTG)。
对DNA应答的细胞似乎是单核细胞,因为用L-亮氨酰-亮氨酸甲基酯(L-LME)处理细胞可以消除细胞因子的分泌,该物质对单核细胞有选择性毒性(对细胞毒性T淋巴细胞和NK细胞也有选择性毒性),并不影响B细胞的Ig分泌(表6)。经过L-LME处理而存活的细胞用锥虫蓝排斥法检测到有>95%的存活率,这表明,这些细胞缺少细胞因子应答并不简单反映所有细胞类型的非特异性死亡。应答大肠杆菌(EC)DNA的细胞因子分泌需要未甲基化CpG基元,因为EC DNA甲基化消除了这种作用(表6中倒数第二行)。LPS对DNA的污染并不能解释这些结果,因为在天然的和甲基化的DNA中污染水平是相同的,而且,加入两倍最高水平的污染LPS也没有产生效应(未示出)。
表6.CpG DNA诱导人PBMC的细胞因子分泌
DNA | TNF-α(pg/ml)1 | IL-6(pg/ml) | IFN-γ(pg/ml) | RANTES(pg/ml) |
EC DNA(50μg/ml) | 900 | 12,000 | 700 | 1560 |
EC DNA(5μg/ml) | 850 | 11,000 | 400 | 750 |
EC DNA(0.5μg/ml) | 500 | ND | 200 | 0 |
EC DNA(0.05μg/ml) | 62.5 | 10,000 | 15.6 | 0 |
EC DNA(50μg/ml)+L-LME2 | 0 | ND | ND | ND |
EC DNA(10μg/ml)Methyl3 | 0 | 5 | ND | ND |
CT DNA(50μg/ml) | 0 | 600 | 0 | 0 |
1所有细胞因子的水平都用ELISA进行测定,采用的是R&D Systems的Quantikine试剂盒,如同前面的表中描述的一样。结果代表从不同供体来的PBMC的情况。
2对细胞用L-亮氨酰-L-亮氨酸甲基酯(M-LME)预处理15分钟,以确定在这样的条件下细胞因子的产生是否是来自单核细胞(或来自于其它的对L-LME敏感的细胞)。
3按照生产商的指示,对大肠杆菌DNA用2U/μg DNA的CpG甲基化酶(New England Biolabs)甲基化,以HpA-II和Msp-I酶解来确认甲基化。作为阴性对照,包括了含有在该实验条件下不能诱导可检测细胞因子生产的最高浓度大肠杆菌DNA中包含的最大量LPS两倍水平的样品。
ND=未进行。
用L-LME处理的PBMC中细胞因子生产的丧失这个现象暗示单核细胞也许对应答CpG DNA的细胞因子生产负责。为了更直接地验证这个假设,测试了CpG DNA对高度纯化的人单核细胞和巨噬细胞的效果。如同所假设的那样,CpG DNA直接活化人巨噬细胞对细胞因子IL-6、GM-CSF和TNF-α的生产,而非CpG DNA则不能(表7)。
表7.CpG DNA诱导纯化的人巨噬细胞中细胞因子的表达
IL-6(pg/ml) | GM-CSF(pg/ml) | TNF-α(pg/ml) | |
仅有细胞 | 0 | 0 | 0 |
CT DNA(50μg/ml) | 0 | 0 | 0 |
EC DNA(50μg/ml) | 2000 | 15.6 | 1000 |
IL-6在应答于CpG基元而诱导小鼠IgM生产中的生物学作
用
上述的动力学研究揭示了在CpG刺激后1小时内发生的IL-6分泌的诱导早于IgM分泌。因为对ODN诱导IL-6分泌的最佳CpG基元与IgM的一样(表2),所以检测了CpG基元是否独立诱导IgM和IL-6生产,或者IgM的生产依赖于早前的IL-6分泌。加入中和性抗-IL-6抗体抑制了由CpG ODN介导的剂量依赖型的体外IgM生产,但是对照抗体则不能(图4A)。相对照的是,加入IL-6则没有影响B细胞增殖的基础水平能够和CpG诱导的B细胞增殖(图4B)。
应答CpG DNA的IL-6启动子的转录活性提高
用CpG DNA刺激后的IL-6mRNA和蛋白质水平的提高可以是由于转录调节或转录后调节的结果。为了确定IL-6启动子的转录活性是否在与CpG ODN一起培养的B细胞中被上调,用IL-6启动子-CAT构建物(pIL-6/CAT)(Pottratz,S.T.etal.,17B-estradio Inhibits expression of humaninterleuking-6-promoter-reporter constructs by areceptor-dependent mechanism.J.Clin.Invest.93:944)转染应答CpG DNA产生IL-6的小鼠B细胞系WEHI-231,在用各种浓度的CpG或非CpG ODN刺激后进行CAT检测。如图5所示,CpG ODN诱导的CAT活性的提高是剂量依赖型的,而非CpGODN则没有诱导CAT活性。这就肯定了CpG诱导IL-6启动子的转录活性。
CpG ODN的B细胞活化对5′和3′硫代磷酸酯核苷酸间连键数
目的依赖性
为了确定ODN主链上的部分硫修饰是否足以提高B细胞的活化,测试了一系列具有相同的序列但在5′和3′端的S核苷酸间连键数目不同的ODN的效果。根据以前的对核酸酶降解ODN的研究,已确定需要在ODN的5′端有至少两个硫代磷酸酯连键才可以最佳地保护ODN不被细胞内外切核酸酶和内切核酸酶所降解。因此,只对含有两个5′硫代磷酸酯修饰的连键以及可变数目的3′修饰连键的嵌合性ODN进行了检测。
测试了这些ODN的淋巴细胞刺激效果,其中使用了三种浓度(3.3,10,和30μM),方法是测定在处理过的脾细胞培养物中RNA合成(由3H尿苷掺入)或DNA合成(有3H胸苷掺入)总水平(实施例10)。带有CpG基元的O-ODN(0/0硫代磷酸酯修饰)对脾细胞没有刺激,除非以的浓度至少10μM加入培养基中(实施例10)。然而,当这个序列在5′端被两个S连接修饰和在3′端被至少3个S连接修饰时,则在3.3μM的剂量时有显著的刺激表现出来。在这种低剂量的条件下,随着3′端被修饰碱基数目的增加,刺激水平显示逐渐增加,直到这种碱基数达到或超过6个,此时刺激指数开始下降。一般地讲,对脾细胞刺激的最佳3′S连键数目为5。在这些实验中测试的所有3种浓度中,S-ODN都比最佳嵌合性化合物的刺激性小。
CpG介导的淋巴细胞活化对主链修饰类型的依赖性
硫代磷酸酯修饰的ODN(S-ODN)比磷酸二酯修饰的ODN(O-ODN)具有远远更强的核酸酶抗性。因此,由S-ODN和S-O-ODN(即,嵌合性硫代磷酸酯ODN,其中的中央连键是磷酸二酯,但有2个5′和5个3′连键是硫代磷酸酯修饰的)所造成的比O-ODN更高的免疫刺激可能是前者对核酸酶的抗性的结果。为了确定ODN核酸酶抗性在CpG ODN的免疫刺激中的作用,测试了嵌合性ODN的刺激效果,在这些ODN中它们的5′端和3′端都因具有甲基膦酸酯(MP-)、甲基硫代磷酸酯(MPS-)硫代磷酸酯(S-)、或二硫代磷酸酯(S2-)核苷酸间连键变得有核酸酶抗性(实施例10)。这些研究显示,无论它们的核酸酶抗性如何,MP-O-ODN实际上都比O-ODN的免疫刺激性低。然而,通过用5′和3′MPS核苷酸间连键取代两个非桥连O分子而将MP和S的修饰结合起来,使得免疫刺激的水平恢复到稍微高于O-ODN所刺激的水平。
S-O-ODN比O-ODN具有远远更高的刺激性,甚至比S-ODN更具有刺激性,至少在高于3.3μM浓度时如此。在低于3μM浓度时,带有3M序列的S-ODN比相应的S-O-ODN更具刺激性,而带有3D序列的S-ODN则比相应的S-O-ODN的刺激性弱(实施例10)。在比较这两个序列的刺激性CpG基元时,注意到了3D序列与侧翼为2个5′嘌呤和2个3′嘧啶的CpG这样的基元完全吻合。然而,在ODN 3D中紧靠CpG的侧翼碱基不是优化的,其具有5′嘧啶和3′嘌呤。根据进一步的试验,发现免疫刺激所需要的序列对S-ODN比对S-O-ODN和O-ODN更为严谨。与优化CpG基元吻合性差的S-ODN对淋巴细胞的活化没有刺激或很小(例如,序列3D)。然而,与该基元吻合很好的S-ODN,特别是在紧靠CpG的侧翼位置,都比相应的S-O-ODN更具有刺激性(例如,序列3M,序列4和6),虽然在高浓度(大于3μM)时的峰值效应是S-O-ODN更强(实施例10)。
S2-O-ODN具有显著的刺激性,并且在每个测试浓度都引起比相应S-ODN或S-O-ODN显著更强烈的淋巴细胞活化。
在带有S或S2取代的CpG ODN中所见到的对B细胞刺激的升高可能是下述一种或所有效应所致:核酸酶抗性、增强的细胞摄入、增强的蛋白质结合和改变了的细胞内定位。然而,核酸酶抗性不会是唯一的解释,因为MP-O-ODN实际上比带有CpG基元的O-ODN的刺激性低。以前的研究已经显示淋巴细胞对ODN的吸收明显地受到主链化学结构的影响[Zhao etal.,(1993)Comparison of cellular binding and uptake ofantisense phosphodiester,phosphorothioate,and mixedphosphorethioate and methylphosphonate olignucleotides.(Andisense Research and Development 3,53-66;Zhao et al.,(1994)Stage specific oligonucleotide uptake in murine bonemarrow B cell precursors.Blood 84,3660-36666.)]。S-ODN有最高细胞膜结合和摄入,随后是S-O-ODN,O-ODN和MP-ODN。这种摄入的区别与免疫刺激的程度非常相关。
含有未甲基化CpG的寡核苷酸具有NK细胞刺激活性
为了确定含有CpG的寡核苷酸除了刺激B细胞外是否还对天然杀伤细胞(NK)具有刺激活性,进行了各种实验。如表8所示,用CpG ODN 1和3Dd培养的脾细胞中有明显的NK活性的诱导。相比之下,已用非CpG对照ODN处理的效应物中相对没有诱导。
表8.CpG寡核苷酸(ODN)诱导的NK活性
含有CpG基元的DNA诱导的NK活性,而非CpG DNA则不
会
在37℃下对细菌DNA培养18小时,然后测定杀死K562(人)或Yac-1(小鼠)靶细胞在去除了B细胞的小鼠脾细胞中和在人PBMC细胞中诱导NK裂解活性,但是,脊椎动物的DNA没有这种效果(表9)。为了确定细菌DNA的刺激活性是否归因于其未甲基化CpG二核苷酸水平的提高,对含有未甲基化CpG二核苷酸、甲基化CpG二核苷酸、或没有CpG二核苷酸的50种以上的合成性ODN的活化性质进行了测验。结果如表9所示,显示了合成的ODN可以显著地刺激NK活性,只要它们含有至少一个未甲基化CpG二核苷酸即可。在CpG处于回文序列中的ODN(例如ODN1585,其含有回文序列AACGTT)与没有回文序列的ODN(例如ODN1613或1619)之间没有观察到明显的刺激效果差异,要注意的是,最佳的刺激一般见于那些CpG侧翼为2个5′嘌呤或5′GpT二核苷酸和2个3′嘧啶的ODN中。动力学实验表明NK活性的峰值出现在加入OND后的约18小时之时。数据指示小鼠NK应答依赖于在先的CpG DNA对单核细胞的活化,导致IL-12、THF-α、和IFN-α/b的产生(实施例11)。
表9.含有CpG基元的DNA诱导NK活性,而非CpG DNA则
没有
在ODN序列中的CpG二核苷酸用下划线标出;Z代表甲基胞嘧啶。小写字母代表被核酸酶抗性的硫代磷酸酯修饰的核苷酸间连键,其在效价实验中显示了比非修饰的ODN强20倍以上,具体根据侧翼碱基而定。在某些ODN中采用多G末端(g),因为它们显著地提高了ODN摄入水平。
从所有这些研究中,得到了对CpG DNA的免疫效应的更为全面的理解,并将其总结于图6中。
CpG基元的免疫活化可能依赖于CpG侧翼的碱基,在ODN中存在的CpG的数量和间隔。虽然在理想的碱基环境下单一CpG可以是非常强和有用的免疫活化子,但在含有几个CpG并具有适宜的侧翼碱基和间隔的ODN中能见到更为优越的效果。对鼠B细胞的活化来讲,最佳的CpG基元是TGACGTT。
下面所进行的研究通过检验改变CpG二核苷酸的数目、间隔和侧翼碱基的效果而确定对刺激人细胞为最佳的ODN序列。
确定带有用于活化人NK细胞的最佳CpG基元的硫代磷酸酯
ODN
要想应用于临床,则ODN必须以受到保护而不被核酸酶降解的形式施用给受试者。用磷酸二酯ODN来达到这个目的的方法是本领域所熟知的,包括将其包被在脂质中或在递送系统中,例如,在纳米颗粒中。这种保护还可以利用对DNA的化学取代来达到,例如被修饰的DNA主链,包括核苷酸间连键为抗核酸酶的那些。有些修饰可以赋予另外的所需性质,例如提高细胞吸收。例如,磷酸二酯连键可以通过用硫替代非桥连氧原子中的一个来进行修饰,其构成硫代磷酸酯DNA。如果硫代磷酸酯DNA具有CpG基元,则其具有增强的细胞摄入(Krieg et al.,Antisense Res.Dev.6:133,1996)和改善的B细胞刺激。因为NK活化与体内佐剂效应强烈相关,所以确定那些可以活化人NK细胞的硫代磷酸酯ODN是十分重要的。
检验了不同的硫代磷酸酯ODNs-在各种碱基环境下含有CpG二核苷酸-对人NK细胞活化的效果(表10)。ODN 1840含有2拷贝的TGTCGTT基元,具有显著的NK裂解活性(表10)。为了进一步确定其它的对NK活化最佳的ODN,对大约100种含有不同数目和间隔的CpG基元的ODN进行了检测,并以ODN 1982作为对照。结果列于表11。
有效的ODNs以TC或TG作为5′端开始,然而,这个要求不是必须的。带有内部CpG基元的ODNs(例如,ODN 1840)一般是比其中GTCGCT基元紧接着5′TC的ODN更弱的刺激物(例如,ODN 1967和1968)。ODN 1968在其3′部分具有第二个GTCGTT基元,其始终比不含该第二个基元的ODN 1967更具有刺激性。然而,ODN 1967在实验1和3中比ODN 1968稍强,在实验2中则不是。ODN 2005具有第三个GTCGTT基元,其所诱导的NK活性平均比1968稍高。然而,由于在每个基元之间都加入了两个T而增加了各GTCGTT基元之间的间隔的ODN2006比ODN 2005和ODN 2007更为优越,后者只有一个基元添加了间隔性的2个T。在CpG基元之间的最小可接受的间隔是一个核苷酸,只要该ODN在3′有两个嘧啶(优选T)即可(如ODN 2015)。令人惊奇的是,用5′的T来把两个GTCGTT基元尾尾连接起来也创造了NK活性的合理强度的诱导物(例如,ODN 2016)。选择胸腺嘧啶(T)来分开相连的CpG二核苷酸不是绝对的,因为ODN 2002诱导相当的NK活化,虽然其中是由腺嘌呤(A)将其CpGs(即CGACGTT)间隔开来。还应该注意的是,不含CpG的ODN(例如ODN 1982),含有成串的CpGs的ODN,以及CpGs存在于坏序列环境中的ODN(例如,ODN 2010)都没有对NK活化的刺激效应。
表10.ODN诱导NK裂解活性(LU)
ODN | 序列(5′-3′) | LU |
仅有细胞 | 0.01 | |
1754 | ACCATGGACGATCTGTTTCCCCTC | 0.02 |
1758 | TCTCCCAGCGTGCGCCAT | 0.05 |
1761 | TACCGCGTGCGACCCTCT | 0.05 |
1776 | ACCATGGACGAACTGTTTCCCCTC | 0.03 |
1777 | ACCATGGACGAGCTGTTTCCCCTC | 0.05 |
1778 | ACCATGGACGACCTGTTTCCCCTC | 0.01 |
1779 | ACCATGGACGTACTGTTTCCCCTC | 0.02 |
1780 | ACCATGGACGGTCTGTTTCCCCTC | 0.29 |
1781 | ACCATGGACGTTCTGTTTCCCCTC | 0.38 |
1823 | GCATGACGTTGAGCT | 0.08 |
1824 | CACGTTGAGGGGCAT | 0.01 |
1825 | CTGCTGAGACTGGAG | 0.01 |
1828 | TCAGCGTGCGCC | 0.01 |
1829 | ATGACGTTCCTGACGTT | 0.42 |
18302 | 随机序列 | 0.25 |
1834 | TCTCCCAGCGGGCGCAT | 0.00 |
1836 | TCTCCCAGCGCGCGCCAT | 0.46 |
1840 | TCCATGTCGTTCCTGTCGTT | 2.70 |
1841 | TCCATAGCGTTCCTAGCGTT | 1.45 |
1842 | TCGTCGCTGTCTCCGCTTCTT | 0.06 |
1851 | TCCTGACGTTCCTGACGTT | 2.32 |
1裂解单位(LU)按照所述(8)进行。简言之,从正常的供体收集PBMC,用Ficoll离心,然后采用或不采用所示ODN(向培养物中加入的剂量为6μg/ml)培养24小时。然后确定它们的对51Cr-标记的K562细胞的裂解能力。给出的结果是从几个不同的正常人供体获得的典型的结果。2该寡核苷酸混合物含有在每个位置上从所有4种碱基中随机选择的碱基。
表11.带有良好基元的硫代磷酸酯CpG ODN诱导NK
LU
ODN1 | 序列(5′-3′) | 实验1 | 实验2 | 实验3 |
仅有细胞 | 0.00 | 1.26 | 0.46 | |
1840 | TCCATGTCGTTCCTGTCGTT | 2.33 | ND | ND |
1960 | TCCTGTCGTTCCTGTCGTT | ND | 0.48 | 8.99 |
1961 | TCCATGTCGTTTTTGTCGTT | 4.03 | 1.23 | 5.08 |
1962 | TCCTGTCGTTCCTTGTCGTT | ND | 1.60 | 5.74 |
1963 | TCCTTGTCGTTCCTGTCGTT | 3.42 | ND | ND |
1965 | TCCTGTCGTTTTTTGTCGTT | 0.46 | 0.42 | 3.48 |
1966 | TCGTCGCTGTCTCCGCTTCTT | 2.62 | ND | ND |
1967 | TCGTCGCTGTCTGCCCTTCTT | 5.82 | 1.64 | 8.32 |
1968 | TCGTCGCTGTTGTCGTTTCTT | 3.77 | 5.26 | 6.12 |
19792 | TCCATGTZGTTCCTGTZGTT | 1.32 | ND | ND |
1982 | TCCAGGACTTCTCTCAGGTT | 0.05 | ND | 0.98 |
1990 | TCCATGCGTGCGTGCGTTTT | 2.10 | ND | ND |
1991 | TCCATGCGTTGCGTTGCGTT | 0.89 | ND | ND |
2002 | TCCACGACGTTTTCGACGTT | 4.02 | 1.31 | 9.79 |
2005 | TCGTCGTTGTCGTTGTCGTT | ND | 4.22 | 12.75 |
2006 | TCGTCGTTTTGTCGTTTTGTCGTT | ND | 6.17 | 12.82 |
2007 | TCGTCGTTGTCGTTTTGTCGTT | ND | 2.68 | 9.66 |
2008 | GCGTGCGTTGTCGTTGTCGTT | ND | 1.37 | 8.15 |
2010 | GCGGCGGGCGGCGCGCGCCC | ND | 0.01 | 0.05 |
2012 | TGTCGTTTGTCGTTTGTCGTT | ND | 2.02 | 11.61 |
2013 | TGTCGTTGTCGTTGTCGTTGTCGTT | ND | 0.56 | 5.22 |
2014 | TGTCGTTGTCGTTGTCGTT | ND | 5.74 | 10.89 |
2015 | TCGTCGTCGTCGTT | ND | 4.53 | 10.13 |
2016 | TGTCGTTGTCGTT | ND | 6.54 | 8.06 |
1PBMC基本如本文所述。结果是6个分别的实验的代表;每个实验代表不同的供体。2这是甲基化形式的ODN 1840;Z=5-甲基胞嘧啶,LU是裂解单位,ND=未进行,CpG二核苷酸用下划线标出。
确定带有人B细胞增殖活化的最佳CpG基元的硫代磷酸酯
ODN
CpG ODN诱导B细胞增殖的能力是其佐剂潜力的良好指标。具有强佐剂效应的ODN确实一般都诱导B细胞增殖。为了确定由于诱导B细胞增殖的最佳CpG ODN是否与诱导NK细胞活性的ODN相同,测试了相似的一组ODN(表12)。表现出最为一致的刺激性的ODN是ODN 2006(表12)。
表12.硫代磷酸酯CpG ODN对人B细胞增殖的诱导
1细胞=手术中收集的并储存于-70℃的人脾细胞,或从正常供体采集的并经过Ficoll离心的PBMC细胞。细胞培养在96孔U底微滴板上,其中加入或不加入所示的ODN(向培养物中加入的剂量为6μml)。N=12个实验。细胞培养4-7天,用1μCi的3H胸苷脉冲18小时,然后收获并闪烁计数。刺激指数=不加入ODN的小孔中的cpm与在整个培养过程中用所示ODN刺激的小孔的cpm的比率(一旦建立培养物后就没有再进一步加入ODN)。ND=未进行。
确定诱导人IL-12分泌的硫代磷酸酯ODN
CpG ODN诱导IL-12分泌的能力是其佐剂潜力的良好指标,特别从其诱导Th1免疫应答这种高度依赖IL-12的能力的角度来讲更是如此。因此,检验了某一组硫代磷酸酯ODN诱导人PBMC体外分泌IL-12的能力(表13)。这些实验显示,在某些人PBMC细胞中,大多数CpG ODN可以诱导IL-12的分泌(例如,实验1)。然而,其它的供体只应答少数的CpG ODN(例如,实验2)。ODN 2006是大多数受试者中IL-12分泌的一致诱导物(表13)。
表13.硫代磷酸酯CpG ODN诱导人IL-12分泌
1PBMC采集于正常供体并用Ficoll离心,然后以106细胞/孔培养在96孔微滴板中,其中加入或不加入所示的ODN,如果在培养物中加入ODN,其剂量为6μg/ml。24小时后收获上清液,用ELISA如方法部分所述检测IL-12的水平。对每个实验建立标准曲线,其代表不同的供体。
确定B细胞和单核细胞/NK细胞特异性的寡核苷酸
如图6所示,CpG DNA可以直接活化高度纯化的B细胞和单核细胞。CpG DNA活化这些种类细胞的机制中有很多相似之处。例如,两者都需要NFkB活化,对此在下面给予进一步解释。
在对CpG DNA的不同免疫效应的进一步研究中,发现有多于一种类型的CpG基元。具体地讲,寡核苷酸1668带有最佳的小鼠B细胞基元,它是B细胞和天然杀伤细胞(NK)活化的强诱导物,而寡核苷酸1758是B细胞的弱活化物,但仍然诱导很好的NK应答(表14)。
表14.不同的CpG基元刺激最佳的小鼠B细胞和NK活
化
ODN | 序列 | B细胞活化1 | NK活化2 |
1668 | TCCATGACGTTCCTGATGCT(SEQ ID NO:44) | 42,849 | 2.52 |
1758 | TCTCCCAGCGTGCGCCAT(SEQ ID NO:55) | 1,747 | 6.66 |
无 | 367 | 0.00 |
CpG二核苷酸用下划线标出,寡核苷酸是合成的,并有硫代磷酸酯修饰的主链,以改善其核酸酶抗性。1按照实施例1所述,用200nM浓度的寡脱氧核苷酸培养48小时后的3H胸苷摄入来进行测定。2按照裂解单位来测定。
免疫刺激性核酸的目的论基础
脊椎动物DNA是高度甲基化的,并且CpG二核苷酸是不足表达的。然而,刺激性CpG基元在微生物基因组DNA中是常见的,但是在脊椎动物DNA中就很少见。此外,细菌DNA已经被报道可以诱导B细胞增殖和免疫球蛋白(Ig)的生产,而哺乳动物DNA则不行[Messina,J.P.et al.,J.Immunol.147:1759(1991)]。在实施例3中进一步描述的实验中,用CpG甲基化酶对细菌DNA的甲基化被发现可消除促细胞分裂原性,这就证实了CpG状态的差异是细菌DNA引起B细胞刺激的原因。这个数据支持了下面的结论:即存在于细菌DNA中的未甲基化CpG二核苷酸负责了细菌DNA的刺激效应。
就目的论而言,看起来CpG基元造成的淋巴细胞活化代表了免疫防御机制,其可以区分细菌DNA和宿主DNA。宿主DNA由于编程性细胞死亡而普遍存在于很多发炎的解剖学组织和区域中,但它通常不诱导或很少诱导淋巴细胞活化,因为存在CpG抑制和甲基化。然而,含有未甲基化CpG基元的细菌DNA的存在可以准确地在感染的解剖学区域引起淋巴细胞活化,这则是有益的。这种新的活化途径提供了T细胞依赖性抗原特异性B细胞活化的快速替代途径。由于CpG途径通过抗原受体与B细胞活化相协同,带有细菌抗原特异性的抗原受体的B细胞将通过其细胞膜Ig接受一个活化信号以及从细菌DNA来的第二个信号,并从而倾向于有区分地被活化。这个途径与其它的B细胞活化途径的相互关系提供了使用多克隆抗原来诱导抗原特异性应答的生理学机制。
然而,B细胞活化似乎不是完全非特异性的。带有细菌产物特异性的抗原受体的B细胞可以通过细胞膜Ig接受一个活化信号,以及从细菌DNA来的第二信号,从而更强烈地启动抗原特异性免疫应答。如同其它的免疫防御机制,对细菌DNA的应答可能在某些环境下具有不期望的后果。例如,对自身抗原的自身免疫应答也将倾向于由细菌感染优先刺激,因为自身抗原还可以向由细菌DNA刺激的自身反应性B细胞提供第二活化信号。确实,细菌感染对自身免疫的诱导是临床观察中常见的。例如,自身免疫性疾病系统性红斑狼疮,其本身是1)以产生抗-DNA抗体为特征,2)由抑制DNA甲基转移酶的药物所诱导[Cornacchia,E.J.et al.,J.Clin.Invest.92:38(1993)],以及3)与降低的DNA甲基化有关[Richardson,B.,L.et al.,Arth.Rheum35:647(1992)],所以,它可能至少部分地由DNA特异性B细胞通过由CpG基元提供的刺激信号的活化来启动,以及细菌DNA同抗原受体的结合来启动。
此外,特征在于对免疫系统的大量非特异性活化而导致高度发病率和死亡率的脓毒病,可能由从死亡细菌释放后的、达到足以直接活化许多淋巴细胞的浓度的细菌DNA和其它产物来启动。脓毒病综合症中CpG DNA作用的进一步证据可见于Cowdery,J.等人的文献[Cowdery,J.,et al.,(1996)The Journalof Immunolgy 156:4570-4575]。
与通过其表面Ig受体来刺激B细胞的抗原不同的是,CpG-ODN不诱导任何可检测到的Ca2+流,蛋白质酪氨酸磷酸化的改变,或IP3的产生。以带有或不带有CpG基元的缀合FITC的ODN进行的流式细胞术按照Zhao,Q等人所述进行[Antisense Research and Development 3:53-66(1993)],其中显示了相等的膜结合,细胞摄入,外流,以及胞内定位。这就暗示也许不存在对CpG ODN特异的细胞膜蛋白质。不同于经过细胞膜来起作用,这些数据暗示的是含有未甲基化CpG的寡核苷酸需要细胞摄入来发挥活性:与固体Teflon支持物共价连接的ODN是非刺激性的,在抗生物素蛋白小珠或抗生物素蛋白涂布的培养皿上固定化的生物素化ODN也一样。与FITC或生物素缀合的CpG ODN保留了全部的促细胞分裂性质,表明没有立体阻碍。
最近的数据表明,转录因子NFkB作为CpG效应的直接或间接介导物而介入其中。例如,用CpG DNA处理B细胞或单核细胞15分钟内,NFkB结合活性的水平被提高了(图7)。然而,那些不含CpG基元的DNA不能引起这种提高。此外,还发现的是,NFkB活化的两个不同的抑制物,即PDTC和胶毒素,完全封闭了CpG DNA对淋巴细胞的刺激,正如B细胞增殖或单核细胞的细胞因子分泌的测定所显示的,这暗示两种细胞类型都需要NFkB活化。
NFkB能够被活化的机制可能有几种。它们包括通过对各种蛋白质激酶的活化,或通过反应性氧类的产生。没有发现在CpG DNA处理B细胞或单核细胞后立即诱导蛋白质激酶活化的任何证据,而且蛋白质激酶A、蛋白质激酶C,以及蛋白质酪氨酸激酶的抑制物都对CpG诱导的活化没有任何影响。然而,CpG DNA在B细胞和单核细胞中都快速诱导反应性氧类的生产,如按照Royall,J.A.和Ischiropoulos,H.(Archives ofBiochemistry and Biophysics 302:348-355(1993))所述用敏感性荧光染料二氢若丹明123检测所证实的。然而,这些反应性氧类产生的抑制物完全封闭了NFkB的诱导以及随后的CpGDNA对细胞增殖和细胞因子分泌的诱导。
下一个问题是,CpG DNA如何快速地导致了反应性氧的产生。本发明人的先前的研究证实了寡核苷酸和质粒或细菌DNA被细胞摄入到内体中。这些内体迅速地在细胞内被酸化。为了确定这个酸化步骤是否在CpG DNA活化反应性氧类的机制中起重要作用,用内体酸化的特异性抑制物封闭该酸化步骤,包括氯喹、莫能菌素、和bafilomycin等,它们通过不同的机制工作。图8A显示了流式细胞术的研究结果,其中采用了小鼠B细胞以及二氢若丹明123染料来确定反应性氧类的水平。该图内A小图中仅仅含有染料的样品显示了细胞对染料的阳性背景水平为28.6%。正如所预期的,反应性氧类的这个水平在用PMA和离子霉素处理20分钟的细胞(即阳性对照)内被大大地提高到80%(B小图)。用CpG寡核苷酸处理的细胞也显示反应性氧类型水平的提高,使大于50%的细胞变为阳性(D小图)。然而,用除了CpG被改变之外序列完全相同的寡核苷酸处理的细胞没有显示反应性氧类型水平的这种显著提高(E小图)。
在有氯喹存在时,这些结果非常不同(图8B)。氯喹将细胞中反应性氧类型的背景水平稍微的降低了一些,使A小图中的未处理细胞只有4.3%为阳性。氯喹完全消除了用CpG DNA处理的细胞中的反应性氧类型的诱导(B小图),但是对用PMA和离子霉素处理的细胞中反应性氧类型的水平没有减弱(E组)。这就证明,与PMA加上离子霉素不同,用CpG DNA处理B细胞后反应性氧类型的产生需要DNA在内体中经历酸化步骤。这是淋巴细胞活化的全新的机制。氯喹、莫能菌素、以及bafilomycin还似乎可以封闭CpG DNA对NFkB的活化,以及对随后的增殖和细胞因子分泌的诱导。
CpG DNA的慢性免疫活化以及自身免疫疾病
CpG DNA对B细胞的活化与通过B细胞受体的信号有协同作用。这就提出了这样的可能,即DNA特异性B细胞可能通过细菌DNA与其抗原受体的共同结合以及共刺激性的CpG介导的信号的刺激来活化。此外,CpG DNA诱导B细胞变为抗编程性细胞死亡的,这种机制被认为在防止对自身抗原如DNA的免疫应答中是重要的。确实,对bDNA的暴露可以启动抗-DNA的抗体的产生。既然CpG DNA具有促进自身免疫的这种潜在能力,那么值得注意的是,患有自身免疫疾病系统性红斑狼疮的患者都具有持续的升高水平的循环血浆DNA,其中富含低甲基化CpG。这个发现暗示在狼疮疾病发病机理中CpG DNA造成的慢性免疫活化所可能扮演的角色。
治疗狼疮疾病的一类有效药剂是抗疟疾药物,例如氯喹。虽然这些药物的治疗机制还不清楚,但是已知的是它们可抑制内体的酸化。CpG DNA对淋巴细胞的活化不是通过与细胞表面受体的结合所介导的,而是需要细胞吸摄入实现的,这种细胞摄入通过吸收性内吞到酸化的氯喹敏感性胞内区室而发生。这就暗示一种假说,即CpG DAN对淋巴细胞的活化可能与酸化的内体一起发生,并且甚至可能是依赖于pH的。为了检验这个假说,采用了DNA酸化的特异性抑制物来确定B细胞或单核细胞是否可能在酸化被抑制的条件下对CpG DNA产生应答。
被检测到的对CpG DNA应答的最早淋巴细胞活化现象是反应性氧类型(ROS)的产生,其在原代脾细胞以及B细胞和单核细胞中都是在5分钟内被诱导出来的。内体酸化的抑制物,包括氯喹、bafilomycin A,以及莫能菌素,它们具有不同的作用机制,可封闭CpG诱导的ROS产生,但是对由PMA、或者与CD40或IgM的连接等所介导的ROS的产生没有影响。这些研究显示,ROS的产生是通过多种途径的淋巴细胞活化中一种所共有的现象。这种ROS的产生一般不依赖于内体的酸化,而酸化仅仅是针对应答CpG DNA的ROS反应所需要的。应答CpG的ROS生产并不被NFkB抑制物胶霉毒素所抑制,确认其不是NFkB活化的继发现象。
为了确定CpG DNA的内体酸化是否也是其它免疫刺激效果所必需的,进行了各种实验。LPS和CpG DNA都诱导相似快速的NFκB活化,原癌基因mRNA水平的增加,以及细胞因子分泌。DNA对NFκB的活化依赖于CpG基元,因为其不被用CpG甲基酶处理的bDNA诱导,也不被其中碱基发生改变而破坏了CpG的ODN所诱导。采用特异性抗体的超迁移实验表明,被活化的NFκB复合物包括p50和p65组分。并非出人意料的是,在LPS或CpG处理的细胞中的NFκB活化伴随有IκBα和IκBβ的降解。然而,内体酸化的抑制物选择性地阻断了所有的CpG诱导的细胞活化现象,但没有抑制LPS诱导的任何细胞活化现象。值得注意的是,已经确定很低浓度的氯喹(<10μM)抑制了CpG介导的淋巴细胞活化,因为该剂量远远低于抗疟疾活性和其它被报道的免疫效应所需要的剂量(例如,100-1000μM)。这些实验支持了pH依赖性信号机制在介导CpG DNA的刺激效果中所起到的作用。
表15.内体酸化或NFkB活化的抑制物对CpG诱导的
TNF-α和IL-12表达的特异性阻断
表15图例说明了IL-2和TNF-α检测:小鼠单核细胞系J774(对IL-12为1×105细胞/毫升,对TNF-α为1×106细胞/毫升),在有给出浓度的所示抑制物或没有抑制物的条件下培养2小时,然后用2μM CpG 寡核苷酸(ODN)1826(TCCATGACGTTCCTGACGTT SEQ ID NO:10)或LPS(10μg/ml)刺激,对TNF-α为4小时,对IL-12为24小时,在此期间收集上清液。对上清液用ELISA检测IL-12或TNF-α(pg/ml),操作参见以前的文献[A.K.Krieg,A.-K.Yi,S.Matson,T.J.Waldschmidt,G.A.Bishop,R.Teasdale,G.Koretzky and D.Klinman,Nature 374,546(1995);Yi,A.-K.,D.M.Klinman,T.L.Martin,S.Matson and A.M.Krieg,J.Immunol,157:5394-5402(1996);Krieg,A.M.,J.Lab.Clin.Med.,128,128-133(1996)]。用不含有CpG基元的ODN培养的细胞没有诱导细胞因子的分泌。在IL-6的检测中也见到了相似的CpG应答的特异性抑制,也见于采用原代脾细胞或B细胞系CH12.LX和WEHI-231的实验中。2.5μg/ml氯喹相当于<5μM。NFkB活化的其它抑制物,包括PDTC和钙蛋白酶抑制物I和II,都给出了与所示抑制物相似的效果。给出的数据代表在10个不同的实验中所得到的结果。
CpG基元的过量免疫活化可能对自身免疫疾病系统性红斑狼疮的发病有作用,其伴随着升高水平的循环低甲基化CpGDNA。氯喹和有关的抗疟疾化合物是对系统性红斑狼疮和其它一些自身免疫疾病的有效治疗药物,虽然它们的作用机制尚不明了。我们对极低浓度氯喹特异性抑制CpG介导的淋巴细胞活化的能力的确定,暗示了其有益效果一种可能的新机制。值得注意的是,狼疮复发经常被认为是微生物感染启动的。在感染的组织中存在的bDNA水平可能足以诱导局部发炎应答。结合CpG DNA作为脓毒综合症和其它疾病的介导物的可能作用,我们的研究暗示作为内体酸化抑制物的抗疟疾药物的新型可能医药用途。
CpG诱导的ROS生产可能是细胞活化的偶然结果,或者是介导这种活化的信号。ROS的清除物N-乙酰基-L-半胱氨酸(NAC)可阻断CpG诱导的NFkB活化,细胞因子产生,以及B细胞增殖,暗示在这些途径中ROS生产的起因角色。这些数据与先前支持ROS在活化NFkB中的作用的证据相吻合。WEHI-231B细胞(5×105细胞/毫升)在有或没有氯喹[5μg/ml(<10μM)]或胶霉毒素(0.2μg/ml)条件下预培养30分钟。然后对细胞等份试样按照上述在RPMI培养基中培养10分钟,其中添加或不添加1μM CpG ODN(1826)或非CpG ODN(1911),或乙酸肉豆蔻佛波酯(phorbol myristate acetate,PMA)加离子霉素(iono),然后对细胞用二氢若丹明123染色并用流式细胞术分析胞内ROS的产生,具体操作按照以前所述的进行[A.K.Krieg,A.-K.Yi,S.Matson,T.J.Waldschmidt,G.A.Bishop,R.Teasdale,G.Koretzky and D.Klinman,Nature 374,546(1995);Yi,A.-K.,D.M.Klinman,T.L.Martin,S.Matson and A.M.Krieg,J.Immunol,157:5394-5402(1996);Krieg,A.M.,J.Lab.Clin.Med.,128,128-133(1996)]。J774细胞,一种单核细胞系,显示了相似的pH依赖性CpG诱导的ROS应答。与之相对照,CpG DNA没有诱导胞外ROS的产生,也没有任何可检测的嗜中性粒细胞ROS。氯喹的这些浓度(以及与其它内体酸化抑制物使用的那些浓度)使用荧光素缀合的ODN如Tonkinson等人所述证实了防止了内化CpG DNA的酸化[Tonkinson et al.,Nucl.Acids Res.22,4268(1994);A.M.Krieg,In:DeliveryStrategies for Antisense Oligonucleotide Therapeutics.Editor,S.Akhtar,CRC Press,Inc.,pp.177(1995)]。在高于抑制内体酸化所需的浓度下,观察到了非特异性的抑制效果。每个实验都进行至少三次并得到相似结果。
虽然已知NFkB对基因表达是重要的调节物,但其在对CpG DNA的转录应答中的作用却始终不清楚。为了确定是否这种NFkB活化是否是CpG介导的基因表达的诱导是必需的,在有或没有二硫代氨基甲酸吡咯烷(PDTC)这种IkB磷酸化抑制物存在的条件下用CpG DNA活化细胞。这些NFkB活化的抑制物完全阻断了CpG诱导的原癌基因和细胞因子mRNA和蛋白质的表达,显示NFkB在这些现象中作为介导物的基本作用。在这些研究中所用的实验条件下,没有任何一种抑制物减弱了细胞的生存力。J774,一种小鼠单核细胞系,在有5μg/ml小牛胸腺(CT)、大肠杆菌(EC)、或甲基化大肠杆菌(mEC)DNA(用CpG甲基化酶按照所述进行甲基化4)或者0.75μM的CpG寡核苷酸(ODN 1826,表15)或非CpGODN(TCCATGAGCTTCCTGAGTCT;ODN 1745)存在下培养1小时,然后,对细胞进行裂解,制备核酸提取物。对含有共有NFkB位点的双链ODN进行5′放射性标记,用作EMSA的探针,具体操作按照以前所述进行[J.D.Dignam,R.M.Lebovitz and R.G.Roeder,Nucliec Acids Res.11,1475(1983);M.Briskin,M.Damore,R.Law,G.Lee,P.W.Kincade,C.H.Sibley,M.Kuehl and R.W all,Mol.Cell.Biol.10,422(1990)]。p50/p65异二聚体的位置通过用p65和p50的特异性抗体以超变动方法确定[Santa Cruz Biotechnology,Santa Cruz,CA]。用J774细胞建立了氯喹对CpG诱导的但不是LPS诱导的NFkB活化的抑制。将细胞在有或没有氯喹(20μg/ml)存在的条件下预培养2小时,然后按照上述用EC DNA、CpG ODN、非CpGODN或LPS(1μg/ml)刺激1小时。在B细胞系WEHI-231和原代脾细胞中见到了相似的氯喹敏感性CpG诱导的NFkB活化。这些实验都进行三次,氯喹的浓度范围是2.5至20μg/ml,得到了相似的结果。
还明白了的是,CpG刺激的mRNA表达需要B细胞和单核细胞中的内体酸化以及NFkB活化。J774细胞(2×106细胞/毫升)在有或没有氯喹[2.5μg/ml(<5μM)]或N-甲苯磺酰基-L-苯丙氨酸氯甲酮(TPCK,50μM)这种丝氨酸/苏氨酸蛋白酶抑制物的存在下进行培养2小时,后者可防止IkB蛋白水解并因此阻断NFkB活化。然后对细胞进行刺激3小时,使用的是大肠杆菌DNA(EC,50μg/ml)、小牛胸腺DNA(CT,50μg/ml)、LPS(10μg/ml)、CpG ODN(1826,1μM)、或对照非CpGODN(1911,1μM)。WEHI-231B细胞(5×105细胞/毫升)在有或没有胶霉毒素(0.1μg/ml)或双胶霉毒素(0.1μg/ml)存在的条件下培养2小时,然后用CpG ODN(1826)或对照非CpGODN(1911,TCCAGGACTTTCCTCAGGTT)以0.5μM刺激8小时。在这两种情况下,细胞被收集后,用RNAzol按照厂商的说明书来制备RNA。进行多探针Rnase保护检测,操作按照以前所述的进行[A.-K.Yi,P.Hornbeck,D.E.Lafrenz andA.M.Krieg,J.Immunol.,157,4918-4925(1996)]。将可比量的RNA上样到每条泳道内,用核糖体μRNA作为上样对照(L32)。对这些实验重复三次,得到相似的结果。
这些结果表明,淋巴细胞对CpG DNA的应答是通过涉及胞内ROS的pH依赖性产生的新途径进行的。该依赖pH的步骤可能是CpG DNA的转运或加工步骤,ROS的产生,或某些其它事件。ROS被广泛地认为是多种类型细胞中的信号途径的第二信使,但是在此之前还没有被证明可以在B细胞中介导刺激性信号。
推测在内体之中或其附近有一种蛋白质,它特异性识别含有CpG基元的DNA,并导致反应性氧类型的产生。为了探测细胞的胞质中可能特异性结合CpG DNA的蛋白质,进行了电泳迁移率变动分析(EMSA),其中使用5′放射性标记的带有或不带有CpG基元的寡核苷酸。发现有一条带似乎代表与具有CpG基元的单链寡核苷酸特异性结合、但不与缺少CpG基元的寡核苷酸或含有已被甲基化了的CpG基元的寡核苷酸结合的蛋白质。这种结合活性在加入过量的含有NFkB结合位点的寡核苷酸时被封阻断。这就暗示NFkB或相关的蛋白质是与刺激性CpG寡核苷酸结合的蛋白质或蛋白质复合体的组成部分。
在NFkB被强烈活化的时间点没有发现CREB/ATF蛋白质的任何活化。因而,这些数据没有提供NFkB蛋白质实际上结合CpG核酸的证据,而是说明了CpG活性在某种方式上需要该蛋白质。可能的是,CREB/ATF或相关的蛋白质与NFkB蛋白质或其它的蛋白质以某种方式相互作用,这样可以解释CREB蛋白质的结合基元与最佳CpG基元之间显著的相似性。还可能的是寡核苷酸结合CREB/ATF或相关的蛋白质,并且这导致NFkB的活化。
另外,很可能的是,CpG核酸可以与TRAF蛋白质中的一种相结合,该蛋白质在CD40被交联时与CD40的胞质区结合,并介导NFkB活性。这样的TRAF蛋白质的例子包括TRAF-2和TRAF-5。
制备免疫刺激性核酸的方法
在本发明中,核酸可以使用本领域熟知的任何数目的方法从头合成。例如,可以采用b-氰乙基亚磷酰胺法[S.L.Beaucageand M.H.Caruthers,(1986)Tet.Let.22:1859],核苷H-膦酸酯法[Caregg et al.,(1986)Tet.Let.27:4051-4054;Froehler et al.,(1986)Nucl.Acid.Res.14:5399-5407;Caregg et al.,(1986)Tet.Let.27:4055-4058,Gaffney et al.,(1988)Tet.Let.29:2619-2622]。这些化学合成可以用市售的各种自动化寡核苷酸合成仪完成。另外,也可以用已知的方法从已经存在的核酸序列(例如,基因组DNA或cDNA)中制备寡核苷酸,所述技术例如有那些利用限制性酶,核酸外切酶或核酸内切酶的技术。
为了用于体内,核酸优选对降解(例如,核酸外切酶或核酸内切酶的降解)相对有抗性。次级结构,例如茎-环结构,可以稳定核酸而不被降解。另外,核酸的稳定化可以通过磷酸酯主链修饰来实现。优选的稳定化核酸具有至少部分的硫代磷酸酯修饰的主链。硫代磷酸酯可以用自动化技术采用亚磷酰胺或H-膦酸酯法来化学合成。芳基和烷基膦酸酯可以通过如美国专利第4,469,863号所描述的方法来制备,并且,烷基磷酸三酯(其中带电的氧基团如美国专利第5,023,243号和欧洲专利第092,574号所述被烷基化)可以用市售的试剂以自动化固相合成法来制备。进行其它的DNA主链修饰和替换的方法已经被描述了[Uhlmann,E.and Peyman,A.(1990)Chem.Rev.90:544;Goodchild,J.(1990)Bioconjugate Chem.1:165]。带有CpG基元的2′-O-甲基核酸也引起免疫活化,乙氧基修饰的CpG核酸也如此。事实上,还没有发现哪些主链修饰可以完全消除CpG效应,虽然用5-甲基C取代C可以极大地削弱之。
为了体内给药,核酸可以结合有能导致与靶细胞[例如,B细胞,单核细胞和天然杀伤细胞(NK)]表面以高亲和力结合和/或靶细胞的细胞摄入增加的分子,从而形成“核酸递送复合物”。核酸可以是离子性地或共价地与适宜的分子通过本领域所熟知的技术相结合。可以使用多种偶联或交联剂,例如,蛋白质A,碳二亚胺,N-琥珀酰亚氨基-3-(2-吡啶二硫基)丙酸盐/酯(SPDP)。核酸还可以用熟知的技术包埋在脂质体或病毒体中。
免疫刺激性核酸分子的医疗应用
根据其免疫刺激性质,可以将含有至少一个未甲基化CpG二核苷酸的核酸分子给受试者体内给药来治疗“免疫系统缺陷”。或者,含有至少一个未甲基化CpG二核苷酸的核酸分子可以同来自免疫系统缺陷疾病的受试者的淋巴细胞(例如,B细胞,单核细胞或NK细胞)离体接触,然后可将活化的淋巴细胞植回到受试者体内。
正如本文所描述的,作为对含有未甲基化CpG的核酸分子的应答,有更多数量的脾细胞分泌了IL-6、IL-12、IFN-γ、IFN-α、IFN-β、IL-1、IL-3、IL-10、TNF-α、TNF-β、GM-CSF、RANTES、甚至还有其它的物质。在B细胞、CD4+T细胞和单核细胞中发现了IL-6表达的提高。
免疫刺激性核酸分子还可以同疫苗一起施用给受试者,以促进其免疫系统并从而产生对疫苗的更好的应答。优选的是,将免疫刺激性核酸分子与疫苗一起或稍微提前一点施用给受试者。任选地常规的佐剂可以同疫苗一起施用,该疫苗最低限度地由抗原组成,因为常规的佐剂可以通过提高抗原的吸收来进一步改善疫苗接种的效果。
如果疫苗是DNA疫苗,则至少有两个成分决定其效力。首先,由疫苗编码的抗原决定免疫应答的特异性。其次,如果质粒的主链含有CpG基元,其就作为疫苗的佐剂起作用。因此,CpG DNA起着有效的“危险信号”的作用,并引起免疫系统对该区域内的新抗原产生强烈的反应。这种作用方式似乎是CpG DNA对树枝状细胞和其它的“专业”抗原呈递细胞的局部刺激性效应以及对B细胞的共同刺激效应的结果。
免疫刺激性寡核苷酸和含有未甲基化CpG的疫苗直接活化淋巴细胞并共同刺激抗原特异性应答,它们与常规的佐剂(例如,铝沉淀物)完全不同,常规佐剂在单独注射时是惰性的,并被认为是通过吸附抗原将其更有效地呈递给免疫细胞而起作用。进而言之,常规佐剂只对某些抗原有效,仅仅诱导抗体(体液)免疫应答(Th2),并且在诱导细胞免疫应答(Th1)方面很差。对于许多的致病物,体液应答对防御仅有很小的保护作用,有时甚至是有害的。
此外,免疫刺激性寡核苷酸可以在化疗或免疫治疗之前、之中或之后给药,以提高肿瘤细胞对后续的化疗或免疫治疗的反应性,或通过诱导恢复性细胞因子如GM-CSF来加速骨髓的恢复。CpG核酸还提高天然杀伤细胞的裂解活性和依赖抗体的细胞毒性(ADCC)。对NK活性和ADCC的诱导在癌症免疫治疗单独或者与其它治疗结合时同样是有益的。
所述的免疫刺激性核酸分子的另外的一种应用是对过敏的去敏化治疗,其中过敏一般由针对无害过敏原的IgE抗体产生所导致的。由未甲基化CpG核酸诱导的细胞因子主要是属于“Th1”类型的,其最主要的特点是细胞免疫应答,并与IL-12和IFN-γ有关。另一种主要类型的免疫应答被称为“Th2”免疫应答,其更多地与抗体免疫应答以及IL-4、IL-5和IL-10的产生有关。一般来讲,似乎所有的过敏疾病都是由Th2型免疫应答介导的,自身免疫疾病是由Th1免疫应答介导的。根据免疫刺激性核酸分子将受试者的免疫应答从Th2(其与IgE抗体的产生和过敏有关)转换为Th1应答(其有抗过敏反应的保护作用)的能力,可以单独或者与过敏原相结合地向受试者施用有效剂量的免疫刺激性核酸(或含有核酸地载体),以便治疗或防止过敏。
含有未甲基化CpG基元的核酸还可能在治疗气喘中有重要的治疗用处。Th2细胞因子,特别是IL-4和IL-5,都是在气喘病人的呼吸道中水平增加。这些细胞因子促进了气喘发炎反应的重要的方面,包括IgE同种型转换,嗜伊红粒细胞趋化性和活化,以及肥大细胞生长。Th1细胞因子,特别是IFN-γ和IL-12,可以对Th2克隆的形成和Th2细胞因子的生产进行抑制。
如同在下面的实施例12中所具体描述的那样,含有未甲基化CpG基元的寡核苷酸(即,TCCATGACGTTCCTGACGTT,SEQ ID NO:10)可以在小鼠气喘模型中防止炎性细胞浸润和嗜伊红细胞增多化,而对照寡核苷酸(TCCATGAGCTTCCTGAGTCT SEQ ID NO:11,)却不能够。进而言之,对嗜伊红细胞性发炎的抑制与对Th2应答的抑制和对Th1应答的诱导相关。
在治疗应用中,可以将有效量的适宜的免疫刺激性核酸分子自己或者配制成递送复合物地形式通过任何能够让寡核苷酸被适宜的靶细胞(例如,B细胞和单核细胞)摄入的方式向受试者给药。优选的给药途径包括口服和透皮给药(例如通过贴片)。其它的给药途径实例包括注射(皮下、静脉内、肠胃外、腹膜内、胸内,等)。注射可以一次给足,也可以连续输注。
核酸自己或作为核酸递送复合物的形式都可以与药理学可接受的载体一起给药。在本文中,术语“药理学可接受的载体”指的是那些能够同核酸或核酸递送复合物一起给药并使核酸发挥其指定功能的物质。这样的载体的例子包括溶液、溶剂、分散介质、延迟剂、乳液,等等。这些介质作为药理学活性物质的用途是本领域熟知的。任何其它的适合用于核酸的常规载体也都在本发明所包括的范围之内。
术语核酸分子的“有效量”指的是对实现所需要的生物学效果所必需的或充足的用量。例如,对含有至少一个未甲基化CpG的核酸用于治疗免疫系统缺陷来讲,有效量是对消除肿瘤、癌症、或者细菌、病毒、或真菌感染所必需的量。对于用作疫苗佐剂来讲,有效量是可用于加强受试者对疫苗的免疫应答的用量。治疗气喘的“有效量”可以是能将与气喘相关的Th2型免疫应答转变为Th1型应答的用量。对于任何具体应用的有效量,可以根据诸多因素来决定,例如,需要治疗的疾病或状态,具体施用的核酸(例如,未甲基化CpG基元的数目或它们在核酸中的位置),治疗受试者的身材,或状况的严重性。本领域的技术人员不需要进行过度实验就可以确定特定寡核苷酸的有效用量。
本发明将由下面的实施例进一步阐述,这些实施例不从任何角度限制本发明。在本申请全文中所提到的文献(包括文献材料,授权的专利,公开的专利申请,和共悬未决的专利申请)都通过引用而明确地并入本文。
实施例
实施例1:ODN对B细胞总RNA合成以及细胞周期的影响
从不带有特定病原体的6-12周龄的DBA/2或BXSB小鼠(饲养在Iowa大学动物实验中心,没有发现明显的品系差异)的脾中获得B细胞,用抗-Thy-1.2和补体消除T细胞,对淋巴细胞M离心(Cedarlane Laboratories,Hornby,Ontario,Canada)(此后称为“B细胞”)。B细胞中含有少于1%的CD4+或CD8+细胞。将8×104个B细胞一式三份加入96孔微滴板中,每孔中含有100μl的RPMI,其中含有10%的FBS(在65℃下热灭活30分钟),50μM的2-巯基乙醇,100U/ml的青霉素,100μg/ml链霉素,以及2mM的L-谷氨酸。在开始培养时加入20μM的ODN,在37℃下进行20小时,细胞用1μCi的3H尿苷脉冲,4小时后收获细胞并计数。全脾细胞用20μM的ODN培养48小时后,对分泌Ig的B细胞用ELISA点检测法计数。表1给出了有关的结果,数据代表与未用ODN培养的细胞比较而言的刺激指数。3H胸苷掺入检测显示了相似的结果,但是有从降解的ODN释放的胸苷造成的一些非特异性抑制[Matson.S and A.M.Krieg(1992)Nonspecific suppression of3H-thymidine incorporation by control oligonucleotides.Antisense Research and Development 2:325]。
实施例2:ODN对B细胞生产IgM的影响
从新杀死的小鼠获得的脾制备单细胞悬浮液,用抗-Thyl,抗-CD4,和抗-CD8以及补体处理,具体方法见Leibson等人的文献[Leibson et al.,J.Exp.Med.154:1681(1981)]。按照DeFranco等人的程序[DeFranco et al.,J.Exp.Med.155:1523(1982)]从不连续Percoll梯度的63-70%条带中分离静息B细胞(T细胞污染<0.2%)。按照上述用30μM的ODN或20μg/ml的LPS培养它们48小时。活跃分泌IgM的B细胞数在此时间点为最大,正如ELISpot检测法所确定的[Klinman,D.M.et al.,J.Immunol.144:506(1990)]。在这个检测中,B细胞在抗-Ig涂布的微滴板上培养6小时。它们所产生的Ig(>99%的IgM)用磷酸酶-标记的抗-Ig检测[Southern Biotechnology Associated,Birmingham,AL]。各B细胞产生的抗体通过加入BCIP(SigmaChemical Co.,St.Louis MO)来观察,在有磷酸酶存在时,BCIP形成不溶性兰色沉淀。将产生20-40点/孔的细胞稀释度用于确定样品中抗体分泌性B细胞的总数。所有的检测都一式三份进行(数据给出在表1)。在有些实验中,培养物上清液用ELISA来检测IgM,显示了响应于CpG-ODN有相似的提高。
实施例3:细菌DNA对B细胞的刺激
不加入DNA、或加入50μg/ml的a)Micrococcuslysodeikticus;b)NZB/N小鼠脾;c)NFS/N小鼠脾基因组DNA对DBA/2B细胞培养48小时后,然后用3H胸苷脉冲4小时,再收获细胞。对一式双份的DNA样品用DNASE I在37℃下酶解30分钟,然后加入细胞培养物。用ELISA-点检测法确定了在48小时的时候,大肠杆菌DNA也诱导了IgM分泌性B细胞数目提高了8.8倍。
不加入任何添加物,或加入50μg/ml的LPS,或20μM的ODN 1、1a、4、或4a对DBA/2B细胞进行培养。培养细胞并在第4、8、24和48小时收集细胞。对BXSB细胞按照实施例1所述进行培养,其中分别采用5、10、20、40或80μM的ODN1、1a、4、4a或LPS。在这个实验中,没加入ODN的小孔中为3833cpm。每个实验都进行至少三次,得到了相似的结果。重复的三个小孔的标准偏差小于5%。
实施例4:ODN对天然杀伤细胞(NK)活性的影响
10×106个C57BL/6脾细胞培养在2ml的RPMI中(按照实施例1进行补充),其中加入或不加入40μM的CpG或非-CpG ODN,培养48小时。洗过细胞后,在短期51Cr释放检测中作为效应细胞,检测中使用了YAC-1和2C11这两种NK敏感性靶细胞系[Ballas,Z.K.et al.(1993)J.Immunol.150:17]。效应细胞以各种浓度加至V底微滴板中0.2ml内含有的104个51Cr标记的靶细胞,在37℃温度于5%的CO2下培养4小时。然后离心,对上清液的等份试样计数放射活性。特异性裂解百分数的计算是,在有效应细胞存在时的51Cr释放减去靶细胞单独培养时的51Cr释放,与用2%乙酸进行细胞裂解后释放的总计数减去细胞单独培养时释放的51Cr cpm之间的比值。
实施例5:对CpG硫代磷酸酯ODN的体内研究
对小鼠称重,腹腔内注射0.25ml的无菌PBS或给定剂量的溶于PBS中的硫代磷酸酯ODN。24小时后,收获脾细胞,洗过之后染色,进行流式细胞术测定,使用缀合藻红蛋白的6B2,来门控B细胞,以及缀合生物素的抗Ly-6A/E或抗-Iad(Pharmingen,San Diego,CA)或抗-Bla-1[Hardy,R.R.et al.,J.Exp.Med.159:1169(1984)]。每种条件都实验了两只小鼠,每只小鼠单独进行分析。
实施例6:硫代磷酸酯ODN对B细胞刺激的效价
用硫代磷酸酯ODN培养B细胞,该ODN具有对照ODN1a的序列,或CpG ODN 1d的序列,或是3Db的序列,20小时后,加入3H尿苷脉冲,或44小时后加入3H胸苷脉冲,然后收获细胞并测定cpm。
实施例7:挽救B细胞免于编程性细胞死亡
在存在或不存在LPS或对照ODN 1a或CpG ODN 1d和3Db的条件下将WEHI-231细胞(5×104个/孔)于37℃下培养1小时,然后加入抗-IgM(1μ/ml)。细胞继续培养20小时,然后加入2μCi/孔的3H胸苷脉冲4小时。在这个实验中,没有ODN的或抗-IgM的细胞有90.4×103cpm的3H胸苷掺入。表1中给出的磷酸二酯ODN也给予了相似的保护,虽然由于ODN的降解有一些非特异性抑制。每个实验都进行至少3次,得到相似结果。
实施例8:体内诱导小鼠IL-6
DBA/2雌性小鼠(2月龄)腹膜内注射500g CpG或对照硫代磷酸酯ODN。在注射后的不同时间点对小鼠采血。每个时间点研究2只小鼠。用ELISA测定IL-6,IL-6的浓度通过与用重组IL-6制备的标准曲线进行比较来计算。用与标准曲线比较来计算。该检测的灵敏度为10pg/ml。8小时后的水平无法检测到。
实施例9:系统性诱导小鼠IL-6转录
小鼠和细胞系.DBA/2,BALB/c,和C3H/HeJ小鼠,5-10周龄,用作淋巴细胞来源。所有的小鼠都来自于The JacksonLaboratory(Bar Harbor,ME),并在Iowa大学的动物饲养中心内在无特异性病原体条件下培育和饲养。小鼠B细胞系CH12.LX由G.Bishop博士(Iowa大学,Iowa City)慷慨提供。
制备细胞.对小鼠断颈处死。从小鼠的脾无菌制备单细胞悬浮液。使用抗-Thy-1.2和补体制备消除了T细胞的小鼠脾细胞,并对淋巴细胞M(Cedarlane Laboratories,Hornby,Ontairo,Canada)离心,具体如文献所述进行[Krieg,A.M.et al.,(1989)A role for endogenous retroviral sequences in theregulation of lymphocyte activation.J.Immunol.143:2448]。
ODN和DNA.磷酸二酯寡核苷酸(O-ODN)和主链修饰的硫代磷酸酯寡核苷酸(S-ODN)得自于Iowa大学DNA中心机构或Operon Technologies(Alameda,CA)。大肠杆菌DNA(菌株B)和小牛胸腺DNA购自于Sigma公司(St.Louis,MO)。所有的DNA和ODN都通过用酚∶氯仿∶异戊醇(25∶24∶1)和/或乙醇沉淀进行纯化。在使用前,对大肠杆菌DNA和小牛胸腺DNA煮沸10分钟,随后冰上冷却5分钟,使它们成为单链。对于某些实验,大肠杆菌DNA和小牛胸腺DNA都用DNase I(2U/μg DNA)在含有5mM MgCl2的1X SSC中在37℃下消化2小时。为了对大肠杆菌DNA中的CpG二核苷酸内的胞嘧啶甲基化,将大肠杆菌DNA用CpG甲基化酶(M.SssI;2U/μg DNA)于NE缓冲液2(补充160μM的S-腺苷酰甲硫氨酸)中处理,37℃下过夜孵育。对甲基化DNA的纯化按照上述进行。甲基化的效率通过Hpa II消化,随后凝胶电泳分析来证实。所有的酶都购自于New England Biolabs(Beverly,MA)。由鲎检测法确定的,在ODN中的LPS水平低于12.5ng/mg,大肠杆菌DNA和小牛胸腺DNA中含有少于2.5ng的LPS/mgDNA。
细胞培养物.所有的细胞都在5% CO2的湿润气氛下在RPMI-1640培养基中于37℃培养24小时(对于IL-6生产)或5天(对于IgM生产),该RPMI-1640中补充了10%(v/v)的热灭活胎牛血清(FCS),1.5mM L-谷氨酰胺(50μg/ml),CpG或非CpG磷酸二酯ODN(O-ODN)(20μM),硫代磷酸酯ODN(S-ODN)(0.5μM),或大肠杆菌DNA(50μg/ml)或小牛胸腺DNA(50μg/ml)。刺激物浓度的选择按照滴定法的初步研究来决定。在某些情况下,细胞用CpG O-ODN以及各种浓度(1-10μg/ml)的抗小鼠IL-6的中和性大鼠IgG1抗体(杂交瘤MP5-20F3)或针对大肠杆菌b-半乳糖苷酶的对照大鼠IgG1单克隆抗体(杂交瘤GL113;ATCC,Rockville,MD)(20)处理5天。在培养结束时,对培养物上清液组分用ELISA按照下述进行分析。
体内诱导IL-6和IgM.对BALB/c小鼠静脉内注射PBS,小牛胸腺DNA(200μg/100μl PBS/小鼠),大肠杆菌DNA(200μg/100μl PBS/小鼠),或者CpG或非CpG S-ODN(200μg/100μl PBS/小鼠)。小鼠(2只/每组)在不同的时间点在后眼窝穿刺采血并折颈处死。取出肝,脾,胸腺和骨髓,从这些器官中用RANzol B(Tel-Test,Friendswood,TX)根据厂商的说明制备RNA。
ELISA.平底Immun 1板(Dynatech Laboratories,Inc.,Chantilly,VA)用100μl/孔抗-小鼠IL-6单克隆抗体(MP5-20F3)(2μg/ml)或抗小鼠IgM μ-链特异性(5μg/ml;Sigma,St.Louis,MO)在碳酸盐-碳酸氢盐pH9.6缓冲液(15nM Na2CO3,35mMNaHCO3)中4℃过夜进行包被。然后,用TPBS(0.5mMMgCl2·6H2O,2.68mM KCl,1.47mM KH2PO4,0.14M NaCl,6.6mM K2HPO4,0.5%Tween 20)洗该板,用TPBS中的10%FCS室温下封闭该板2小时,然后再次洗该板。培养物上清、小鼠血清、重组的小鼠IL-6(Pharmingen,San Diego,CA)或纯化的小鼠IgM(Calbiochem,San Diego,CA)都用10%FCS进行适宜的稀释,在一式三份的小孔内在室温下培育6小时,洗该板,将生物素化大鼠抗-小鼠IL-6单克隆抗体(MP5-32C11,Pharmingen,San Diego,CA)(1μg/ml,在10%FCS中)或生物素化的抗-小鼠Ig(Sigma,St.Louis,MO)以100μl/孔的剂量加入到各个小孔中,室温下培育45分钟,然后用TPBS洗。加入以1∶4000的稀释度在10%FCS(100μl/孔)中稀释的缀合了辣根过氧化物酶(HRP)的抗生物素蛋白(Bio-rad Laboratories,Hercules,CA),室温下培育30分钟。洗板后,加入邻苯二胺二盐酸盐(OPD,Sigma,St.Louis MO),0.05M磷酸盐-柠檬酸盐缓冲液,pH 5.0显色30分钟。加入0.67N的H2SO4终止反应,用微滴板读数仪(Cambridge Technology,Inc.,Watertown,MA)在490-600nm处读板。结果在图1和2中给出。
RT-PCR.有义引物、反义引物、以及IL-6的内部寡核苷酸探针都用公开的序列来合成[Montgomery,R.A.and M.S.Dallman(1991),Analysis of cytokine gene expression duringfetal thymic ontogeny using the polymerase chain reaction(J.Immunol.)147:554]。cDNA合成以及IL-6的PCR都基本按照Montgomery和D allman所述的方法进行[Montgomery,R.A.and M.S.Dallman(1991),Analysis of cytokine geneexpression during fetal thymic ontogeny using the polymerasechain reaction(J.Immunol.)147:554],其中采用了来自Perkin-Elmer公司(Hayward,CA)的RT-PCR试剂。扩增30个循环后采用凝胶电泳及随后unblot分析方法[Stoye,J.P.etal.,(1991)DNA hybridization in dried gels with fragmentedprobes:an improvement over blotting techniques,Techniques3:123]分析样品。简言之,凝胶在变性缓冲液(0.05M NaOH,1.5M NaCl)中于室温下杂交30分钟,然后在复性缓冲液(1.5M NaCl,1M Tris,pH 8)中培育30分钟,再用双蒸水洗30分钟。干燥凝胶后,在47℃预杂交2小时,杂交缓冲液(5X SSPE,0.1%SDS)中含有10μg/ml的变性鲑鱼精子DNA。对凝胶用2×106cpm/ml的针对IL-6的g-[32P]ATP末端标记的内部寡核苷酸探针[(5′CATTTCCACGATTTCCCA3′)SEQ ID NO:56]在47℃过夜杂交,室温下洗4次(2X SSC,0.2%SDS),然后放射性自显影。结果在图3中给出。
细胞增殖检测.DBA/2小鼠脾B细胞(5×104个细胞/100μl/孔)在37℃下用培养基、CpG或非CpG S-ODN(0.5μM)或O-ODN(20μM)处理24小时。最后4小时加入[3H]胸苷或[3H]尿苷(1μCi/孔)对细胞进行脉冲。[3H]掺入量用液体闪烁分析仪(Packard Instrument Co.,Downers Grove,IL)测定。
转染和CAT检测.WEHI-231细胞(107细胞)用20μg对照或人IL-6启动子-CAT构建物(由阿肯色大学的S.Manolagas慷慨提供)[Pottratz,S.T.et al.,(1994)17B-estradiol inhibitsexpression of human interleukin-6 promoter-reporterconstructs by a receptor-dependent mechanism.J.Clin.Invest.93:944]在250mV和960μF下进行电穿孔。电穿孔后,对细胞用各种浓度的CpG或非-CpG ODN刺激。转染16小时后,用溶液检测法来测定氯霉素乙酰转移酶(CAT)的活性[Seed,B.and J.Y.Sheen(1988)A single phase-extraction assay forchloramphenical acetyl transferase activity.Gene 76:271]。结果在图5中给出。
实施例10:寡脱氧核苷酸修饰
决定了CpG基元的B细胞刺激程度
采用标准程序在Applied Biosystem公司(AppliedBiosystems Inc.,Foster City,CA)的型号为380A、380B、或394的DNA合成仪上合成ODN[Beacage and Caruthers(1981)Deoxynucleoside phosphoramidites--A new class of keyintermediates for deoxypolynucleotide syntheses.TetrahedronLetters 22,1859-1862]。磷酸二酯ODN用标准的β-氰基乙基亚磷酰胺化学方法合成。硫代磷酸酯连键用元素硫氧化亚磷酸连键来引入,而不是采用标准的碘氧化法。四种常见的核苷亚磷酰胺购自于Applied Bisystem公司。所有含磷酸二酯和硫代磷酸酯的ODN都用浓氨水在55℃处理12小时来去保护。对ODN用凝胶排阻层析提纯并在使用前冻至干燥。二硫代磷酸酯连键用脱氧核苷S-(b-苯甲酰基巯基乙基)吡咯烷硫代亚磷酰胺来引入[Wiesler,W.T.et al.,(1993)In Methods in Molecular Biology:Protocols for Oligonucleotides and Analogs-Synthesis andProperties,Agrawal,S.(ed),Humana Press,191-206.]。含有ODN的二硫代酯用浓氨水在55℃处理12小时,然后用反向HPLC提纯来去保护。
为了合成在所需要的核苷酸间连键位置含有甲基硫代膦酸酯或甲基膦酸酯以及磷酸二酯的寡聚物,采用了两种不同的合成途径。这两种途径的主要合成区别是采用二烷基氨基甲基核苷磷化氢时的偶连,而对甲基硫代膦酸酯采用了氧化试剂。为了合成任一种衍生物,对二烷基氨基甲基核苷磷化氢延长了其缩合时间,因为偶连动力学比较缓慢[Jager and Engels,(1984)Synthesis of deoxynucleoside methylphophonates via aphosphonamidite approach.Tetrahedron Letters 24,1437-1440]。在偶连步骤完成后,对甲基磷酸二酯用硫化试剂处理[5%元素硫,100mM的N,N-二甲基氨基吡啶,存在于二硫化碳/吡啶/三乙胺中],连续四次的450秒处理,每次都产生了甲基硫代膦酸酯。为了产生硫代膦酸酯连键,对甲基磷酸二酯用标准的氧化试剂处理(0.1M碘,在四氢呋喃/2,6-二甲基吡啶/水中)。
对硅胶结合的寡聚物用蒸馏吡啶/浓氨水1∶1(v/v)在4℃下处理4天。上清液真空干燥后,溶解于水中,在G50/50 Sephadex柱上色谱。
在本文中,O-ODN指的是磷酸二酯ODN;S-ODN指的是完全硫代磷酸酯修饰的ODN;S-O-ODN指的是嵌合性ODN,其中的中央连键是磷酸二酯,但是2个5′和5个3′连键是硫代磷酸酯修饰的;S2-O-ODN指的是嵌合性ODN,其中的中央连键是磷酸二酯,但2个5′和5个3′连键是二硫代磷酸酯修饰的;MP-O-ODN是嵌合性ODN,其中的中央连键是磷酸二酯,但2个5′和5个3′连键是甲基膦酸酯修饰的。所研究的ODN序列(CpG二核苷酸用下划线标出)包括:
3D(5″GAGAACGCTGGACCTTCCAT),(SEQ ID NO.14);
3M(5′TCCATGTCGGTCCTGATGCT),(SEQ ID NO.31);
5(5′GGCGTTATTCCTGACTCGCC),(SEQ ID NO.57);
6(5′CCTACGTTGTATGCGCCCAGCT),(SEQ ID NO.58)。
这些序列基本上代表了在这些研究过程上所测验过的数百种CpG和非-CpG的ODN。
小鼠.DBA/2或BXSB来自于The JacksonLaboratory(Bar Harbor,ME),饲养在特定的物病原体条件下,用5-10周龄的小鼠作淋巴细胞来源,得到基本相同的结果。
细胞增殖检测.对于细胞增殖检测,将小鼠脾细胞(5×104个细胞/100μl/孔)于37℃在5%CO2润湿箱中培养于RPMI-1640中,该培养基中补充以10%(v/v)热灭活胎牛血清(对O-ODN实验加热到65℃,对仅仅使用修饰的ODN的实验加热到56℃),1.5μM L-谷氨酰胺,50μM的2-巯基乙醇,100U/ml青霉素和100μg/ml链霉素,按照给出的要求培养24小时或48小时。每个小孔中加入1μCi的3H尿苷或胸苷(按给出的要求进行),继续培养4小时后,收获细胞。对过滤物用闪烁仪计数。一式三份小孔的标准偏差小于5%。结果在图6-8中给出。
实施例11:NK活性的诱导
磷酸二酯ODN购自于Operon Technologies公司(OperonTechnologies,Alameda,CA)。硫代磷酸酯ODN购自于Iowa大学的DNA中心机构,或购自于Midland Certified ReagentCompany(Midland,TX)。大肠杆菌(菌株B)DNA和小牛胸腺DNA购自于Sigma公司(Sigma,St.Louis,MO)。所有的DNA和ODN都用酚∶氯仿∶异戊醇(25∶24∶1)萃取和/或乙醇沉淀来纯化。在ODN中的LPS水平低于12.5ng/mg,大肠杆菌DNA和小牛胸腺DNA含有低于2.5ng LPS/mg DNA,由鲎检测方法确定。
根据合同通过Veterans Affairs由National CancerInstitute(Bethesda,MD)获得不含有病毒的4-6周龄DBA/2小鼠、C57BL/6(B6)小鼠,以及先天无胸腺的BALB/C小鼠。C57BL/6SCID小鼠饲养在Iowa大学动物饲养站的SPF封闭饲养设施中。
人外周血单核淋巴细胞(PBMC)按照前述获得[Ballas,Z.K.et al.,(1990)J.Allergy Clin.Immunol.85:453;Ballas,Z.K.andW.Rasmussen(1990)J.Immunol.145:1039;Ballas,Z.K.andW.Rasmussen(1993)J.Immunol.150:17]。人或小鼠的细胞按5×106个细胞/孔的数量放在24孔微滴板中,培养于37℃、5% CO2润湿气氛下[Ballas,Z.K.et al.,(1990)J.Allergy Clin.Immunol.85:453;Ballas,Z.K.and W.Rasmussen(1990)J.Immunol 145:1039;and Ballas,Z.K.and W.Rasmussen(1993)J.Immunol.150:17],其中仅加入培养基,或以所示浓度加入CpG或非CpG ODN,或加入大肠杆菌DNA或小牛胸腺DNA(50μg/ml)并在37℃培养24小时。所有的培养物在18小时后收获,将这些细胞,按照以前的描述在标准的4小时51Cr-释放检测中用作针对K562(人)或YAC-1(小鼠)靶细胞的效应细胞。在计算裂解单位(LU)时,1LU定义为实现30%特异性裂解所需要的细胞数。在指示时,在开始培养的时候,加入中和性抗IFN-β抗体(Lee Biomolecular,San Diego,CA),或IL-12(C15.1,C15.6,C17.8,和C17.15;来自于GiorgioTrinchieri博士,The Wistar Institute,Philadelphia,PA),或它们的同型型对照,至浓度为10μg/ml。在加入抗-IL-12时,同时加入4种单克隆抗体(MAB)(或同型型对照)各10μg。重组的人IL-2的使用浓度为100U/ml。
实施例12:在小鼠气喘模型中防止炎性细胞浸润
和嗜伊红粒细胞增多症的发展
6-8周龄的C56BL/6小鼠(来自The Jackson Laboratory,Bar Harbor,ME)在第0天和第7天腹膜内注射5000个血吸虫卵(Schistosoma mansoni eggs)进行免疫。这些血吸虫卵含有抗原[血吸虫卵抗原(SEA)],其诱导Th2免疫应答(例如产生IgE抗体)。IgE抗体的产生已知是气喘的重要诱因。
然后,对免疫的小鼠用寡核苷酸(30μg在200μl盐水中,腹膜内注射)处理,这些寡核苷酸中要么含有未甲基化CpG基元(即,TCCATGACGTTCCTGACGTT;SEQ ID NO.10),或不含这种基元(即,对照物,TCCATGAGCTTCCTGAGTCT;SEQ ID NO.11)。可溶性SEA(10μg在25μl盐水中)在第14天和第21天鼻内滴入给药。盐水用作对照。
在呼吸道攻击后的不同时间点处死小鼠。进行全肺灌洗,收集呼吸道和肺泡的炎性细胞。用ELISA测定灌洗液的细胞因子水平。从全肺中分离RNA,进行Northern分析和RT-PCR研究,使用了CsCl梯度。对肺部组织充气并灌注4%低聚甲醛来进行组织学检查。
图9显示的是,小鼠开始被腹膜内注射血吸虫卵,然后吸入血吸虫卵抗原(空心环)时,则在肺部有很多的炎性细胞。然而,当小鼠在开始的时候与血吸虫卵一起接受了含有未甲基化CpG基元的核酸,则在随后吸入血吸虫卵抗原(空心三角形)后,肺部炎性细胞没有增多。
图10显示的是,当测定肺部灌洗液中存在的嗜伊红粒细胞时获得相同结果。嗜伊红粒细胞是与气喘非常密切相关的炎性细胞类型。
图11显示,当小鼠在开始暴露于血吸虫卵的时候用对照寡核苷酸进行处理,则在吸入了SEA后,对随后的嗜伊红粒细胞向肺部的流入没有影响。因此,当小鼠在第14天或第21天吸入血吸虫卵后,它们发生了肺部的急性炎性反应。然而,在第0天和第7天开始接触抗原的时候将CpG寡核苷酸与血吸虫卵一起提供给小鼠的话,则几乎彻底消除了小鼠在第14天吸入血吸虫卵抗原时所造成的嗜伊红粒细胞的增高。
图12显示,很低剂量的寡核苷酸(<10μg)就可以提供这样的保护。
图13显示,所发生的炎性应答与肺部Th2细胞因子IL-4的水平相关。
图14显示,施用含有未甲基化CpG基元的寡核苷酸确实能够将肺部的细胞因子应答改变为IL-12的生产,表明Th1类型的免疫应答。
图15显示,施用含有未甲基化CpG基元的寡核苷酸还可以将肺部的细胞因子应答改变为IFN-γ的生产,表明Th1类型的免疫应答。
实施例13:CpG寡核苷酸诱导人PBMC分泌细胞因子
对Ficoll Hypaque用标准离心从全血中制备人PBMC。细胞(5×105/ml)在96孔微滴板内,在与10%自体血清中,用CpG或对照寡脱氧核苷酸(对磷酸二酯寡核苷酸为24μg/ml,对核酸酶抗性硫代磷酸酯寡核苷酸为6μg/ml)一起培养,对TNF-α而言为4小时,对其它的细胞因子而言为24小时,然后收获上清并用ELISA检测,使用Quantikine试剂盒,或使用来自R&D Systems(pg/ml)的试剂,或使用来自Biosource的细胞因子ELISA试剂盒(对于IL-12检测)。各检测都按照厂商的说明书进行。表6提供了这些实验的数据,以比没有加入寡脱氧核苷酸的小孔高出的细胞因子水平来表示。
本领域的技术人员将能够认识到或采用不超过常规的实验可以确定本文所述本发明具体实施方案的众多等同物。这些等同物都意图包括在本发明的权利要求书中。
序列表
<110>艾奥华大学研究基金会
美国政府,其由健康与人类服务部部长作为代表
<120>免疫刺激性核酸分子
<130>C1039.70005CN01
<140>200710130052.0
<141>2007-07-25
<150>US 08/738,652
<151>1996-10-30
<150>PCT/US97/19791(97199352.1)
<151>1997-10-30
<160>104
<170>PatentIn version 3.3
<210>1
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>1
atggaaggtc cagtgttctc 20
<210>2
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>2
atcgacctac gtgcgttctc 20
<210>3
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>3
atcgactctc gagcgttctc 20
<210>4
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>4
atggaggctc catcgttctc 20
<210>5
<211>19
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>5
gagaacgtcg accttcgat 19
<210>6
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<220>
<221>修饰的碱基
<222>(3)..(3)
<223>其中n是5-甲基胞嘧啶
<220>
<221>修饰的碱基
<222>(10)..(10)
<223>其中n是5-甲基胞嘧啶
<220>
<221>修饰的碱基
<222>(14)..(14)
<223>其中n是5-甲基胞嘧啶
<400>6
atngactctn gagngttctc 20
<210>7
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>7
tccatgacgt tcctgatgct 20
<210>8
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>8
tccatgagct tcctgagtct 20
<210>9
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>9
tccaagacgt tcctgatgct 20
<210>10
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>10
tccatgacgt tcctgacgtt 20
<210>11
<211>21
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>11
tccatgagct tcctgagtgc t 21
<210>12
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>12
ggggtcaacg ttcagggggg 20
<210>13
<211>15
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>13
gctagacgtt agcgt 15
<210>14
<211>15
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<220>
<221>修饰的碱基
<222>(7)..(7)
<223>其中n是5-甲基胞嘧啶
<400>14
gctagangtt agcgt 15
<210>15
<211>15
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<220>
<221>修饰的碱基
<222>(13)..(13)
<223>其中n是5-甲基胞嘧啶
<400>15
gctagacgtt agngt 15
<210>16
<211>15
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>16
gcatgacgtt gagct 15
<210>17
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>17
atggaaggtc cagcgttctc 20
<210>18
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>18
atcgactctc gagcgttctc 20
<210>19
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<220>
<221>修饰的碱基
<222>(3)..(3)
<223>其中n是5-甲基胞嘧啶
<220>
<221>修饰的碱基
<222>(10)..(10)
<223>其中n是5-甲基胞嘧啶
<220>
<221>修饰的碱基
<222>(14)..(14)
<223>其中n是5-甲基胞嘧啶
<400>19
atngactctn gagngttctc 20
<210>20
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<220>
<221>修饰的碱基
<222>(3)..(3)
<223>其中n是5-甲基胞嘧啶
<400>20
atngactctc gagcgttctc 20
<210>21
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<220>
<221>修饰的碱基
<222>(18)..(18)
<223>其中n是5-甲基胞嘧啶
<400>21
atcgactctc gagcgttntc 20
<210>22
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>22
atggaaggtc caacgttctc 20
<210>23
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>23
gagaacgctg gaccttccat 20
<210>24
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>24
gagaacgctc gaccttccat 20
<210>25
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>25
gagaacgctc gaccttcgat 20
<210>26
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>26
gagcaagctg gaccttccat 20
<210>27
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<220>
<221>修饰的碱基
<222>(6)..(6)
<223>其中n是5-甲基胞嘧啶
<400>27
gagaangctg gaccttccat 20
<210>28
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<220>
<221>修饰的碱基
<222>(14)..(14)
<223>其中n是5-甲基胞嘧啶
<400>28
gagaacgctg gacnttccat 20
<210>29
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>29
gagaacgatg gaccttccat 20
<210>30
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>30
gagaacgctc cagcactgat 20
<210>31
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>31
tccatgtcgg tcctgatgct 20
<210>32
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>32
tccatgctgg tcctgatgct 20
<210>33
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<220>
<221>修饰的碱基
<222>(8)..(8)
<223>其中n是5-甲基胞嘧啶
<400>33
tccatgtngg tcctgatgct 20
<210>34
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<220>
<221>修饰的碱基
<222>(12)..(12)
<223>其中n是5-甲基胞嘧啶
<400>34
tccatgtcgg tnctgatgct 20
<210>35
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>35
tccatgacgt tcctgatgct 20
<210>36
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>36
tccatgtcgg tcctgctgat 20
<210>37
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>37
atggactctc cagcgttctc 20
<210>38
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>38
tccatgccgg tcctgatgct 20
<210>39
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>39
tccatggcgg tcctgatgct 20
<210>40
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>40
tccatgacgg tcctgatgct 20
<210>41
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>41
tccatgtcgatcctgatgct 20
<210>42
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>42
tccatgtcgc tcctgatgct 20
<210>43
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>43
tccatgtcgt tcctgatgct 20
<210>44
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>44
tccatgacgt tcctgatgct 20
<210>45
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>45
tccataacgt tcctgatgct 20
<210>46
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>46
tccatgacgt ccctgatgct 20
<210>47
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>47
tccatcacgt gcctgatgct 20
<210>48
<211>15
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>48
gcatgacgtt gagct 15
<210>49
<211>15
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>49
gctagatgtt agcgt 15
<210>50
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>E0
ggggtcaagt cttgacgggg 20
<210>51
<211>15
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>51
gctagacgtt agtgt 15
<210>52
<211>15
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<220>
<221>修饰的碱基
<222>(7)..(7)
<223>其中n是5-甲基胞嘧啶
<220>
<221>修饰的碱基
<222>(7)..(7)
<223>其中n是甲基胞嘧啶
<400>52
gctagangtt agtgt 15
<210>53
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<220>
<221>修饰的碱基
<222>(8)..(8)
<223>其中n是甲基胞嘧啶
<400>53
tccatgtngt tcctgatgct 20
<210>54
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<220>
<221>修饰的碱基
<222>(14)..(14)
<223>其中n是5-甲基胞嘧啶
<400>54
atcgactctc gagngttctc 20
<210>55
<211>18
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>55
tctcccagcg tgcgccat 18
<210>56
<211>24
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>56
tcgtcgtttt gtcgttttgt cgtt 24
<210>57
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>57
tcgtcgttgt cgttgtcgtt 20
<210>58
<211>24
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>58
tcgtcgtttt gtcgttttgt cgtt 24
<210>59
<211>22
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>59
tcgtcgttgt cgttttgtcg tt 22
<210>60
<211>19
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>60
tgtcgttgtc gttgtcgtt 19
<210>61
<211>14
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>61
tcgtcgtcgt cgtt 14
<210>62
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>62
tcctgtcgtt ccttgtcgtt 20
<210>63
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>63
tcctgtcgtt ttttgtcgtt 20
<210>64
<211>21
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>64
tcgtcgctgt ctgcccttct t 21
<210>65
<211>21
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>65
tcgtcgctgt tgtcgtttct t 21
<210>66
<211>24
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>66
tcgtcgtttt gtcgttttgt cgtt 24
<210>67
<211>22
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>67
tcgtcgttgt cgttttgtcg tt 22
<210>68
<211>19
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>68
tgtcgttgtc gttgtcgtt 19
<210>69
<211>19
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>69
ggggtcaacg ttgacgggg 19
<210>70
<211>18
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>70
catttccacg atttccca 18
<210>71
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>71
ggcgttattc ctgactcgcc 20
<210>72
<211>22
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>72
cctacgttgt atgcgcccag ct 22
<210>73
<211>24
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>73
accatggacg atctgtttcc cctc 24
<210>74
<211>18
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>74
taccgcgtgc gaccctct 18
<210>75
<211>24
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>75
accatggacg aactgtttcc cctc 24
<210>76
<211>24
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>76
accatggacg agctgtttcc cctc 24
<210>77
<211>24
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>77
accatggacg acctgtttcc cctc 24
<210>78
<211>24
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>78
accatggacg tactgtttcc cctc 24
<210>79
<211>24
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>79
accatggacg gtctgtttcc cctc 24
<210>80
<211>24
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>80
accatggacg ttctgtttcc cctc 24
<210>81
<211>15
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>81
cacgttgagg ggcat 15
<210>82
<211>15
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>82
ctgctgagac tggag 15
<210>83
<211>12
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>83
tcagcgtgcg cc 12
<210>84
<211>17
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>84
atgacgttcc tgacgtt 17
<210>85
<211>17
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>85
tctcccagcg ggcgcat 17
<210>86
<211>18
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>86
tctcccagcg cgcgccat 18
<210>87
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>87
tccatgtcgt tcctgtcgtt 20
<210>88
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>88
tccatagcgt tcctagcgtt 20
<210>89
<211>21
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>89
tcgtcgctgt ctccgcttct t 21
<210>90
<211>19
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>90
tcctgacgtt cctgacgtt 19
<210>91
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>91
tccaggactt tcctcaggtt 20
<210>92
<211>19
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>92
tcctgtcgtt cctgtcgtt 19
<210>93
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>93
tccatgtcgt ttttgtcgtt 20
<210>94
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>94
tccttgtcgt tcctgtcgtt 20
<210>95
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<220>
<221>修饰的碱基
<222>(8)..(8)
<223>其中n是5-甲基胞嘧啶
<220>
<221>修饰的碱基
<222>(17)..(17)
<223>其中n是5-甲基胞嘧啶
<400>95
tccatgtngt tcctgtngtt 20
<210>96
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>96
tccaggactt ctctcaggtt 20
<210>97
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>97
tccatgcgtg cgtgcgtttt 20
<210>98
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>98
tccatgcgtt gcgttgcgtt 20
<210>99
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>99
tccacgacgt tttcgacgtt 20
<210>100
<211>21
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>100
gcgtgcgttg tcgttgtcgt t 21
<210>101
<211>20
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>101
gcggcgggcg gcgcgcgccc 20
<210>102
<211>21
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>102
tgtcgtttgt cgtttgtcgt t 21
<210>103
<211>25
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>103
tgtcgttgtc gttgtcgttg tcgtt 25
<210>104
<211>13
<212>DNA
<213>人工序列
<220>
<223>合成的寡核苷酸
<400>104
tgtcgttgtc gtt 13
Claims (72)
1. 一种免疫刺激性寡核苷酸,其中包含两个或多于两个的未甲基化CpG二核苷酸,其序列包括:5’N1X1X2CGTTN23’,其中所述免疫刺激性寡核苷酸包含一个或多个具有磷酸主链修饰的核苷酸间连键,其中一个或多个核苷酸将连续的CpGs分开;X1X2是GpT或ApT;N1是任何包括5’TC或TG的核苷酸,并且N1+N2为约0-26个碱基,条件是N1和N2均不含有CCGG四元体或多于一个的CCG或CGG三元体;并且该免疫刺激性寡核酸的长度为8-30个碱基。
2. 一种免疫刺激性寡核苷酸,其中包含两个或多于两个的未甲基化CpG二核苷酸,其用来治疗、预防或改善受试体的病变,其序列包括:5’N1X1X2CGTTN23’,其中一个或多个核苷酸将连续的CpGs分开;X1X2是GpT或ApT;N1是任何包括5’TC或TG的核苷酸,并且N1+N2是约0-26个碱基,条件是N1和N2均不含有CCGG四元体或多于一个的CCG或CGG三元体;并且该免疫刺激性寡核酸的长度为8-30个碱基。
3. 根据权利要求1或2的免疫刺激性寡核苷酸,其中N1包括5’TC。
4. 根据权利要求1或2的免疫刺激性寡核苷酸,其中包含被胸腺嘧啶分开的两个或多于两个的连续CpGs。
5. 根据权利要求3的免疫刺激性寡核苷酸,其中GTCGT基元紧跟在5’TC后。
6. 根据权利要求2的免疫刺激性寡核苷酸,其中进一步包含抗原。
7. 根据权利要求1或2的免疫刺激性寡核苷酸,其中所述寡核苷酸是合成的。
8. 根据权利要求2的免疫刺激性寡核苷酸,其中所述寡核苷酸包括一个或多个具有磷酸主链修饰的核苷酸间连键。
9. 根据权利要求1或8的免疫刺激性寡核苷酸,其中所述磷酸主链修饰是硫代磷酸酯修饰或二硫代磷酸酯修饰。
10. 根据权利要求9的免疫刺激性寡核苷酸,其中每个核苷酸间连键是硫代磷酸酯连键。
11. 根据权利要求1或2的免疫刺激性寡核苷酸,其中寡核苷酸包括GTCGCT或GTCGTT基元。
12. 根据权利要求1或2的免疫刺激性寡核苷酸,其不是回文的。
13. 一种免疫刺激性寡核苷酸,其具有如下序列:
TCGTCGTTTTGTCGTTTTGTCGTT。
14. 一种免疫刺激性寡核苷酸,其具有序列
TCGTCGTTGTCGTTTTGTCGTT,
TCCATGTCGTTCTGTTCGTT,
TCCTGTCGTTCCTGTCGTT,
TCCTGTCGTTCCTTGTCGTT,
TCCTTGTCGTTCCTGTCGTT,
TCCTGTCGTTTTTTGTCGTT,
TCGTCGCTGTTGTCGTTTCTT,
TCGTCGTTGTCGTTGTCGTT,
TCGTCGTTTTGTCGTTTTGTCGTT,
TCGTCGTTGTCGTTTTGTCGTT,
TGTCGTTGTCGTTGTCGTTGTCGTT,
TGTCGTTGTCGTTGTCGTT,
TCGTCGTCGTCGTT或
TGTCGTTGTCGTT。
15. 根据权利要求13或14的免疫刺激性寡核苷酸,其中所述寡核苷酸包含一个或多个具有磷酸主链修饰的核苷酸间连键。
16. 根据权利要求15的免疫刺激性寡核苷酸,其中所述磷酸主链修饰是硫代磷酸酯修饰或二硫代磷酸酯修饰。
17. 根据权利要求15的免疫刺激性寡核苷酸,其中每个核苷酸间连键是硫代磷酸酯连键。
18. 一种组合物,其中包含权利要求1、2、8、13或14中任何一项所述免疫刺激性寡核苷酸,并结合有固醇、阳离子脂质、病毒粒子或脂质体,以形成核酸递送复合物。
19. 一种组合物,其中包含权利要求1、2、8、13或14中任何一项所述免疫刺激性寡核苷酸和药理学可接受的载体。
20. 一种组合物,其基本上由权利要求1、2、8、13或14中任何一项所述免疫刺激性寡核苷酸组成。
21. 权利要求1、2、8、13或14中任何一项所述免疫刺激性寡核苷酸在制备用于通过刺激受试体的免疫系统来治疗、预防或改善该受试体内病变的药物中的应用。
22. 根据权利要求21的应用,其中所述药物用来治疗或预防受试体的癌症。
23. 根据权利要求21的应用,其中所述药物用于诱导受试体内的细胞毒性淋巴细胞应答。
24. 根据权利要求21的应用,其中所述药物用于治疗或预防受试体的病毒性,真菌性,细菌性,或寄生虫性感染。
25. 根据权利要求21的应用,其中所述药物用于刺激受试体内对疫苗的应答。
26. 根据权利要求21的应用,其中所述药物用作为刺激受试体的免疫活化的佐剂。
27. 根据权利要求21的应用,其中所述药物用于治疗或预防受试体内的过敏。
28. 根据权利要求21的应用,其中所塑药物用于治疗或预防受试体内的气喘。
29. 包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸在制备治疗或预防气喘的药物中的应用,其中所述免疫刺激性寡核苷酸不与所施用的过敏原一起使用。
30. 包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸在制备用于治疗或预防气喘的口服药物中的应用。
31. 包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸在制备用于治疗或预防过敏的药物中的应用,其中所述免疫刺激性寡核苷酸不与所施用的过敏原一起使用。
32. 包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸在制备用于治疗或预防过敏的口服药物中的应用。
33. 包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸在制备用于治疗或预防湿疹,过敏性鼻炎,鼻炎,枯草热,风疹或食物过敏的药物中的应用。
34. 根据权利要求29-33中任何一项的应用,其中所述免疫刺激性寡核苷酸具有包含通式如下表示的CpG基元的序列:
5′N1X1CGX2N23′
其中一个或多个核苷酸将连续的CpGs分开;X1是腺嘌呤,鸟嘌呤,或胸腺嘧啶;X2是胞嘧啶或胸腺嘧啶;N是任何核苷酸,并且N1+N2是0-26个碱基,条件是N1和N2不含有CCGG四元体或多于一个的CCG或CGG三元体;并且该寡核苷酸的长度为8-30个碱基。
35. 根据权利要求29-33中任何一项的应用,其中所述免疫刺激性寡核苷酸包含通式如下表示的CpG基元:
5′N1X1X2CGX3X4N23′
其中一个或多个核苷酸将连续的CpGs分开;其中X1X2是GpT,GpG,GpA,ApT,或ApA,X3X4是TpT或CpT;N是任何核苷酸,并且N1+N2是0-26个碱基,条件是N1和N2不含有CCGG四元体或多于一个的CCG或CGG三元体;并且所述免疫刺激性寡核苷酸的长度为8-30个碱基。
36. 根据权利要求35中的应用,其中X1X2是GpT,GpG,GpA,或ApA,X3X4是TpT,CpT或GpT。
37. 根据权利要求34的应用,所述药物用来治疗气喘,其中所述免疫刺激性寡核苷酸是:
(a)GTCG(T/C)T或TGACGTT;
(b)TGTCG(T/C)T。
38. 根据权利要求29-33中任何一项的应用,其中包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸的长度为8-30个碱基。
39. 根据权利要求29-33中任何一项的应用,其中包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸在5’端有TC或TG。
40. 根据权利要求29-33中任何一项的应用,其中包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸包括被一个或多个胸腺嘧啶分开的两个或更多个连续CpG。
41. 根据权利要求29-33中任何一项的应用,其中包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸不包括回文CpG基元。
42. 根据权利要求29-33中任何一项的应用,其中包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸是磷酸二酯寡核苷酸。
43. 根据权利要求29-33中任何一项的应用,其中包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸包括磷酸主链修饰。
44. 根据权利要求43的应用,其中所述磷酸主链修饰包括硫代磷酸酯修饰的连键。
45. 根据权利要求29-33中任何一项的应用,其中包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸是核糖核苷酸或脱氧核糖核苷酸。
46. 根据权利要求29-33中任何一项的应用,其中包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸是合成的。
47. 根据权利要求29-33中任何一项的应用,其中包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸是稳定化的。
48. 包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸在制备用于通过增强抗体依赖性细胞毒性效果来治疗癌或肉瘤的药物中的应用。
49. 根据权利要求48的应用,其中癌是脑、肺、卵巢、乳腺、前列腺或结肠肿瘤。
50. 包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸在制备与化疗一起施用或化疗之后施用以增加恶性细胞对后来的化疗或免疫治疗的反应的药物中的应用。
51. 包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸在制备用于与免疫治疗一起施用、之前施用或之后施用以增加恶性细胞对后来的化疗或免疫治疗的反应的药物中的应用。
52. 包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸在制备用于与化疗或免疫治疗一起施用、之前施用或之后施用以加快骨髓的恢复的药物中的应用。
53. 包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸在制备用于治疗乙型肝炎病毒感染的药物中的应用。
54. 包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸在制备用于治疗丙型肝炎病毒感染的药物中的应用。
55. 根据权利要求29-33或48-54中任何一项的应用,其中所述免疫刺激性寡核苷酸是权利要求1、2、8、13或14中任何一项所述的免疫刺激性寡核苷酸。
56. 根据权利要求29-33或48-54中任何一项的应用,其中所述药物包含固醇、阳离子脂质、病毒体或脂质体,以形成核酸递送复合物或药理学可接受的载体。
57. 根据权利要求29-33或48-54中任何一项的应用,其中所述药物是供人类使用的。
58. 根据权利要求29-33或48-54中任何一项的应用,其中包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸经口服、经皮或通过皮下注射、静脉注射、非肠道注射、腹膜内注射或胸内注射而施用。
59. 根据权利要求22的应用,其中所述药物是供人类使用的。
60. 根据权利要求22的应用,其中包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸是经口服、经皮或通过皮下注射、静脉内注射、胃肠外注射、腹膜内注射或胸内注射而施用。
61. 根据权利要求23的应用,其中所述药物是供人类使用的。
62. 根据权利要求23的应用,其中包括一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸经口服、经皮或通过皮下注射、静脉内注射、胃肠外注射、腹膜内注射或胸内注射而施用。
63. 根据权利要求24的应用,其中所述药物是供人类使用的。
64. 根据权利要求24的应用,其中包括一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸经口服、经皮或通过皮下注射、静脉内注射、胃肠外注射、腹膜内注射或胸内注射而施用。
65. 根据权利要求25的应用,其中所述药物是供人类使用的。
66. 根据权利要求25的应用,其中包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸经口服的、经皮或通过皮下注射、静脉内注射、胃肠外注射、腹膜内注射或胸内注射而施用。
67. 根据权利要求26的应用,其中所述药物是供人类使用的。
68. 根据权利要求26的应用,其中包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸经口服、经皮或通过皮下注射、静脉内注射、胃肠道外注射、腹膜内注射或胸内注射而施用。
69. 根据权利要求27的应用,其中所述药物是供人类使用的。
70. 根据权利要求27的应用,其中包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸经口服、经皮或通过皮下注射、静脉内注射、胃肠外注射、腹膜内注射或胸内注射。
71. 根据权利要求28的应用,其中所述药物是供人类使用的。
72. 根据权利要求28的应用,其中包含一个或多个未甲基化CpG二核苷酸的免疫刺激性寡核苷酸经口服、经皮或通过皮下注射、静脉内注射、胃肠外注射、腹膜内注射或胸内注射而施用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/738,652 US6207646B1 (en) | 1994-07-15 | 1996-10-30 | Immunostimulatory nucleic acid molecules |
US08/738,652 | 1996-10-30 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB971993521A Division CN100338086C (zh) | 1996-10-30 | 1997-10-30 | 免疫刺激性核酸分子 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101265285A true CN101265285A (zh) | 2008-09-17 |
Family
ID=24968901
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007101300520A Pending CN101265285A (zh) | 1996-10-30 | 1997-10-30 | 免疫刺激性核酸分子 |
CNB971993521A Expired - Lifetime CN100338086C (zh) | 1996-10-30 | 1997-10-30 | 免疫刺激性核酸分子 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB971993521A Expired - Lifetime CN100338086C (zh) | 1996-10-30 | 1997-10-30 | 免疫刺激性核酸分子 |
Country Status (14)
Country | Link |
---|---|
US (32) | US6207646B1 (zh) |
EP (5) | EP2360252B8 (zh) |
JP (5) | JP2001503267A (zh) |
KR (1) | KR100689942B1 (zh) |
CN (2) | CN101265285A (zh) |
AT (1) | ATE332966T1 (zh) |
AU (3) | AU5242498A (zh) |
CA (1) | CA2270345C (zh) |
DE (1) | DE69736331T2 (zh) |
DK (1) | DK0948510T3 (zh) |
ES (2) | ES2624859T3 (zh) |
NZ (1) | NZ335397A (zh) |
PT (1) | PT948510E (zh) |
WO (1) | WO1998018810A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107513533A (zh) * | 2011-05-26 | 2017-12-26 | 英特维特国际股份有限公司 | 免疫刺激性寡脱氧核苷酸 |
WO2020228606A1 (en) * | 2019-05-10 | 2020-11-19 | Microbio (Shanghai) Co., Ltd. | Dimeric cpg oligonucleotides for use in modulating immune responses |
CN112118847A (zh) * | 2018-03-02 | 2020-12-22 | 伊莱西奥治疗有限公司 | 包含突变kras序列和脂质的化合物及其用途 |
CN112263675A (zh) * | 2013-07-19 | 2021-01-26 | 财团法人卫生研究院 | CpG寡脱氧核苷酸、包含其的免疫组合物及制备组合物并通过其刺激免疫反应的方法 |
Families Citing this family (829)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL105325A (en) * | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
US6498147B2 (en) * | 1992-05-22 | 2002-12-24 | The Scripps Research Institute | Suppression of nuclear factor-κb dependent processes using oligonucleotides |
CA2110946A1 (en) * | 1992-12-09 | 1994-06-10 | Elazar Rabbani | Induction of immunocompatibility by nucleic acid |
US20030109469A1 (en) * | 1993-08-26 | 2003-06-12 | Carson Dennis A. | Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen |
US5849719A (en) * | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7935675B1 (en) * | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US7422902B1 (en) * | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US7034007B1 (en) * | 1995-06-07 | 2006-04-25 | East Carolina University | Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion |
US6825174B2 (en) * | 1995-06-07 | 2004-11-30 | East Carolina University | Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation |
AU1463097A (en) | 1996-01-04 | 1997-08-01 | Rican Limited | Helicobacter pylori bacterioferritin |
US20030078223A1 (en) * | 1996-01-30 | 2003-04-24 | Eyal Raz | Compositions and methods for modulating an immune response |
WO1997028259A1 (en) * | 1996-01-30 | 1997-08-07 | The Regents Of The University Of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US20050119470A1 (en) * | 1996-06-06 | 2005-06-02 | Muthiah Manoharan | Conjugated oligomeric compounds and their use in gene modulation |
WO2005121371A2 (en) * | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US20040147022A1 (en) * | 1996-06-06 | 2004-07-29 | Baker Brenda F. | 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
US20040171031A1 (en) * | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
ES2241042T3 (es) | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora. |
ATE367159T1 (de) | 1996-10-25 | 2007-08-15 | Minnesota Mining & Mfg | Verbindungen, die die immunantwort verändern, zur behandlung von th2-vermittelten und -verwandten krankheiten |
EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
ATE235890T1 (de) * | 1997-01-30 | 2003-04-15 | Chiron Corp | Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr |
US6884435B1 (en) * | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
US6214806B1 (en) * | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
CA2283557A1 (en) * | 1997-03-10 | 1998-09-17 | Heather L. Davis | Use of nucleic acids containing unmethylated cpg dinucleotide as an adjuvant |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
US20030104044A1 (en) * | 1997-05-14 | 2003-06-05 | Semple Sean C. | Compositions for stimulating cytokine secretion and inducing an immune response |
DE69841002D1 (de) | 1997-05-14 | 2009-09-03 | Univ British Columbia | Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln |
WO1998052581A1 (en) | 1997-05-20 | 1998-11-26 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
EP1374894A3 (en) * | 1997-06-06 | 2004-09-22 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
DE69840850D1 (de) * | 1997-06-06 | 2009-07-09 | Dynavax Tech Corp | Inhibitoren von immunstimulatorischen dna sequenz aktivität |
US20040006034A1 (en) * | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
EP1009440B1 (en) * | 1997-07-03 | 2008-09-17 | MacFarlane, Donald E. | Method for inhibiting immunostimulatory dna associated responses |
AU2003203948B2 (en) * | 1997-09-05 | 2005-12-22 | The Regents Of The University Of California | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
AU757175B2 (en) * | 1997-09-05 | 2003-02-06 | Regents Of The University Of California, The | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
AU760549B2 (en) * | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
JP2002513763A (ja) * | 1998-05-06 | 2002-05-14 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Cpgオリゴヌクレオチドを使用して寄生生物感染および関連する疾患を予防および処置するための方法 |
CA2328406A1 (en) * | 1998-05-14 | 1999-11-18 | Hermann Wagner | Methods for regulating hematopoiesis using cpg-oligonucleotides |
CN102274272A (zh) | 1998-05-19 | 2011-12-14 | 研究发展基金会 | 三萜组合物和它们的使用方法 |
DK1077722T3 (da) * | 1998-05-22 | 2006-11-27 | Ottawa Health Research Inst | Fremgangsmåder og produkter til induktion af mukosaimmunitet |
KR19990086271A (ko) * | 1998-05-27 | 1999-12-15 | 손경식 | 면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제 |
US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
US20040247662A1 (en) * | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US20030022854A1 (en) * | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
EP1100807A1 (en) * | 1998-07-27 | 2001-05-23 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
ATE315405T1 (de) * | 1998-08-10 | 2006-02-15 | Antigenics Inc | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung |
ATE326239T1 (de) * | 1998-09-18 | 2006-06-15 | Dynavax Tech Corp | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren |
AU6425999A (en) * | 1998-10-09 | 2000-05-01 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
US6423493B1 (en) * | 1998-10-26 | 2002-07-23 | Board Of Regents The University Of Texas System | Combinatorial selection of oligonucleotide aptamers |
CA2357413A1 (en) * | 1998-12-22 | 2000-06-29 | Panacea Pharmaceuticals, Llc | Sensitizing agents for the treatment of skin lesions |
US6558951B1 (en) * | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
US7776343B1 (en) | 1999-02-17 | 2010-08-17 | Csl Limited | Immunogenic complexes and methods relating thereto |
ES2242604T3 (es) | 1999-02-26 | 2005-11-16 | Chiron Corporation | Microemulsiones con macroparticulas y microparticulas adsorbidas. |
EP1154790B1 (en) * | 1999-02-26 | 2004-10-20 | Chiron S.r.l. | Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs |
GB2348132B (en) * | 1999-03-02 | 2004-08-04 | Nedaa Abdul-Ghani Nasif | Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils |
FR2790955B1 (fr) * | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
WO2000061151A2 (en) | 1999-04-12 | 2000-10-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US6562801B1 (en) | 1999-04-15 | 2003-05-13 | Board Of Regents, The University Of Texas System | PpGpp and pppGpp as immunomodulatory agents |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
GB9908885D0 (en) * | 1999-04-19 | 1999-06-16 | Smithkline Beecham Biolog | Vccine |
HU229255B1 (en) | 1999-04-19 | 2013-10-28 | Smithkline Beecham Biolog | Vaccines |
AU762857B2 (en) * | 1999-04-20 | 2003-07-10 | Smithkline Beecham Biologicals (Sa) | Vaccine |
WO2001000232A2 (en) * | 1999-06-29 | 2001-01-04 | Smithkline Beecham Biologicals S.A. | Use of cpg as an adjuvant for hiv vaccine |
US20050002958A1 (en) * | 1999-06-29 | 2005-01-06 | Smithkline Beecham Biologicals Sa | Vaccines |
US6514948B1 (en) | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
FR2795963A1 (fr) * | 1999-07-08 | 2001-01-12 | Pasteur Merieux Serums Vacc | Polynucleotide immunostimulant |
DE19935756A1 (de) | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation |
US20050226890A1 (en) * | 1999-08-12 | 2005-10-13 | Cohen David I | Tat-based vaccine compositions and methods of making and using same |
PT1200580E (pt) * | 1999-08-13 | 2005-03-31 | Hybridon Inc | Modulacao da estimulacao imunitaria mediada por oligonucleotidos cpg atraves de modificacao posicional de nucleosidos |
ATE419869T1 (de) * | 1999-08-19 | 2009-01-15 | Dynavax Tech Corp | Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür |
US20050249794A1 (en) * | 1999-08-27 | 2005-11-10 | Semple Sean C | Compositions for stimulating cytokine secretion and inducing an immune response |
CA2382611A1 (en) * | 1999-08-27 | 2001-03-08 | Inex Pharmaceuticals Corp. | Compositions for stimulating cytokine secretion and inducing an immune response |
DK1221955T3 (da) * | 1999-09-25 | 2006-01-30 | Univ Iowa Res Found | Immunstimulerende nukleinsyre |
EP1688147A1 (en) * | 1999-09-27 | 2006-08-09 | Coley Pharmaceutical Group, Inc. | Methods Related to Immunostimulatory Nucleic Acid-Induced Interferon |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
IL148844A0 (en) * | 1999-09-27 | 2002-09-12 | Coley Pharm Group Inc | Methods related to immunostimulatory nucleic acid-induced interferon |
ES2559317T3 (es) | 1999-10-29 | 2016-02-11 | Glaxosmithkline Biologicals Sa | Péptidos antigénicos de Neisseria |
US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
ATE378348T1 (de) * | 2000-01-14 | 2007-11-15 | Us Health | Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion |
AU3108001A (en) * | 2000-01-20 | 2001-12-24 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing a th2 immune response |
WO2001055341A2 (en) * | 2000-01-31 | 2001-08-02 | The Regents Of The University Of California | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US20030130217A1 (en) * | 2000-02-23 | 2003-07-10 | Eyal Raz | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
CA2399550A1 (en) * | 2000-02-23 | 2001-08-30 | The Regents Of The University Of California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
WO2001062092A1 (en) * | 2000-02-25 | 2001-08-30 | Thomas Jefferson University | Formulations and methods for using the same to elicit an immune response |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US7157437B2 (en) | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US7129222B2 (en) * | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US20010046967A1 (en) | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
US20020142978A1 (en) * | 2000-04-07 | 2002-10-03 | Eyal Raz | Synergistic improvements to polynucleotide vaccines |
EP1278761B1 (en) * | 2000-05-01 | 2005-04-06 | Hybridon, Inc. | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
US6696064B2 (en) * | 2000-06-20 | 2004-02-24 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of protecting vasculature from damage by diphtheria toxin-and pseudomonas toxin-based immunotoxins during therapy |
AU7013401A (en) | 2000-06-22 | 2002-01-02 | Univ Iowa Res Found | Methods for enhancing antibody-induced cell lysis and treating cancer |
WO2001098206A1 (en) | 2000-06-22 | 2001-12-27 | Rxkinetix, Inc. | Delivery vehicle composition and methods for delivering antigens and other drugs |
JP5008244B2 (ja) * | 2000-06-23 | 2012-08-22 | ワイス・ホールディングズ・コーポレイション | 野性型およびキメラのインフルエンザウイルス様粒子(vlp)のアセンブリー |
WO2002002172A1 (en) * | 2000-06-30 | 2002-01-10 | Univ Jefferson | Dna palindrome - oligoguanylic acid compositions and uses thereof |
KR100917101B1 (ko) * | 2000-08-04 | 2009-09-15 | 도요 보세키 가부시키가이샤 | 플렉시블 금속적층체 및 그 제조방법 |
US20080044435A1 (en) * | 2004-03-16 | 2008-02-21 | Cohen David I | Tat-Based Tolerogen Compositions and Methods of Making and Using Same |
JP2005503320A (ja) * | 2000-08-25 | 2005-02-03 | イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド | CpG−含有ポリヌクレオチドで自己免疫疾患を処置または防止する方法 |
EP1366077B1 (en) * | 2000-09-15 | 2011-05-25 | Coley Pharmaceutical GmbH | PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST |
AU9475001A (en) * | 2000-09-26 | 2002-04-08 | Hybridon Inc | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
CA2881568C (en) | 2000-10-27 | 2019-09-24 | Novartis Vaccines And Diagnostics, Inc. | Nucleic acids and proteins from streptococcus groups a & b |
US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
WO2006091720A2 (en) * | 2000-12-08 | 2006-08-31 | 3M Innovative Properties Company | Compositions and methods for targeted delivery of immune response modifiers |
ES2307568T3 (es) | 2000-12-08 | 2008-12-01 | Coley Pharmaceutical Gmbh | Acidos nucleicos de tipo cpg y metodos de uso de los mismos. |
WO2002052002A2 (en) * | 2000-12-27 | 2002-07-04 | Dynavax Technologies Corporation | Immunomodulatory polynucleotides and methods of using the same |
CA2434573A1 (en) * | 2001-01-12 | 2002-07-18 | Amato Pharmaceutical Products, Ltd. | Agent for protection against microorganism infection |
US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
DE10290185D2 (de) * | 2001-01-31 | 2004-04-15 | Mologen Forschungs Entwicklung | Tumorvakzine |
US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
WO2002083859A2 (en) * | 2001-04-13 | 2002-10-24 | Wyeth | Surface proteins of streptococcus pyogenes |
US20070128229A1 (en) * | 2002-04-12 | 2007-06-07 | Wyeth | Surface proteins of Streptococcus pyogenes |
KR20080081201A (ko) | 2001-04-16 | 2008-09-08 | 와이어쓰 홀딩스 코포레이션 | 폴리펩티드 항원을 암호화하는 신규한 스트렙토코쿠스뉴모니애 개방형 판독 프레임 및 이를 포함하는 조성물 |
US7034140B2 (en) * | 2001-04-24 | 2006-04-25 | E.I. Du Pont De Nemours And Company | Genes involved in isoprenoid compound production |
WO2002094845A2 (en) | 2001-05-21 | 2002-11-28 | Intercell Ag | Method for stabilising of nucleic acids |
US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
ES2487645T3 (es) * | 2001-06-21 | 2014-08-22 | Dynavax Technologies Corporation | Compuestos inmunomoduladores quiméricos y métodos de uso de los mismos |
US7785610B2 (en) * | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
US20030138458A1 (en) * | 2001-06-29 | 2003-07-24 | Michael Houghton | HCV E1E2 vaccine compositions |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
US20030148316A1 (en) * | 2001-08-01 | 2003-08-07 | Lipford Grayson B. | Methods and compositions relating to plasmacytoid dendritic cells |
WO2003025119A2 (en) * | 2001-08-03 | 2003-03-27 | Medarex, Inc. | Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies |
EP1420829A4 (en) * | 2001-08-07 | 2006-05-17 | Dynavax Tech Corp | IMMUNOMODULATING COMPOSITIONS, FORMULATIONS AND METHOD FOR THEIR USE |
WO2003020884A2 (en) * | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
DE60229422D1 (de) * | 2001-08-17 | 2008-11-27 | Coley Pharm Gmbh | Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung |
JP4319908B2 (ja) | 2001-08-24 | 2009-08-26 | ユニバーシティ オブ ビクトリア イノベーション アンド ディベロップメント コーポレーション | プロテアーゼ活性化配列を含むプロアエロリシンおよび前立腺癌の治療のための使用方法 |
WO2003020889A2 (en) * | 2001-08-30 | 2003-03-13 | 3M Innovative Properties Company | Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
JP2005501917A (ja) * | 2001-09-07 | 2005-01-20 | ザ トラスティーズ オブ ボストン ユニバーシティ | 免疫複合体関連疾患を処置するための方法および組成物 |
EP1425040A2 (en) * | 2001-09-14 | 2004-06-09 | Cytos Biotechnology AG | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
AU2002339224B2 (en) * | 2001-09-14 | 2008-10-09 | Kuros Us Llc | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
WO2003027313A2 (en) | 2001-09-24 | 2003-04-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE |
US20030119774A1 (en) * | 2001-09-25 | 2003-06-26 | Marianna Foldvari | Compositions and methods for stimulating an immune response |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
EP1451581A4 (en) * | 2001-10-05 | 2006-01-11 | Coley Pharm Gmbh | AGONISTS AND ANTAGONISTS OF THE SIGNALING OF THE GREAT-SIMILAR RECEPTOR 3 |
WO2003030656A2 (en) | 2001-10-06 | 2003-04-17 | Merial Limited | Methods and compositions for promoting growth and innate immunity in young animals |
US20050238660A1 (en) * | 2001-10-06 | 2005-10-27 | Babiuk Lorne A | Cpg formulations and related methods |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
WO2003094836A2 (en) * | 2001-10-12 | 2003-11-20 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
WO2003039595A2 (en) * | 2001-11-07 | 2003-05-15 | Inex Pharmaceuticals Corporation | Mucosal adjuvants comprising an oligonucleotide and a cationic lipid |
US20050085433A1 (en) * | 2001-11-09 | 2005-04-21 | Claudia Breidenstein | Cellular vaccines comprising adjuvants |
US7179798B2 (en) * | 2001-11-16 | 2007-02-20 | Russell R. Roby | Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions |
US20040014779A1 (en) * | 2001-11-16 | 2004-01-22 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and toll-like recptor pathways |
US20050250716A1 (en) * | 2001-12-07 | 2005-11-10 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
US7615227B2 (en) * | 2001-12-20 | 2009-11-10 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce angiogenesis |
CA2365732A1 (en) * | 2001-12-20 | 2003-06-20 | Ibm Canada Limited-Ibm Canada Limitee | Testing measurements |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
CA2471092A1 (en) * | 2001-12-21 | 2003-07-10 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
JP2005526497A (ja) * | 2002-02-04 | 2005-09-08 | ビオミラ,インコーポレーテッド | 免疫刺激性、共有結合性脂質化オリゴヌクレオチド |
US8088388B2 (en) * | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
JP4646516B2 (ja) | 2002-02-20 | 2011-03-09 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 吸着したポリペプチド含有分子を有する微粒子 |
PT1478327E (pt) * | 2002-02-22 | 2015-08-04 | Meda Ab | Método de redução e tratamento de imunossupressão induzida por uvb |
US6923958B2 (en) * | 2002-03-02 | 2005-08-02 | The Scripps Research Institute | DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
CA2479187A1 (en) * | 2002-03-15 | 2003-09-25 | Astral, Inc. | Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response |
EP2258712A3 (en) | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
NZ535754A (en) * | 2002-03-15 | 2007-01-26 | Wyeth Corp | Mutants of the P4 protein of nontypable haemophilus influenzae with reduced enzymatic activity |
WO2003086280A2 (en) * | 2002-04-04 | 2003-10-23 | Coley Pharmaceutical Gmbh | Immunostimulatory g,u-containing oligoribonucleotides |
US20030224013A1 (en) * | 2002-04-19 | 2003-12-04 | Cole Garry T. | Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein |
US20040009943A1 (en) * | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Pathogen vaccines and methods for using the same |
US20040009944A1 (en) * | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Methylated immunostimulatory oligonucleotides and methods of using the same |
US20040013649A1 (en) * | 2002-05-10 | 2004-01-22 | Inex Pharmaceuticals Corporation | Cancer vaccines and methods of using the same |
US9045727B2 (en) | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
US20060088909A1 (en) * | 2002-05-17 | 2006-04-27 | Compans Richard W | Virus-like particles, methods of preparation, and immunogenic compositions |
KR100456681B1 (ko) * | 2002-05-22 | 2004-11-10 | 주식회사 대웅 | 박테리아의 염색체 dna 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물 |
CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
US20040009949A1 (en) * | 2002-06-05 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids |
BR0311995A (pt) * | 2002-06-20 | 2005-04-05 | Cytos Biotechnology Ag | Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso |
US7807803B2 (en) * | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040053880A1 (en) * | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) * | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
CN1678188B (zh) * | 2002-07-03 | 2012-10-10 | 科勒制药集团有限公司 | 调节免疫反应的核酸成份 |
US7576066B2 (en) * | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
AU2003255969A1 (en) * | 2002-07-17 | 2004-02-02 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
US20060270620A1 (en) * | 2002-07-23 | 2006-11-30 | University Of South Florida | Method of Enhancing Therapeutic Effect of Nucleic Acids |
EP1523557A2 (en) | 2002-07-24 | 2005-04-20 | Intercell AG | Antigens encoded by alternative reading frame from pathogenic viruses |
EP1575504A4 (en) | 2002-08-01 | 2009-11-04 | Us Gov Health & Human Serv | METHOD FOR THE TREATMENT OF INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF THE CPG OLIGONUCLEOTIDES |
DK1545597T3 (da) | 2002-08-15 | 2011-01-31 | 3M Innovative Properties Co | Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons |
AR040996A1 (es) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
US7785608B2 (en) * | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
US7595303B1 (en) * | 2002-09-05 | 2009-09-29 | University Of South Florida | Genetic adjuvants for immunotherapy |
US20050196382A1 (en) * | 2002-09-13 | 2005-09-08 | Replicor, Inc. | Antiviral oligonucleotides targeting viral families |
EP1537418A2 (en) | 2002-09-13 | 2005-06-08 | Intercell AG | Method for isolating hepatitis c virus peptides |
EP1537208A1 (en) * | 2002-09-13 | 2005-06-08 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
US7301554B2 (en) * | 2002-09-20 | 2007-11-27 | Ricoh Company, Ltd. | Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method |
AU2003268737A1 (en) * | 2002-10-02 | 2004-04-23 | Mochida Pharmaceutical Co., Ltd. | Novel method of constructing monoclonal antibody |
US8043622B2 (en) | 2002-10-08 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
BRPI0315228A8 (pt) | 2002-10-11 | 2018-04-03 | Chiron Srl | Vacinas de polipeptídeo para ampla proteção contra linhagens meningocócicas hipervirulentas |
CA2503457A1 (en) * | 2002-10-25 | 2004-05-06 | University Of Connecticut Health Center | Apparatus and method for immunotherapy of a cancer through controlled cell lysis |
CN1753687A (zh) * | 2002-10-29 | 2006-03-29 | 科勒制药集团股份有限公司 | Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用 |
AU2003304107B2 (en) * | 2002-11-01 | 2008-05-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides |
WO2004044139A2 (en) * | 2002-11-05 | 2004-05-27 | Isis Parmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
WO2004046177A2 (en) | 2002-11-15 | 2004-06-03 | Chiron Srl | Unexpected surface proteins in neisseria meningitidis |
US8039443B2 (en) * | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US10100316B2 (en) * | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
EP2298360A3 (en) * | 2002-11-21 | 2011-07-13 | Bayhill Therapeutics, Inc. | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US20050124565A1 (en) * | 2002-11-21 | 2005-06-09 | Diener John L. | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
JP2006512927A (ja) | 2002-12-11 | 2006-04-20 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 5’cpg核酸およびその使用方法 |
AU2003287316A1 (en) * | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
WO2004052293A2 (en) * | 2002-12-11 | 2004-06-24 | Hawaii Biotech, Inc. | Recombinant vaccine against flavivirus infection |
WO2004053057A2 (en) * | 2002-12-11 | 2004-06-24 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
AU2003302743B2 (en) * | 2002-12-23 | 2008-09-04 | Dynavax Technologies Corporation | Branched immunomodulatory compounds and methods of using the same |
ATE544772T1 (de) | 2002-12-23 | 2012-02-15 | Dynavax Tech Corp | Immunstimulierende sequenz-oligonukleotide und verwendungsverfahren dafür |
CA2511512C (en) | 2002-12-27 | 2013-10-29 | Chiron Corporation | Immunogenic compositions containing phospholipid |
EP2572714A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
PT1587537E (pt) | 2003-01-30 | 2012-05-30 | Novartis Ag | Vacinas injetáveis contra múltiplos serogrupos meningocócicos |
US7354907B2 (en) * | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
EP1592302A4 (en) * | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8 |
ATE491463T1 (de) | 2003-02-20 | 2011-01-15 | Univ Connecticut Health Ct | Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen |
GB2398783A (en) | 2003-02-26 | 2004-09-01 | Antonio Lanzavecchia | A method for producing immortalised human B memory lymphocytes |
WO2004075865A2 (en) * | 2003-02-27 | 2004-09-10 | 3M Innovative Properties Company | Selective modulation of tlr-mediated biological activity |
EP1601365A4 (en) | 2003-03-04 | 2009-11-11 | 3M Innovative Properties Co | PROPHYLACTIC TREATMENT OF UV-INDUCED EPIDERMAL NEOPLASIA |
CN100439386C (zh) * | 2003-03-05 | 2008-12-03 | 长春华普生物技术有限公司 | 增强蛋白类疫苗免疫效果的含CpG单链脱氧寡核苷酸 |
ATE556711T1 (de) * | 2003-03-13 | 2012-05-15 | 3M Innovative Properties Co | Verfahren zur verbesserung der hautqualität |
WO2004080292A2 (en) | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Method of tattoo removal |
ES2562456T3 (es) | 2003-03-24 | 2016-03-04 | Valneva Austria Gmbh | Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes |
US20040192585A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
CA2520181A1 (en) * | 2003-03-26 | 2004-10-14 | Astral Inc. | Selected rna motifs to include cell death and/or apoptosis |
US20060210588A1 (en) * | 2003-03-26 | 2006-09-21 | Cytos Biotechnology Ag | Hiv-peptide-carrier-conjugates |
AU2004224761A1 (en) | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | HIV-peptide-carrier-conjugates |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
AU2004226605A1 (en) * | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
US20040265351A1 (en) * | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
EP1617871A4 (en) * | 2003-04-10 | 2010-10-06 | 3M Innovative Properties Co | DISTRIBUTION OF IMMUNE-RESPONSE-MODIFYING COMPOUNDS USING PARTICULATE CARRIER MATERIALS CONTAINING METAL |
US20060257852A1 (en) | 2003-04-10 | 2006-11-16 | Chiron Corporation | Severe acute respiratory syndrome coronavirus |
EP2623601B1 (en) | 2003-04-21 | 2015-02-18 | Archemix LLC | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
JP4673217B2 (ja) * | 2003-04-23 | 2011-04-20 | 由紀夫 佐藤 | メチル化CpGポリヌクレオチド |
US20050250106A1 (en) * | 2003-04-24 | 2005-11-10 | David Epstein | Gene knock-down by intracellular expression of aptamers |
AU2004233851B2 (en) * | 2003-04-25 | 2009-07-30 | Novartis Vaccines And Diagnostics, Inc. | Compositions comprising cationic microparticles and HCV E1E2 DNA and methods of use thereof |
EP1617845A4 (en) * | 2003-04-28 | 2006-09-20 | 3M Innovative Properties Co | COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS |
WO2004100965A1 (ja) * | 2003-05-15 | 2004-11-25 | Japan Science And Technology Agency | 免疫刺激剤 |
US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
ES2328697T5 (es) | 2003-06-02 | 2017-07-25 | Novartis Vaccines And Diagnostics, Inc. | Composiciones inmunogénicas basadas en micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido |
US7803386B2 (en) | 2003-06-05 | 2010-09-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli |
ES2569927T3 (es) * | 2003-06-11 | 2016-05-13 | Idera Pharmaceuticals, Inc. | Oligonucleótidos inmunomoduladores estabilizados |
US7410975B2 (en) * | 2003-06-20 | 2008-08-12 | Coley Pharmaceutical Group, Inc. | Small molecule toll-like receptor (TLR) antagonists |
KR20060031607A (ko) * | 2003-07-10 | 2006-04-12 | 사이토스 바이오테크놀로지 아게 | 패킹된 바이러스-양 입자 |
US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
US20080039533A1 (en) * | 2003-07-31 | 2008-02-14 | 3M Innovative Properties Company | Bioactive Compositions Comprising Triazines |
CA2534313C (en) * | 2003-08-05 | 2013-03-19 | 3M Innovative Properties Company | Formulations containing an immune response modifier |
JP2007502288A (ja) * | 2003-08-12 | 2007-02-08 | スリーエム イノベイティブ プロパティズ カンパニー | オキシム置換イミダゾ含有化合物 |
US20050065136A1 (en) * | 2003-08-13 | 2005-03-24 | Roby Russell R. | Methods and compositions for the treatment of infertility using dilute hormone solutions |
US20060035242A1 (en) | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
WO2005020902A2 (en) * | 2003-08-21 | 2005-03-10 | Cytokine Pharmasciences, Inc. | Compositions and methods for treating and diagnosing irritable bowel syndrome |
WO2005020912A2 (en) * | 2003-08-25 | 2005-03-10 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
WO2005018574A2 (en) * | 2003-08-25 | 2005-03-03 | 3M Innovative Properties Company | Immunostimulatory combinations and treatments |
AU2004268625B2 (en) * | 2003-08-27 | 2011-03-31 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
EP1663222A4 (en) * | 2003-09-02 | 2008-05-21 | 3M Innovative Properties Co | METHODS RELATING TO THE TREATMENT OF GIANCES |
JP2007504269A (ja) * | 2003-09-05 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | Cd5+b細胞リンパ腫の治療方法 |
US8541002B2 (en) | 2003-09-12 | 2013-09-24 | Agenus Inc. | Vaccine for treatment and prevention of herpes simplex virus infection |
CA2536139A1 (en) * | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
ES2397923T3 (es) | 2003-10-02 | 2013-03-12 | Novartis Ag | Vacunas líquidas para múltiples serogrupos meningocócicos |
US20090075980A1 (en) * | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
US7544697B2 (en) * | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
ES2544477T3 (es) * | 2003-10-03 | 2015-08-31 | 3M Innovative Properties Company | Imidazoquinolinas sustituidas con alcoxi |
WO2005034979A2 (en) * | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
GB0323965D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
UA88457C2 (ru) * | 2003-10-30 | 2009-10-26 | Коли Фармасьютикал Гмбх | Иммуностимулирующая нуклеиновая кислота с улучшенной иммуностимулирующей эффективностью |
US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
WO2005041891A2 (en) * | 2003-10-31 | 2005-05-12 | 3M Innovative Properties Company | Neutrophil activation by immune response modifier compounds |
US20050100983A1 (en) * | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
CA2545774A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Oxime substituted imidazo ring compounds |
EP1682544A4 (en) * | 2003-11-14 | 2009-05-06 | 3M Innovative Properties Co | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS |
NZ547467A (en) * | 2003-11-25 | 2010-06-25 | 3M Innovative Properties Co | Substituted imidazo ring system and methods |
US20050287118A1 (en) * | 2003-11-26 | 2005-12-29 | Epitomics, Inc. | Bacterial plasmid with immunological adjuvant function and uses thereof |
US20050277127A1 (en) * | 2003-11-26 | 2005-12-15 | Epitomics, Inc. | High-throughput method of DNA immunogen preparation and immunization |
US20050226878A1 (en) * | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
WO2005055932A2 (en) * | 2003-12-02 | 2005-06-23 | 3M Innovative Properties Company | Therapeutic combinations and methods including irm compounds |
US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
HUE026000T2 (en) | 2003-12-17 | 2016-04-28 | Wyeth Llc | Immunogenic peptide-bearing conjugates and methods for their preparation |
EP2336147B1 (en) | 2003-12-17 | 2014-04-30 | Janssen Alzheimer Immunotherapy | A beta immunogenic peptide carrier conjugates and methods of producing same |
JP4817599B2 (ja) * | 2003-12-25 | 2011-11-16 | 独立行政法人科学技術振興機構 | 免疫活性増強剤とこれを用いた免疫活性の増強方法 |
JP2007517035A (ja) * | 2003-12-29 | 2007-06-28 | スリーエム イノベイティブ プロパティズ カンパニー | アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン |
EP1699788A2 (en) * | 2003-12-30 | 2006-09-13 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides |
EP1699398A4 (en) * | 2003-12-30 | 2007-10-17 | 3M Innovative Properties Co | IMPROVING THE IMMUNE RESPONSE |
KR100558851B1 (ko) * | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | 면역조절능력이 증가된 CpG 올리고데옥시뉴클레오티드변형체 |
US7973016B2 (en) * | 2004-01-23 | 2011-07-05 | Joslin Diebetes Center | Methods of treating, reducing, or preventing autoimmune conditions |
US20050181035A1 (en) * | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
TW200533750A (en) * | 2004-02-19 | 2005-10-16 | Coley Pharm Group Inc | Immunostimulatory viral RNA oligonucleotides |
WO2005080567A1 (de) * | 2004-02-20 | 2005-09-01 | Mologen Ag | Substituiertes, nicht-kodierendes nukleinsäuremolekül zur therapeutischen und prophylaktischen immunstimulation in menschen und höheren tieren |
US20060193821A1 (en) * | 2004-03-05 | 2006-08-31 | Diener John L | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
JP5600375B2 (ja) | 2004-03-09 | 2014-10-01 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | インフルエンザウイルスワクチン |
WO2005090968A1 (en) * | 2004-03-16 | 2005-09-29 | Inist Inc. | Tat-based immunomodulatory compositions and methods of their discovery and use |
US7820175B2 (en) | 2004-03-19 | 2010-10-26 | Herbal Spring, Llc | Herbal therapy for the treatment of food allergy |
US8697873B2 (en) * | 2004-03-24 | 2014-04-15 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
TWI235440B (en) * | 2004-03-31 | 2005-07-01 | Advanced Semiconductor Eng | Method for making leadless semiconductor package |
JP2007531746A (ja) * | 2004-04-02 | 2007-11-08 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Il−10応答を誘導するための免疫活性化核酸 |
US20050260755A1 (en) * | 2004-04-06 | 2005-11-24 | Isis Pharmaceuticals, Inc. | Sequential delivery of oligomeric compounds |
WO2005105106A2 (en) * | 2004-04-21 | 2005-11-10 | Roby Russell R | Hormone treatment of macular degeneration |
US20050239758A1 (en) * | 2004-04-21 | 2005-10-27 | Roby Russell R | Hormone treatment of multiple sclerosis |
US7579450B2 (en) * | 2004-04-26 | 2009-08-25 | Archemix Corp. | Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics |
CN101426524A (zh) * | 2004-04-28 | 2009-05-06 | 3M创新有限公司 | 用于粘膜接种疫苗的组合物和方法 |
GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
PT1740217E (pt) | 2004-04-30 | 2011-08-02 | Novartis Ag | Vacinação meningocócica conjugada |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
EP1751612B1 (en) * | 2004-05-06 | 2009-02-25 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Methods and compositions for the treatment of uveitis |
GB0410220D0 (en) | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
CN1296378C (zh) * | 2004-05-17 | 2007-01-24 | 中国人民解放军第三军医大学 | 高免疫活性 CpG-S ODN 和拮抗 CpG-S ODN 作用的 CpG-N ODN 的基因序列及其应用 |
EP1766094A4 (en) * | 2004-05-18 | 2009-11-25 | Vical Inc | INFLUENZA VIRUS VACCINE COMPOSITION AND METHODS OF USE |
WO2006078294A2 (en) | 2004-05-21 | 2006-07-27 | Novartis Vaccines And Diagnostics Inc. | Alphavirus vectors for respiratory pathogen vaccines |
MXPA06013448A (es) | 2004-05-21 | 2007-01-23 | Wyeth Corp | Proteina alterada que liga a la fibronectina en staphylococcus aureus. |
US20050267145A1 (en) * | 2004-05-28 | 2005-12-01 | Merrill Bryon A | Treatment for lung cancer |
DK1765310T3 (en) | 2004-05-28 | 2016-01-11 | Oryxe | MIXING for transdermal delivery of LAV AND HØJMOLEKYLVÆGTFORBINDELSER |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
AU2005326144A1 (en) * | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
WO2005123080A2 (en) * | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
WO2006009832A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
WO2006065280A2 (en) * | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
US8026366B2 (en) * | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
WO2006038923A2 (en) * | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
US7482158B2 (en) * | 2004-07-01 | 2009-01-27 | Mathison Brian H | Composite polynucleic acid therapeutics |
JP2008506789A (ja) * | 2004-07-18 | 2008-03-06 | シーエスエル、リミテッド | インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物 |
US20060025390A1 (en) * | 2004-07-28 | 2006-02-02 | Roby Russell R | Treatment of hormone allergy and related symptoms and disorders |
EP2612679A1 (en) | 2004-07-29 | 2013-07-10 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
ES2534288T3 (es) | 2004-08-03 | 2015-04-21 | Innate Pharma | Composiciones terapéuticas contra el cáncer que seleccionan como objetivo 4Ig-B7-H3 |
US20060045886A1 (en) * | 2004-08-27 | 2006-03-02 | Kedl Ross M | HIV immunostimulatory compositions |
WO2006026760A2 (en) * | 2004-09-02 | 2006-03-09 | 3M Innovative Properties Company | 1-amino imidazo-containing compounds and methods |
US7884086B2 (en) * | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
PT1791858E (pt) | 2004-09-24 | 2010-07-26 | Intercell Ag | PROTENA DE CáPSIDE VP1 MODIFICADA DO PARVOVRUS B19 |
JP2008000001A (ja) * | 2004-09-30 | 2008-01-10 | Osaka Univ | 免疫刺激オリゴヌクレオチドおよびその医薬用途 |
KR101376889B1 (ko) | 2004-10-06 | 2014-03-25 | 메디뮨 엘엘씨 | 냉장 온도 안정성 인플루엔자 백신 조성물 |
AU2005294129B2 (en) | 2004-10-08 | 2010-12-23 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Modulation of replicative fitness by using less frequently used synonymous codons |
US20070243215A1 (en) * | 2004-10-08 | 2007-10-18 | Miller Richard L | Adjuvant for Dna Vaccines |
MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
WO2007001423A2 (en) | 2004-10-21 | 2007-01-04 | Wyeth | Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
EP2436391A3 (en) | 2004-11-02 | 2012-07-04 | Archemix LLC | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US7332324B2 (en) | 2004-12-03 | 2008-02-19 | University Of Toledo | Attenuated vaccine useful for immunizations against Coccidioides spp. infections |
WO2006063072A2 (en) * | 2004-12-08 | 2006-06-15 | 3M Innovative Properties Company | Immunomodulatory compositions, combinations and methods |
WO2006065751A2 (en) * | 2004-12-13 | 2006-06-22 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods |
WO2006073760A2 (en) | 2004-12-17 | 2006-07-13 | Dana-Farber Cancer Institute, Inc. | Regulation of mink in thymocytes and t lymphocytes |
CA2592922A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
US8034938B2 (en) | 2004-12-30 | 2011-10-11 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
WO2006071997A2 (en) | 2004-12-30 | 2006-07-06 | 3M Innovative Properties Company | Treatment for cutaneous metastases |
ES2392647T3 (es) * | 2004-12-30 | 2012-12-12 | 3M Innovative Properties Company | Compuestos tetracíclicos quirales que inducen la biosíntesis de interferón |
LT2682126T (lt) | 2005-01-27 | 2017-02-27 | Children`s Hospital & Research Center at Oakland | Gna1870 pagrindu gaminamos pūslelių pavidalo vakcinos, skirtos plataus spektro apsaugai nuo neisseria meningitidis sukeltų ligų |
JP4836145B2 (ja) * | 2005-01-28 | 2011-12-14 | クウォン,ヒュン−ジョ | マイコバクテリアに由来する、免疫機能刺激用、免疫疾患治療用、アトピー性皮膚炎治療用および/または正常免疫細胞保護用オリゴヌクレオチド |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
WO2006084251A2 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune reponse modifiers |
US7968563B2 (en) | 2005-02-11 | 2011-06-28 | 3M Innovative Properties Company | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
US8062644B2 (en) | 2005-02-18 | 2011-11-22 | Novartis Vaccines & Diagnostics Srl. | Immunogens from uropathogenic Escherichia coli |
PL2351772T3 (pl) | 2005-02-18 | 2017-01-31 | Glaxosmithkline Biologicals Sa | Białka i kwasy nukleinowe z bakterii Escherichia coli związanej z zapaleniem opon mózgowo-rdzeniowych/posocznicą |
JP2008531018A (ja) * | 2005-02-24 | 2008-08-14 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 免疫刺激性オリゴヌクレオチド |
JP2008531722A (ja) | 2005-03-04 | 2008-08-14 | ダイナバックス テクノロジーズ コーポレイション | 構造的に安定なコンジュゲート分子を含む組成物 |
US8101345B1 (en) | 2005-03-25 | 2012-01-24 | Isis Pharmaceuticals, Inc. | Proinflammatory nucleic acids |
AU2006232375A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
EP1869043A2 (en) | 2005-04-01 | 2007-12-26 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
CN113198013B (zh) | 2005-04-08 | 2024-02-20 | 惠氏有限责任公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
JP2008535862A (ja) * | 2005-04-08 | 2008-09-04 | キメリクス,インコーポレイテッド | ポックスウイルス感染の治療のための化合物、組成物および方法 |
WO2006110656A2 (en) * | 2005-04-08 | 2006-10-19 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
SG161260A1 (en) * | 2005-04-08 | 2010-05-27 | Coley Pharm Group Inc | Methods for treating infectious disease exacerbated asthma |
US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
CA2604683C (en) | 2005-04-12 | 2019-04-30 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
EP2329843A3 (en) | 2005-04-18 | 2011-09-14 | Novartis Vaccines and Diagnostics, Inc. | Expressing Hepatitis B Virus surface antigen for vaccine preparation |
US20080193474A1 (en) * | 2005-04-25 | 2008-08-14 | Griesgraber George W | Immunostimulatory Compositions |
US20090075342A1 (en) * | 2005-04-26 | 2009-03-19 | Sharon Cload | Metabolic profile directed aptamer medicinal chemistry |
US20060241076A1 (en) * | 2005-04-26 | 2006-10-26 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
CN101238145B (zh) | 2005-06-14 | 2013-04-24 | 普罗陶克斯有限公司 | 修饰的成孔蛋白在制备治疗或预防良性前列腺增生的药物中的应用 |
MX2007016561A (es) | 2005-06-30 | 2008-03-10 | Archemix Corp | Materiales y metodos para la generacion de transcriptos de acido nucleico completamente modificados en la posicion 2. |
US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
ES2450593T3 (es) | 2005-07-01 | 2014-03-25 | Index Pharmaceuticals Ab | Método inmunoestimulante |
PL2179737T3 (pl) | 2005-07-01 | 2014-01-31 | Index Pharmaceuticals Ab | Sposób do modulowania wrażliwości na steroidy |
US20090117132A1 (en) * | 2005-07-07 | 2009-05-07 | Pfizer, Inc. | Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment |
WO2007008904A2 (en) * | 2005-07-08 | 2007-01-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections |
EP2614709A1 (en) | 2005-07-18 | 2013-07-17 | Novartis AG | Small animal model for HCV replication |
WO2007012285A1 (fr) * | 2005-07-28 | 2007-02-01 | Changchun Huapu Biotechnology Co., Ltd. | Desoxynucleosides monocatenaires resistant aux infections virales |
KR20080047463A (ko) * | 2005-09-16 | 2008-05-28 | 콜리 파마슈티칼 게엠베하 | 뉴클레오티드 변형에 의한 짧은 간섭 리보핵산(sirna)의 면역자극 특성의 조절 |
BRPI0616235A2 (pt) * | 2005-09-16 | 2011-06-14 | Coley Pharm Gmbh | acido ribonuclÉico monofilamentado imunoestimulante com cadeia principal de fosfodiÉster |
WO2007041190A2 (en) * | 2005-09-30 | 2007-04-12 | The University Of Iowa Research Foundation | Polymer-based delivery system for immunotherapy of cancer |
WO2007047749A1 (en) | 2005-10-18 | 2007-04-26 | Novartis Vaccines And Diagnostics Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
CA2625969A1 (en) | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
PT2368572T (pt) | 2005-11-04 | 2020-06-16 | Seqirus Uk Ltd | Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular |
AU2006310339B2 (en) | 2005-11-04 | 2013-01-10 | Novartis Ag | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
EP1951302A2 (en) | 2005-11-04 | 2008-08-06 | Novartis Vaccines and Diagnostics S.r.l. | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
CN102755645A (zh) | 2005-11-04 | 2012-10-31 | 诺华疫苗和诊断有限公司 | 佐剂配制的包含细胞因子诱导剂的流感疫苗 |
CN102864152B (zh) * | 2005-11-07 | 2015-11-18 | 艾德拉药物股份有限公司 | 包含经修饰的免疫刺激性二核苷酸的基于寡核苷酸的化合物之免疫刺激特性 |
JP5215865B2 (ja) | 2005-11-22 | 2013-06-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | ノロウイルス抗原およびサポウイルス抗原 |
AU2006318464B2 (en) | 2005-11-25 | 2011-02-17 | Zoetis Belgium Sa | Immunostimulatory oligoribonucleotides |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
US20070184068A1 (en) | 2005-12-14 | 2007-08-09 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
WO2007085969A2 (en) | 2006-01-27 | 2007-08-02 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Influenza vaccines containing hemagglutinin and matrix proteins |
EP2405002B1 (en) | 2006-02-15 | 2014-09-24 | AdiuTide Pharmaceuticals GmbH | Compositions and methods for oligonucleotide formulations |
EP1988896A4 (en) * | 2006-02-22 | 2011-07-27 | 3M Innovative Properties Co | CONJUGATES TO MODIFY IMMUNE REACTIONS |
BRPI0708912B8 (pt) | 2006-03-14 | 2021-07-27 | Univ Oregon Health & Science | métodos in vitro para detecção de mycobacterium tuberculosis e de células t expressando cd8 que especificamente reconhecem seq id no: 11 em um indivíduo |
ES2388556T3 (es) * | 2006-03-23 | 2012-10-16 | Novartis Ag | Compuestos inmunopotenciadores |
EP2357184B1 (en) | 2006-03-23 | 2015-02-25 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
CA2646349A1 (en) | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
WO2007126825A2 (en) | 2006-03-31 | 2007-11-08 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
WO2007119815A1 (ja) | 2006-04-14 | 2007-10-25 | Kyowa Hakko Kirin Co., Ltd. | Toll様受容体9作動薬 |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
CN101460620B (zh) | 2006-05-31 | 2012-02-15 | 东丽株式会社 | 免疫刺激寡核苷酸及其药物用途 |
WO2007143582A2 (en) * | 2006-06-05 | 2007-12-13 | Baylor College Of Medicine | Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling |
ATE522541T1 (de) | 2006-06-09 | 2011-09-15 | Novartis Ag | Bakterielle adhäsine konformere |
SG172696A1 (en) | 2006-06-12 | 2011-07-28 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
BRPI0713711A2 (pt) | 2006-06-20 | 2012-10-30 | Transgene Sa | vacina viral recombinante, kit para vacinação, e, método para usar pelo menos um composto |
US8153116B2 (en) | 2006-07-11 | 2012-04-10 | University Of Connecticut | Use of conditional plasmodium strains lacking an essential gene in malaria vaccination |
WO2008094183A2 (en) * | 2006-07-11 | 2008-08-07 | University Of Connecticut | Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination |
WO2008008432A2 (en) * | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
EP2586790A3 (en) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogens from uropathogenic Escherichia coli |
ES2536401T3 (es) | 2006-09-11 | 2015-05-25 | Novartis Ag | Fabricación de vacunas contra virus de la gripe sin usar huevos |
PT2078080E (pt) * | 2006-09-27 | 2015-09-18 | Coley Pharm Gmbh | Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada |
DE102006050655A1 (de) * | 2006-10-24 | 2008-04-30 | Halmon Beheer B.V. | Pharmazeutische Zusammensetzung zur Behandlung allergischer Erkrankungen |
US20100144846A1 (en) * | 2006-10-26 | 2010-06-10 | Coley Pharmaceutical Gmbh | Oligoribonucleotides and uses thereof |
EP3564674B1 (en) | 2006-11-01 | 2021-08-25 | Ventana Medical Systems, Inc. | Haptens, hapten conjugates, compositions thereof and method for their preparation and use |
WO2008057529A2 (en) * | 2006-11-06 | 2008-05-15 | Coley Pharmaceutical Group, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp) |
US8252757B2 (en) * | 2006-11-09 | 2012-08-28 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
WO2008140571A2 (en) * | 2006-11-15 | 2008-11-20 | Functional Genetics, Inc. | Methods and compositions for treating influenza |
EP2679240A1 (en) | 2006-12-06 | 2014-01-01 | Novartis AG | Vaccines including antigen from four strains of influenza virus |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
JP5596980B2 (ja) | 2007-02-28 | 2014-10-01 | アメリカ合衆国 | ブラキュリポリペプチドおよび使用方法 |
CA2683752A1 (en) * | 2007-04-13 | 2008-10-23 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
US8518903B2 (en) | 2007-04-19 | 2013-08-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of toll-like receptor-9 agonists |
EP2377952A1 (en) | 2007-04-26 | 2011-10-19 | Ludwig Institute For Cancer Research | Methods for diagnosing and treating astrocytomas |
MX2009012482A (es) * | 2007-05-17 | 2009-12-02 | Coley Pharm Group Inc | Oligonucleotidos de clase a con potencia inmunoestimuladora. |
DK2170353T3 (en) * | 2007-05-18 | 2015-07-27 | Adiutide Pharmaceuticals Gmbh | The phosphate-modified oligonucleotide analogs with immunostimulatory activity |
CA2687178C (en) * | 2007-05-23 | 2014-02-04 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
TW200911304A (en) * | 2007-05-24 | 2009-03-16 | Glaxosmithkline Biolog Sa | Lyophillised antigen composition |
WO2009001217A2 (en) | 2007-06-27 | 2008-12-31 | Novartis Ag | Low-additive influenza vaccines |
GB0713880D0 (en) * | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
US7879812B2 (en) | 2007-08-06 | 2011-02-01 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides and methods of use therefor |
CN101835487A (zh) * | 2007-08-21 | 2010-09-15 | 戴纳瓦克斯技术公司 | 制备和使用流感蛋白质的组合物和方法 |
WO2009034473A2 (en) | 2007-09-12 | 2009-03-19 | Novartis Ag | Gas57 mutant antigens and gas57 antibodies |
CN101820908A (zh) * | 2007-10-09 | 2010-09-01 | 科利制药公司 | 包含改性糖部分的免疫刺激寡核苷酸类似物 |
US20110014231A1 (en) * | 2007-11-05 | 2011-01-20 | Mor Research Applications Ltd | Anti-measles cancer immunotherapy |
WO2010008411A1 (en) | 2007-11-09 | 2010-01-21 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
WO2009076158A1 (en) | 2007-12-07 | 2009-06-18 | Novartis Ag | Compositions for inducing immune responses |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
EP2235046B1 (en) | 2007-12-21 | 2012-08-01 | Novartis AG | Mutant forms of streptolysin o |
PE20091104A1 (es) * | 2007-12-21 | 2009-07-18 | Wyeth Corp | Virus de la estomatitis vesicular atenuado modificado geneticamente, composiciones y metodos de uso del mismo |
CN102670628B (zh) * | 2008-01-25 | 2015-11-25 | 奇默里克斯公司 | 治疗病毒感染的方法 |
DK2176408T5 (en) * | 2008-01-31 | 2015-12-14 | Curevac Gmbh | Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS. |
ES2532946T3 (es) | 2008-02-21 | 2015-04-06 | Novartis Ag | Polipéptidos PUfH meningocócicos |
US9511131B2 (en) | 2008-03-10 | 2016-12-06 | Children's Hospital & Research Center Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
EP3459563A1 (en) | 2008-03-18 | 2019-03-27 | Seqirus UK Limited | Improvements in preparation of influenza virus vaccine antigens |
US8815817B2 (en) * | 2008-05-15 | 2014-08-26 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
US8222225B2 (en) | 2008-05-21 | 2012-07-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating pneumoconiosis with oligodeoxynucleotides |
US8703490B2 (en) | 2008-06-05 | 2014-04-22 | Ventana Medical Systems, Inc. | Compositions comprising nanomaterials and method for using such compositions for histochemical processes |
MX2010014358A (es) | 2008-06-20 | 2011-07-04 | Wyeth Llc | Composiciones y metodos de uso del orf1358 de cepas estreptococicas beta-hemoliticas. |
CA2960734C (en) | 2008-06-27 | 2021-08-24 | Zoetis Services Llc | Adjuvants containing saponins, sterols and quaternary amines |
TWI351288B (en) * | 2008-07-04 | 2011-11-01 | Univ Nat Pingtung Sci & Tech | Cpg dna adjuvant in avian vaccines |
US20110136897A1 (en) * | 2008-08-14 | 2011-06-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders |
EP3301116A1 (en) | 2008-08-25 | 2018-04-04 | Dana Farber Cancer Institute, Inc. | Conserved influenza hemagglutinin epitope and antibodies thereto |
EP2331127A2 (en) | 2008-09-18 | 2011-06-15 | Novartis AG | Vaccine adjuvant combinations |
EP2385371B1 (en) | 2008-09-22 | 2014-10-22 | Oregon Health and Science University | Methods for detecting a mycobacterium tuberculosis infection |
HUE028497T2 (en) * | 2008-10-16 | 2016-12-28 | The Univ Of Saskatchewan | Combination adjuvant composition |
US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
JP2012508174A (ja) * | 2008-11-05 | 2012-04-05 | ワイス・エルエルシー | β溶血性連鎖球菌(BHS)疾患を予防するための多成分免疫原性組成物 |
EP2346529B1 (en) | 2008-11-12 | 2016-02-10 | Theraclone Sciences, Inc. | Human m2e peptide immunogens |
RU2015151857A (ru) | 2008-12-02 | 2019-01-15 | Уэйв Лайф Сайенсес Джапан, Инк. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
PE20142330A1 (es) | 2008-12-09 | 2015-01-14 | Pfizer Vaccines Llc | Vacuna de peptido ch3 de ige |
CN102333538B (zh) | 2008-12-09 | 2014-01-15 | 科勒制药集团有限公司 | 免疫刺激性寡核苷酸 |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
BRPI1005670A8 (pt) | 2009-01-05 | 2017-12-26 | Epitogenesis Inc | composições adjuvantes e processos de uso. |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
CN103897045A (zh) | 2009-01-12 | 2014-07-02 | 诺华股份有限公司 | 抗革兰氏阳性细菌疫苗中的Cna_B结构域 |
WO2010099472A2 (en) | 2009-02-27 | 2010-09-02 | The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services | Spanx-b polypeptides and their use |
EP2403526B1 (en) | 2009-03-06 | 2019-05-15 | GlaxoSmithKline Biologicals SA | Chlamydia antigens |
WO2010111292A1 (en) | 2009-03-23 | 2010-09-30 | Nanirx, Inc. | Treatment of cancer with immunostimulatory hiv tat derivative polypeptides |
SI2411048T1 (sl) | 2009-03-24 | 2020-08-31 | Glaxosmithkline Biologicals Sa | Meningokokni faktor H vezavni protein uporabljen kot adjuvans |
CN102439153B (zh) | 2009-03-25 | 2015-07-22 | 德克萨斯大学系统董事会 | 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物 |
US9402917B2 (en) | 2009-04-03 | 2016-08-02 | Duke University | Methods for the induction of broadly anti-HIV-1 neutralizing antibody responses employing liposome-MPER peptide compositions |
WO2010115118A2 (en) | 2009-04-03 | 2010-10-07 | Antigenics, Inc. | Methods for preparing and using multichaperone-antigen complexes |
MX363222B (es) | 2009-04-14 | 2019-03-15 | Novartis Ag | Composiciones para inmunizacion contra staphylococcus aureus. |
KR20120022984A (ko) * | 2009-04-21 | 2012-03-12 | 셀렉타 바이오사이언시즈, 인크. | Th1 편향 반응을 제공하는 면역나노치료법 |
CA2757620C (en) | 2009-04-30 | 2016-04-26 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
EA201791383A1 (ru) | 2009-05-27 | 2018-06-29 | Селекта Байосайенсиз, Инк. | Наноносители, имеющие компоненты с различными скоростями высвобождения |
CN102802665B (zh) | 2009-06-15 | 2015-11-25 | 新加坡国立大学 | 流感疫苗、组合物及使用方法 |
TW201544119A (zh) | 2009-06-22 | 2015-12-01 | Wyeth Llc | 組合物及製備金黃色葡萄球菌血清型5及8莢膜多醣結合物之免疫原性組合物之方法 |
PE20110023A1 (es) | 2009-06-22 | 2011-01-31 | Wyeth Llc | Composiciones inmunogenicas de antigenos de staphylococcus aureus |
RU2612521C2 (ru) | 2009-07-06 | 2017-03-09 | Онтории, Инк. | Новые пролекарства нуклеиновых кислот и способы их применения |
TW201116294A (en) | 2009-07-15 | 2011-05-16 | Novartis Ag | RSV F protein compositions and methods for making same |
PT2464658E (pt) | 2009-07-16 | 2015-01-14 | Novartis Ag | Imunogénios de escherichia coli desintoxicados |
KR101346197B1 (ko) | 2009-07-17 | 2014-02-06 | 한림대학교 산학협력단 | 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물 |
US8614200B2 (en) | 2009-07-21 | 2013-12-24 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
MX2012001194A (es) | 2009-07-30 | 2012-03-07 | Pfizer Vaccines Llc | Peptidos tau antigenicos y usos de los mismos. |
US20110033515A1 (en) * | 2009-08-04 | 2011-02-10 | Rst Implanted Cell Technology | Tissue contacting material |
IN2012DN01984A (zh) * | 2009-08-18 | 2015-07-24 | Baxter Int | |
US8598327B2 (en) | 2009-08-18 | 2013-12-03 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
CN107617110A (zh) | 2009-08-26 | 2018-01-23 | 西莱克塔生物科技公司 | 诱导t细胞辅助的组合物 |
US8858958B2 (en) | 2009-08-27 | 2014-10-14 | Novartis Ag | Adjuvant comprising aluminum, oligonucleotide and polycation |
CN102596240B (zh) | 2009-08-27 | 2015-02-04 | 诺华股份有限公司 | 包括脑膜炎球菌fHBP序列的杂交多肽 |
WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
NO2473605T3 (zh) | 2009-09-03 | 2018-09-08 | ||
JP2013504556A (ja) | 2009-09-10 | 2013-02-07 | ノバルティス アーゲー | 気道疾患に対する組み合わせワクチン |
GB0917002D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
CN102596254B (zh) | 2009-09-30 | 2016-10-19 | 诺华股份有限公司 | 金黄色葡萄球菌5型和8型荚膜多糖的偶联 |
CA2776004A1 (en) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
CN102782138A (zh) | 2009-10-07 | 2012-11-14 | Uvic工业合伙公司 | 包含热敏性转基因的疫苗 |
WO2011047340A1 (en) | 2009-10-16 | 2011-04-21 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine |
GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
WO2011051893A1 (en) | 2009-10-27 | 2011-05-05 | Novartis Ag | Modified meningococcal fhbp polypeptides |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
EP3360566B1 (en) | 2009-11-20 | 2019-12-25 | Oregon Health&Science University | Methods for detecting a mycobacterium tuberculosis infection |
SG10201408505SA (en) | 2009-12-22 | 2015-02-27 | Celldex Therapeutics Inc | Vaccine compositions |
AU2011216243B2 (en) | 2010-02-12 | 2015-07-09 | Chimerix, Inc. | Nucleoside phosphonate salts |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
US8685416B2 (en) | 2010-03-02 | 2014-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment of cancer |
EP2542670A2 (en) | 2010-03-05 | 2013-01-09 | President and Fellows of Harvard College | Induced dendritic cell compositions and uses thereof |
WO2011112599A2 (en) | 2010-03-12 | 2011-09-15 | The United States Of America, As Represented By The Secretary. Department Of Health & Human Services | Immunogenic pote peptides and methods of use |
WO2012020326A1 (en) | 2010-03-18 | 2012-02-16 | Novartis Ag | Adjuvanted vaccines for serogroup b meningococcus |
AU2011238670B2 (en) | 2010-03-30 | 2015-04-23 | Children's Hospital & Research Center Oakland | Factor H binding proteins (FHBP) with altered properties and methods of use thereof |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
EP2556151A1 (en) | 2010-04-07 | 2013-02-13 | Novartis AG | Method for generating a parvovirus b19 virus-like particle |
CA2796314A1 (en) | 2010-04-13 | 2011-10-20 | Novartis Ag | Benzonapthyridine compositions and uses thereof |
AU2011248620B2 (en) | 2010-04-26 | 2015-11-26 | Chimerix, Inc. | Methods of treating retroviral infections and related dosage regimes |
PT2772265T (pt) | 2010-05-14 | 2018-04-20 | Univ Oregon Health & Science | Vectores de hcmv e rhcmv recombinantes e seus usos |
NO2575876T3 (zh) | 2010-05-26 | 2018-05-05 | ||
WO2011149564A1 (en) | 2010-05-28 | 2011-12-01 | Tetris Online, Inc. | Interactive hybrid asynchronous computer game infrastructure |
DK2575878T3 (en) | 2010-05-28 | 2018-08-13 | Zoetis Belgium S A | VACCINES INCLUDING CHOLESTEROL AND CPG AS THE ONLY ADJUVENT CARRIER MOLECULES |
AU2011261185A1 (en) | 2010-06-03 | 2013-01-10 | Pharmacyclics, Inc. | The use of inhibitors of Bruton's tyrosine kinase (Btk) |
CA2799747C (en) | 2010-06-04 | 2016-10-18 | Wyeth Llc | Vaccine formulations comprising 2-phenoxyethanol |
WO2011154878A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
US10478483B2 (en) | 2010-06-25 | 2019-11-19 | Glaxosmithkline Biologicals Sa | Combinations of meningococcal factor H binding proteins |
JP2013533745A (ja) | 2010-07-06 | 2013-08-29 | ノバルティス アーゲー | ノロウイルスに由来する免疫原性組成物および方法 |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
EP2608805B1 (en) | 2010-08-23 | 2017-07-05 | Wyeth LLC | STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS |
EP2613806B2 (en) | 2010-09-10 | 2022-10-26 | Wyeth LLC | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
EP3431100B1 (en) | 2010-09-14 | 2021-09-08 | University of Pittsburgh- Of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for influenza |
GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
US9072760B2 (en) | 2010-09-24 | 2015-07-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders |
US10668092B2 (en) | 2010-09-24 | 2020-06-02 | The John Hopkins University | Compositions and methods for treatment of inflammatory disorders |
GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
EP2468866A1 (en) * | 2010-12-21 | 2012-06-27 | Index Pharmaceuticals AB | Biologically active oligonucleotides capable of modulating the immune system |
WO2012088425A2 (en) | 2010-12-22 | 2012-06-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease |
PL2654785T3 (pl) | 2010-12-22 | 2019-09-30 | Bayer Intellectual Property Gmbh | Wzmocniona odpowiedź immunologiczna u gatunków wołowatych |
AU2011346535B2 (en) | 2010-12-22 | 2015-09-24 | Wyeth Llc | Stable immunogenic compositions of Staphylococcus aureus antigens |
GB201021867D0 (en) | 2010-12-23 | 2011-02-02 | Mologen Ag | Non-coding immunomodulatory DNA construct |
US20130315959A1 (en) | 2010-12-24 | 2013-11-28 | Novartis Ag | Compounds |
EP2471926A3 (en) | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunostimulatory oligodeoxynucleotides |
US10342862B2 (en) | 2011-01-26 | 2019-07-09 | Glaxosmithkline Biologicals, Sa | RSV immunization regimen |
WO2012109675A1 (en) | 2011-02-11 | 2012-08-16 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
US20140004142A1 (en) | 2011-03-02 | 2014-01-02 | Pfizer Inc. | Pcsk9 vaccine |
EA027236B1 (ru) | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
US9452212B2 (en) | 2011-04-14 | 2016-09-27 | Dynavax Technologies Corporation | Methods and compositions for eliciting an immune response against hepatitis B virus |
WO2012149307A2 (en) | 2011-04-27 | 2012-11-01 | Immune Design Corp. | Synthetic long peptide (slp)-based vaccines |
LT3275892T (lt) | 2011-05-13 | 2020-04-10 | Glaxosmithkline Biologicals S.A. | Struktūros prieš suliejimą rsv f antigenai |
FR2975600B1 (fr) | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | Agents pour le traitement de tumeurs |
KR102052215B1 (ko) | 2011-06-01 | 2019-12-04 | 야누스 바이오테라퓨틱스, 인크. | 신규한 면역 시스템 조절제 |
EP2713737B1 (en) | 2011-06-01 | 2016-04-20 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
MX355623B (es) | 2011-06-03 | 2018-04-25 | 3M Innovative Properties Co | Hidrazino-1h-imidazoquinolin-4-aminas y conjugados elaborados a partir de las mismas. |
US9475804B2 (en) | 2011-06-03 | 2016-10-25 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
KR102033185B1 (ko) | 2011-06-17 | 2019-10-16 | 유니버시티 오브 테네시 리서치 파운데이션 | 그룹 a 스트렙토콕쿠스 다가 백신 |
US9580475B2 (en) | 2011-06-20 | 2017-02-28 | University of Pittsburgh—of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for H1N1 influenza |
ITMI20111182A1 (it) | 2011-06-28 | 2012-12-29 | Canio Buonavoglia | Vaccino per coronavirus canino |
JP2014522842A (ja) | 2011-07-06 | 2014-09-08 | ノバルティス アーゲー | 免疫原性組み合わせ組成物およびその使用 |
EP2729168A2 (en) | 2011-07-06 | 2014-05-14 | Novartis AG | Immunogenic compositions and uses thereof |
WO2013007703A1 (en) * | 2011-07-08 | 2013-01-17 | Universität Zürich | CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS |
WO2013009564A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Tyrosine ligation process |
MX347361B (es) | 2011-07-19 | 2017-04-12 | Wave Life Sciences Ltd | Metodos para la sintesis de acidos nucleicos funcionalizados. |
US20130023736A1 (en) | 2011-07-21 | 2013-01-24 | Stanley Dale Harpstead | Systems for drug delivery and monitoring |
ES2687129T3 (es) | 2011-07-25 | 2018-10-23 | Glaxosmithkline Biologicals Sa | Composiciones y métodos para evaluar la inmunogenicidad funcional de vacunas contra parvovirus |
EP2736537A4 (en) | 2011-07-29 | 2015-04-15 | Selecta Biosciences Inc | SYNTHETIC NANOTRANSPORTERS FOR THE PRODUCTION OF HUMOROUS AND CYTOTOXIC T-LYMPHOCY (CTL) IMMUNE REACTIONS |
GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
US20140348865A1 (en) | 2011-09-12 | 2014-11-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser. | Immunogens based on an hiv-1 v1v2 site-of-vulnerability |
WO2013038385A2 (en) | 2011-09-14 | 2013-03-21 | Novartis Ag | Escherichia coli vaccine combination |
TR201909110T4 (tr) | 2011-09-14 | 2019-07-22 | Glaxosmithkline Biologicals Sa | Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler. |
WO2013049535A2 (en) | 2011-09-30 | 2013-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Influenza vaccine |
US9873694B2 (en) | 2011-10-04 | 2018-01-23 | Janus Biotherapeutics, Inc. | Imidazole quinoline-based immune system modulators |
US20140286983A1 (en) | 2011-10-20 | 2014-09-25 | The Government of the USA as represented by the Secretaryof the Dept. of Health and Human Services | Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes |
WO2013068949A1 (en) | 2011-11-07 | 2013-05-16 | Novartis Ag | Carrier molecule comprising a spr0096 and a spr2021 antigen |
BR112014013876A2 (pt) | 2011-12-08 | 2019-09-24 | Novartis Ag | vacina à base de toxina de clostridium difficile |
EA201491081A1 (ru) | 2012-01-16 | 2016-11-30 | Элизабет Маккенна | Композиции и способы для лечения заболеваний и расстройств печени |
US20140086849A1 (en) | 2012-09-21 | 2014-03-27 | Elizabeth McKenna | Naturally-Occurring CpG Oligonucleotide Compositions and Therapeutic Applications Thereof |
WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
CN104136456A (zh) | 2012-02-07 | 2014-11-05 | 高等教育联邦系统-匹兹堡大学 | 以计算方式优化的h3n2、h2n2和b型流感病毒的广泛反应性抗原 |
IN2014DN05695A (zh) | 2012-02-13 | 2015-05-15 | Univ Pittsburgh | |
JP2015509713A (ja) | 2012-02-24 | 2015-04-02 | ノバルティス アーゲー | 線毛タンパク質および組成物 |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
US8986710B2 (en) | 2012-03-09 | 2015-03-24 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
WO2013142808A1 (en) | 2012-03-23 | 2013-09-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pathogenic phlebovirus isolates and compositions and methods of use |
EP2841098A4 (en) | 2012-04-23 | 2016-03-02 | Allertein Therapeutics Llc | NANOPARTICLES FOR THE TREATMENT OF ALLERGIES |
US10279026B2 (en) | 2012-04-26 | 2019-05-07 | Glaxosmithkline Biologicals Sa | Antigens and antigen combinations |
RU2727476C2 (ru) | 2012-04-26 | 2020-07-21 | Новартис Аг | Антигены и антигенные композиции |
WO2013162828A1 (en) | 2012-04-27 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing |
NZ701324A (en) | 2012-05-04 | 2016-09-30 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
AU2013265336A1 (en) | 2012-05-22 | 2014-12-04 | Novartis Ag | Meningococcus serogroup X conjugate |
US9409956B2 (en) | 2012-05-23 | 2016-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Salmonella typhi Ty21a expressing Yersinia pestis F1-V fusion protein and uses thereof |
CN104428008B (zh) | 2012-05-24 | 2020-10-09 | 美国政府(由卫生和人类服务部的部长所代表) | 多价脑膜炎球菌缀合物及制备缀合物的方法 |
US9687542B2 (en) | 2012-06-19 | 2017-06-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Rift valley fever virus replicon particles and use thereof |
EP2861834B1 (en) | 2012-06-19 | 2021-04-14 | Volvo Lastvagnar AB | A device for controlling a gas flow, an exhaust aftertreatment system and a system for propelling a vehicle |
KR102057217B1 (ko) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
JP2015522580A (ja) | 2012-07-06 | 2015-08-06 | ノバルティス アーゲー | 免疫学的組成物およびその使用 |
US9982257B2 (en) | 2012-07-13 | 2018-05-29 | Wave Life Sciences Ltd. | Chiral control |
JP6246121B2 (ja) * | 2012-07-13 | 2017-12-13 | 株式会社新日本科学 | キラル核酸アジュバント |
US9598458B2 (en) | 2012-07-13 | 2017-03-21 | Wave Life Sciences Japan, Inc. | Asymmetric auxiliary group |
WO2014015091A2 (en) | 2012-07-19 | 2014-01-23 | Zoetis Llc | Bovine influenza virus compositions |
CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
AU2013295770A1 (en) | 2012-07-27 | 2015-01-29 | Zoetis Services Llc | Tick toxin compositions |
SI2885007T1 (sl) | 2012-08-16 | 2018-12-31 | Pfizer Inc. | Postopki in kompozicije glikokonjugacij |
US10973892B2 (en) | 2012-09-04 | 2021-04-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
RU2662970C2 (ru) | 2012-09-18 | 2018-07-31 | Новартис Аг | Везикулы наружной мембраны |
US9562066B2 (en) * | 2012-09-25 | 2017-02-07 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oral therapy of necrotizing enterocolitis |
US9855325B2 (en) | 2012-10-03 | 2018-01-02 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
KR20150080592A (ko) | 2012-11-02 | 2015-07-09 | 파마시클릭스, 인코포레이티드 | Tec 패밀리 키나제 억제제 애쥬번트 요법 |
WO2014074785A1 (en) | 2012-11-08 | 2014-05-15 | Ludwig Institute For Cancer Research Ltd. | Methods of predicting outcome and treating breast cancer |
KR20140075201A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
TWI465241B (zh) | 2012-12-19 | 2014-12-21 | Ind Tech Res Inst | 圓柏(Juniperus chinensis)萃取物或木酚素(lignan)用於製造抑制血管新生之藥物的用途 |
CN104870463B (zh) | 2012-12-20 | 2018-09-28 | 辉瑞公司 | 糖缀合方法 |
EP2948469A4 (en) | 2013-01-23 | 2016-11-02 | Univ Leland Stanford Junior | STABILIZED HEPATITIS B CORE POLYPEPTIDE |
US11576958B2 (en) | 2013-02-07 | 2023-02-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
EP2964665B1 (en) | 2013-03-08 | 2018-08-01 | Pfizer Inc | Immunogenic fusion polypeptides |
KR20150127206A (ko) | 2013-03-14 | 2015-11-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 나노입자-기재 조성물 |
CA2907098A1 (en) | 2013-03-15 | 2014-09-25 | Zoetis Services Llc | Cross-protection of bovines against b. trehalosi infection by a multi-valent vaccine |
DE102013004595A1 (de) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
WO2014165679A1 (en) | 2013-04-03 | 2014-10-09 | Allertein Therapeutics, Llc | Novel nanoparticle compositions |
EP2986717A1 (en) | 2013-04-19 | 2016-02-24 | The Regents of The University of California | Lone star virus |
AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
CN103550783A (zh) * | 2013-04-27 | 2014-02-05 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种核酸类药物靶向递送系统及其制备方法 |
WO2015132619A1 (en) | 2013-05-15 | 2015-09-11 | The Governors Of The University Of Alberta | E1e2 hcv vaccines and methods of use |
WO2014201245A1 (en) | 2013-06-12 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors |
CA2919268C (en) | 2013-07-25 | 2023-09-05 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
EP3632458A1 (en) | 2013-07-26 | 2020-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of bacterial infections |
EP3041502A2 (en) | 2013-09-08 | 2016-07-13 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
CA3005608C (en) | 2013-09-19 | 2020-06-30 | Zoetis Services Llc | Water-in-oil emulsions comprising immunostimulatory oligonucleotides |
US10076567B2 (en) | 2013-09-27 | 2018-09-18 | Duke University | MPER-liposome conjugates and uses thereof |
US10010606B2 (en) | 2013-09-30 | 2018-07-03 | Los Alamos National Security, Llc | Mosaic conserved region HIV immunogenic polypeptides |
EP3052127A1 (en) | 2013-10-04 | 2016-08-10 | PIN Pharma, Inc. | Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment |
JP2016535989A (ja) | 2013-11-01 | 2016-11-24 | ファイザー・インク | 前立腺関連抗原を発現させるためのベクター |
EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
HUE056105T2 (hu) | 2013-11-28 | 2022-01-28 | Bavarian Nordic As | Készítmények és eljárások fokozott immunválasz indukálására poxvírusvektorok alkalmazásával |
CN112107693B (zh) * | 2013-12-03 | 2023-05-26 | 西北大学 | 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途 |
JP6758185B2 (ja) | 2013-12-13 | 2020-09-23 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | マルチエピトープtarpペプチドワクチンおよびその使用 |
US11708411B2 (en) | 2013-12-20 | 2023-07-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
EP3095460A4 (en) * | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
JPWO2015108048A1 (ja) * | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
JPWO2015108047A1 (ja) * | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
CA2936712A1 (en) | 2014-01-16 | 2015-07-23 | Meena | Chiral design |
DK3096783T3 (da) | 2014-01-21 | 2021-08-02 | Pfizer | Streptococcus pneumoniae-kapselpolysaccharider og konjugater deraf |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
IL296681A (en) | 2014-01-21 | 2022-11-01 | Pfizer | Immunogenic preparations that include conjugated capsular saccharide antigens and their uses |
SG11201605883UA (en) | 2014-01-21 | 2016-08-30 | Immune Design Corp | Compositions for use in the treatment of allergic conditions |
DK3583947T3 (da) | 2014-01-21 | 2023-11-06 | Pfizer | Streptococcus pneumoniae-kapselpolysaccharider og konjugater deraf |
WO2016130569A1 (en) | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | A composition comprising pedv antigens and methods for making and using the composition |
WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
US10668164B2 (en) | 2014-02-14 | 2020-06-02 | Pfizer Inc. | Immunogenic glycoprotein conjugates |
GB2523187A (en) | 2014-02-18 | 2015-08-19 | Mologen Ag | Covalently closed non-coding immunomodulatory DNA construct |
WO2015130584A2 (en) | 2014-02-25 | 2015-09-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
PE20170404A1 (es) | 2014-02-28 | 2017-05-14 | Bayer Animal Health Gmbh | Plasmidos inmunoestimuladores |
CN106535930A (zh) | 2014-03-11 | 2017-03-22 | 明尼苏达大学董事会 | 猪流行性腹泻病毒疫苗及其使用方法 |
EP3119910A4 (en) | 2014-03-20 | 2018-02-21 | Pharmacyclics LLC | Phospholipase c gamma 2 and resistance associated mutations |
SI3122378T1 (sl) | 2014-03-26 | 2020-03-31 | Glaxosmithkline Biologicals S.A. | Mutantni stafilokokni antigeni |
US9549914B2 (en) | 2014-04-03 | 2017-01-24 | The Johns Hopkins University | Treatment of human cytomegalovirus by modulating Wnt |
EP3134104B1 (en) | 2014-04-25 | 2018-12-26 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
RU2016150941A (ru) * | 2014-05-23 | 2018-06-26 | Грегори КОЧОН | Способ нанесения покрытия и материалы |
CA2986096A1 (en) | 2014-05-30 | 2015-12-03 | Sanofi Pasteur Inc. | Expression and conformational analysis of engineered influenza hemagglutinin |
PL3164113T3 (pl) | 2014-06-04 | 2019-09-30 | Exicure, Inc. | Wielowartościowe dostarczanie modulatorów immunologicznych w liposomowych kolistych kwasach nukleinowych do zastosowań profilaktycznych lub terapeutycznych |
WO2015200728A1 (en) | 2014-06-25 | 2015-12-30 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
EP3169352A1 (en) | 2014-07-15 | 2017-05-24 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
EP3398948A3 (en) | 2014-08-22 | 2018-12-05 | Janus Biotherapeutics, Inc. | 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
MX2017004448A (es) | 2014-10-06 | 2017-10-23 | Exicure Inc | Compuestos anti-factor de necrosis tumoral (tnf). |
US20160129097A1 (en) * | 2014-11-06 | 2016-05-12 | Jeremy Delk | Method of processing a veterinary tumor vaccine and a veterinary tumor vaccine processing kit |
CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
US20180256630A1 (en) * | 2014-12-26 | 2018-09-13 | National Institutes Of Biomedical Innovation, Health And Nutrition | Use of nucleic acid-polysaccharide complexes having immunopotentiating activity as anti-tumor drug |
WO2016109310A1 (en) | 2014-12-31 | 2016-07-07 | Checkmate Pharmaceuticals, Llc | Combination tumor immunotherapy |
SI3244917T1 (sl) | 2015-01-15 | 2023-07-31 | Pfizer Inc. | Imunogenske kompozicije za uporabo v pnevmokoknih cepivih |
KR102382773B1 (ko) | 2015-01-16 | 2022-04-04 | 조에티스 서비시즈 엘엘씨 | 구제역 백신 |
CA3014427A1 (en) | 2015-02-13 | 2016-08-18 | Icahn School Of Medicine At Mount Sinai | Rna containing compositions and methods of their use |
BR112017017460A2 (pt) | 2015-02-19 | 2018-04-10 | Pfizer Inc. | composições de neisseria meningitidis e métodos das mesmas |
DK3268380T3 (en) | 2015-03-12 | 2019-02-18 | Zoetis Services Llc | PYOLYSIS METHODS AND COMPOSITIONS |
WO2016178123A1 (en) | 2015-05-04 | 2016-11-10 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
WO2016180852A1 (en) | 2015-05-12 | 2016-11-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preparing antigen-specific t cells from an umbilical cord blood sample |
EP3294324A1 (en) | 2015-05-13 | 2018-03-21 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
WO2016183371A1 (en) | 2015-05-13 | 2016-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for the treatment or prevention of ischemic tissue damage |
AU2016270979B2 (en) | 2015-06-02 | 2020-11-12 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
WO2016200787A2 (en) | 2015-06-09 | 2016-12-15 | The Board Of Regents Of The University Of Oklahoma | Compositions and treatments for haemophilus influenzae |
JP6886410B2 (ja) | 2015-06-10 | 2021-06-16 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 核酸含有組成物の作製および精製のためのプロセス |
JP2018524323A (ja) | 2015-06-26 | 2018-08-30 | セキラス ユーケー リミテッド | 抗原がマッチしたインフルエンザワクチン |
US10449212B2 (en) | 2015-07-09 | 2019-10-22 | National Institute For Materials Science | Immunostimulating oligonucleotide complex |
RU2721128C2 (ru) | 2015-07-21 | 2020-05-18 | Пфайзер Инк. | Иммуногенные композиции, содержащие конъюгированные антигены капсульного сахарида, наборы, содержащие эти композиции, и их применения |
TW201718001A (zh) | 2015-07-31 | 2017-06-01 | 拜耳動物保健有限公司 | 豬物種中增強之免疫反應 |
HUE060545T2 (hu) | 2015-08-14 | 2023-03-28 | Zoetis Services Llc | Mycoplasma bovis-készítmények |
WO2017040885A1 (en) | 2015-09-03 | 2017-03-09 | The Board Of Regents Of The University Of Oklahoma | Peptide inhibitors of clostridium difficile tcdb toxin |
LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
CN108024914A (zh) | 2015-09-17 | 2018-05-11 | Jrx生物技术有限公司 | 改善皮肤的水合作用或润湿作用的方法 |
GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
WO2017059280A1 (en) | 2015-10-02 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Novel pan-tam inhibitors and mer/axl dual inhibitors |
US10548970B2 (en) | 2015-10-05 | 2020-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human rotavirus G9P[6] strain and use as a vaccine |
WO2017075570A1 (en) | 2015-10-30 | 2017-05-04 | The United States Of America, As Represented By Secretary, Department Of Health And Human Sevices | Compositions and methods for the treatment of her2-expressing solid tumors |
WO2017085586A1 (en) | 2015-11-20 | 2017-05-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
CA3006779A1 (en) | 2015-12-09 | 2017-06-15 | Admedus Vaccines Pty Ltd | Immunomodulating composition for treatment |
EP3402878A1 (en) | 2016-01-11 | 2018-11-21 | Zoetis Services LLC | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus |
PL3407910T3 (pl) | 2016-01-29 | 2022-08-16 | Bavarian Nordic A/S | Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni |
WO2017189448A1 (en) | 2016-04-25 | 2017-11-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bivalent immunogenic conjugate for malaria and typhoid |
WO2017192874A1 (en) | 2016-05-04 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Albumin-binding immunomodulatory compositions and methods of use thereof |
WO2017201390A1 (en) | 2016-05-19 | 2017-11-23 | The Regents Of The University Of Michigan | Novel adjuvant compositions |
WO2017210215A1 (en) | 2016-05-31 | 2017-12-07 | The Government Of The United States Of America As Represented By The Secretary Of The Army | Zika virus vaccine and methods of production |
CA3026096A1 (en) | 2016-06-02 | 2017-12-07 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
MA45159A (fr) | 2016-06-03 | 2019-04-10 | Sanofi Pasteur Inc | Polypeptides d'hémagglutinine d'influenza modifiés |
US10947277B2 (en) | 2016-06-13 | 2021-03-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays |
WO2017220753A1 (en) | 2016-06-22 | 2017-12-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
EP3269385A1 (en) | 2016-07-12 | 2018-01-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
WO2018009604A1 (en) | 2016-07-08 | 2018-01-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric dengue/zika viruses live-attenuated zika virus vaccines |
WO2018009603A1 (en) | 2016-07-08 | 2018-01-11 | The United State of America, as represented by the Secretary, Department of Health and Human Service | Chimeric west nile/zika viruses and methods of use |
WO2018027123A1 (en) | 2016-08-05 | 2018-02-08 | Sanofi Pasteur, Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US11241489B2 (en) | 2016-08-05 | 2022-02-08 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US10182146B2 (en) * | 2016-08-22 | 2019-01-15 | Nice Ltd. | System and method for dynamic redundant call recording |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
EP3504239A1 (en) | 2016-08-25 | 2019-07-03 | H. Hoffnabb-La Roche Ag | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
US10172933B2 (en) | 2016-10-31 | 2019-01-08 | The United States Of America, As Represented By The Secretary Of Agriculture | Mosaic vaccines for serotype a foot-and-mouth disease virus |
US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
WO2018115051A1 (en) | 2016-12-22 | 2018-06-28 | F. Hoffmann-La Roche Ag | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
HRP20220573T1 (hr) | 2017-01-20 | 2022-06-10 | Pfizer Inc. | Imunogeni pripravci, namijenjeni upotrebi u pneumokoknim cjepivima |
CN110225757A (zh) | 2017-01-31 | 2019-09-10 | 默沙东公司 | 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法 |
SG11201906519RA (en) | 2017-01-31 | 2019-08-27 | Pfizer | Neisseria meningitidis compositions and methods thereof |
AU2018214451B2 (en) | 2017-02-06 | 2022-02-03 | Meat & Livestock Australia Limited | Immunostimulating compositions and uses therefore |
GB201703529D0 (en) | 2017-03-06 | 2017-04-19 | Cambridge Entpr Ltd | Vaccine composition |
WO2018183666A1 (en) | 2017-03-31 | 2018-10-04 | Boston Medical Center Corporation | Methods and compositions using highly converved pneumococcal surface proteins |
WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
CA3066915A1 (en) | 2017-06-11 | 2018-12-20 | Molecular Express, Inc. | Methods and compositions for substance use disorder vaccine formulations and uses thereof |
WO2018237221A1 (en) | 2017-06-23 | 2018-12-27 | Nosocomial Vaccine Corporation | IMMUNOGENIC COMPOSITIONS |
BR112020001255A2 (pt) | 2017-07-21 | 2020-07-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | composições imunogênicas de neisseria meningitidis |
JP7438102B2 (ja) | 2017-09-07 | 2024-02-26 | メルク・シャープ・アンド・ドーム・エルエルシー | 肺炎球菌多糖体および免疫原性多糖体-キャリアタンパク質コンジュゲートでのその使用 |
AU2018330494A1 (en) | 2017-09-08 | 2020-03-26 | Mina Therapeutics Limited | HNF4a saRNA compositions and methods of use |
WO2019066571A2 (ko) | 2017-09-28 | 2019-04-04 | 연세대학교 산학협력단 | 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도 |
US11235046B2 (en) | 2017-11-04 | 2022-02-01 | Nevada Research & Innovation Corporation | Immunogenic conjugates and methods of use thereof |
CA3084436A1 (en) | 2017-12-06 | 2019-07-18 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
WO2019126197A1 (en) | 2017-12-18 | 2019-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bacterial polysaccharide-conjugated carrier proteins and use thereof |
CN111741767A (zh) | 2017-12-19 | 2020-10-02 | 麻省理工学院 | 抗原-佐剂偶联剂和使用方法 |
CN111629751A (zh) | 2018-01-22 | 2020-09-04 | 美国政府(由卫生和人类服务部的部长所代表) | 广泛保护性灭活流感病毒疫苗 |
CA3034912A1 (en) | 2018-02-28 | 2019-08-28 | Pfizer Inc. | Il-15 variants and uses thereof |
US11633471B2 (en) | 2018-03-06 | 2023-04-25 | Unm Rainforest Innovations | Compositions and methods for reducing serum triglycerides |
JP7329529B2 (ja) | 2018-03-28 | 2023-08-18 | サノフィ パスツール インコーポレイテッド | ヘマグルチニンを含む広範に防御的なワクチン組成物を生成する方法 |
CN112512565A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性流感-铁蛋白多肽 |
MX2020010199A (es) | 2018-04-03 | 2021-01-08 | Sanofi Sa | Polipeptidos antigenicos del virus sincitial respiratorio. |
EP3773698A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Ferritin proteins |
CN112584858A (zh) | 2018-04-03 | 2021-03-30 | 赛诺菲 | 抗原性ospa多肽 |
CN112512566A (zh) | 2018-04-03 | 2021-03-16 | 赛诺菲 | 抗原性爱泼斯坦-巴尔病毒多肽 |
US11434292B2 (en) | 2018-05-23 | 2022-09-06 | Pfizer Inc. | Antibodies specific for CD3 and uses thereof |
MX2020012607A (es) | 2018-05-23 | 2021-01-29 | Pfizer | Anticuerpos especificos para gucy2c y sus usos. |
EP3574915A1 (en) | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
CN110004150B (zh) * | 2018-08-01 | 2023-03-10 | 中国农业科学院兰州兽医研究所 | 一种具有免疫增强活性的CpG寡聚核苷酸序列及其应用 |
US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
KR20210124205A (ko) | 2018-12-04 | 2021-10-14 | 더 락커펠러 유니버시티 | Hiv 백신 면역원 |
EP3894547A1 (en) | 2018-12-12 | 2021-10-20 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins |
WO2020121159A1 (en) | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
US20220023410A1 (en) | 2018-12-14 | 2022-01-27 | University Of Georgia Research Foundation, Inc. | Crimean-congo hemorrhagic fever virus replicon particles and use thereof |
CN113453708A (zh) | 2018-12-19 | 2021-09-28 | 默沙东公司 | 包含肺炎链球菌多糖-蛋白缀合物的组合物及其使用方法 |
US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
EP3946446A1 (en) | 2019-04-02 | 2022-02-09 | Sanofi | Antigenic multimeric respiratory syncytial virus polypeptides |
WO2020208502A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
CA3143198A1 (en) * | 2019-06-14 | 2020-12-17 | G Tech Bio Llc | Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions |
US20220280636A1 (en) | 2019-07-19 | 2022-09-08 | Merck Sharp & Dohme Corp. | Antigenic glycoprotein e polypeptides, compositions, and methods of use thereof |
EP4003411A1 (en) | 2019-07-30 | 2022-06-01 | Phibro Animal Health Corporation | A composition for mucosal administration to avians |
MX2022001241A (es) | 2019-07-31 | 2022-04-20 | Sanofi Pasteur Inc | Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos. |
JP2022545181A (ja) | 2019-08-30 | 2022-10-26 | ユニバーシティ オブ ロチェスター | がん治療のためのセプチン阻害剤 |
CN110646557A (zh) * | 2019-10-12 | 2020-01-03 | 北京航空航天大学 | 携带idh基因突变的胶质母细胞瘤患者的尿液代谢标志物及其用途 |
JP2021087420A (ja) | 2019-11-01 | 2021-06-10 | ファイザー・インク | Escherichia coli組成物およびその方法 |
BR112022010228A2 (pt) | 2019-12-17 | 2022-09-06 | Us Health | Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas |
BR112022009723A2 (pt) | 2019-12-17 | 2022-08-09 | Pfizer | Anticorpos específicos para cd47, pd-l1, e usos dos mesmos |
WO2021154745A1 (en) | 2020-01-27 | 2021-08-05 | Oregon State University | Gonorrhea subunit vaccine |
WO2021163448A2 (en) | 2020-02-13 | 2021-08-19 | The Board Of Trustees Of The University Of Illinois | Vaccine and methods for detecting and preventing filariasis |
IL295632A (en) | 2020-02-23 | 2022-10-01 | Pfizer | Escherichia coli preparations and their methods |
JP2023515829A (ja) | 2020-02-28 | 2023-04-14 | サノフィ パスツール インコーポレイテッド | 小児対象のための高用量インフルエンザワクチン |
US11213482B1 (en) | 2020-03-05 | 2022-01-04 | University of Pittsburgh—Of the Commonwealth System of Higher Educat | SARS-CoV-2 subunit vaccine and microneedle array delivery system |
WO2021211279A1 (en) | 2020-04-17 | 2021-10-21 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF |
EP3900739A1 (en) | 2020-04-21 | 2021-10-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein |
CA3178252A1 (en) | 2020-05-11 | 2021-11-18 | Erytech Pharma | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof |
CN116323668A (zh) | 2020-07-17 | 2023-06-23 | 辉瑞公司 | 治疗性抗体及其用途 |
JP2023538736A (ja) | 2020-08-26 | 2023-09-11 | ファイザー・インク | B群レンサ球菌多糖-タンパク質コンジュゲート、コンジュゲートを生成するための方法、コンジュゲートを含む免疫原性組成物、およびそれらの使用 |
AU2021343290A1 (en) | 2020-09-17 | 2023-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Immunogenic product comprising an IgE fragment for treating IgE-mediated inflammatory disorders |
JP2023542528A (ja) | 2020-09-24 | 2023-10-10 | フレッド ハッチンソン キャンサー センター | Sox2抗原を標的とする免疫療法 |
WO2022066973A1 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
TW202227467A (zh) | 2020-10-27 | 2022-07-16 | 美商輝瑞大藥廠 | 大腸桿菌組合物及其方法 |
CA3200602A1 (en) | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
WO2022101745A2 (en) | 2020-11-10 | 2022-05-19 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US20220202923A1 (en) | 2020-12-23 | 2022-06-30 | Pfizer Inc. | E. coli fimh mutants and uses thereof |
WO2022147373A1 (en) | 2020-12-31 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
WO2022169835A1 (en) | 2021-02-03 | 2022-08-11 | The Board Of Trustees Of The University Of Illinois | Vaccine and methods for preventing filariasis and dirofilariasis |
TW202306969A (zh) | 2021-05-28 | 2023-02-16 | 美商輝瑞大藥廠 | 包含結合之莢膜醣抗原的免疫原組合物及其用途 |
BR112023023671A2 (pt) | 2021-05-28 | 2024-02-06 | Pfizer | Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos |
WO2022261251A1 (en) | 2021-06-08 | 2022-12-15 | Glyde Bio Inc. | Immunogenic compositions comprising tumour-associated antigen |
EP4104830A1 (en) | 2021-06-16 | 2022-12-21 | Burghardt Wittig | Sequential innate and adaptive immune modulation for cancer treatment |
WO2023288263A1 (en) | 2021-07-16 | 2023-01-19 | The Board Of Trustees Of The University Of Illinois | Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs |
WO2023018817A1 (en) | 2021-08-11 | 2023-02-16 | Sanofi Pasteur Inc. | Truncated influenza neuraminidase and methods of using the same |
WO2023059857A1 (en) | 2021-10-08 | 2023-04-13 | Sanofi Pasteur Inc. | Multivalent influenza vaccines |
WO2023079507A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Respiratory syncytial virus rna vaccine |
WO2023081798A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi Pasteur Inc. | Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same |
WO2023079113A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same |
US20230310571A1 (en) | 2021-11-30 | 2023-10-05 | Sanofi Pasteur Inc. | Human metapneumovirus vaccines |
WO2023102388A1 (en) | 2021-11-30 | 2023-06-08 | Sanofi Pasteur Inc. | Human metapneumovirus viral vector-based vaccines |
WO2023111262A1 (en) | 2021-12-17 | 2023-06-22 | Sanofi | Lyme disease rna vaccine |
WO2023135515A1 (en) | 2022-01-13 | 2023-07-20 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2023144206A1 (en) | 2022-01-27 | 2023-08-03 | Sanofi Pasteur | Modified vero cells and methods of using the same for virus production |
WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
WO2023177579A1 (en) | 2022-03-14 | 2023-09-21 | Sanofi Pasteur Inc. | Machine-learning techniques in protein design for vaccine generation |
WO2023201109A1 (en) | 2022-04-15 | 2023-10-19 | Yale University | Exatecan formulation |
WO2023214082A2 (en) | 2022-05-06 | 2023-11-09 | Sanofi | Signal sequences for nucleic acid vaccines |
WO2023218322A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Process for producing of vaccine formulations with preservatives |
WO2024003239A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN |
Family Cites Families (524)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2003A (en) * | 1841-03-12 | Improvement in horizontal windivhlls | ||
US2005A (en) * | 1841-03-16 | Improvement in the manner of constructing molds for casting butt-hinges | ||
US2002A (en) * | 1841-03-12 | Tor and planter for plowing | ||
US2010A (en) * | 1841-03-18 | Machine foe | ||
US2004A (en) * | 1841-03-12 | Improvement in the manner of constructing and propelling steam-vessels | ||
US3521637A (en) * | 1967-11-28 | 1970-07-28 | Nelson J Waterbury | Tampon or similar sanitary napkin containing vitamin a |
US3627874A (en) | 1969-07-16 | 1971-12-14 | Merck & Co Inc | Vaccine preparation |
US3761585A (en) | 1971-04-05 | 1973-09-25 | Beecham Group Ltd | Vaccines containing modified allergenic material |
US3906092A (en) | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
DE2643213C2 (de) * | 1976-09-25 | 1985-02-21 | Bayer Ag, 5090 Leverkusen | Verfahren zum Abschwächen oder Inaktivieren von Mikroorganismen |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
EP0092574B1 (en) | 1981-10-23 | 1992-04-29 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and methods of making same |
US5023243A (en) * | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
ES8301593A1 (es) | 1981-11-16 | 1983-01-01 | Union Ind Y Agro Ganader S A U | Procedimiento de obtencion de una leche humanizada adiciona-da de nucleotidos con destino a la alimentacion infantil. |
US5766920A (en) * | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
US4452775A (en) * | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
US5308626A (en) * | 1985-06-28 | 1994-05-03 | Toni N. Mariani | Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases |
ES2039229T3 (es) | 1986-01-14 | 1993-09-16 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos. |
US5194428A (en) | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
US4806463A (en) | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
US5059519A (en) | 1986-07-01 | 1991-10-22 | University Of Massachusetts Medical School | Oligonucleotide probes for the determination of the proclivity for development of autoimmune diseases |
US5075109A (en) * | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
ES2007350A6 (es) | 1987-05-29 | 1989-06-16 | Ganadera Union Ind Agro | Productos alimenticios enriquecidos con nucleosidos yno nucleotidos para la nutricion infantil y de adultos, y procedimiento para su preparacion. |
CA1339596C (en) | 1987-08-07 | 1997-12-23 | New England Medical Center Hospitals, Inc. | Viral expression inhibitors |
US5004810A (en) | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5112605A (en) * | 1989-03-17 | 1992-05-12 | Genentech, Inc. | Temporal gamma-interferon administration for allergies |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5629158A (en) * | 1989-03-22 | 1997-05-13 | Cemu Bitecknik Ab | Solid phase diagnosis of medical conditions |
US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US4981684A (en) * | 1989-10-24 | 1991-01-01 | Coopers Animal Health Limited | Formation of adjuvant complexes |
US5178860A (en) * | 1989-09-01 | 1993-01-12 | Coopers Animal Health Limited | Adjuvant complexes and vaccine made therefrom |
US5399676A (en) * | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
US5786189A (en) | 1989-11-29 | 1998-07-28 | Smithkline Beecham Biologicals (S.A.) | Vaccine |
US5457189A (en) | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5514788A (en) * | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
US5514577A (en) * | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
US5248670A (en) | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
EP1493825A3 (en) | 1990-06-11 | 2005-02-09 | Gilead Sciences, Inc. | Method for producing nucleic acid ligands |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US5245022A (en) * | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
ATE154947T1 (de) | 1990-08-16 | 1997-07-15 | Isis Pharmaceuticals Inc | Oligonukleotide zur modulation der effekte von cytomegalovirusinfektionen |
US6042838A (en) | 1991-02-15 | 2000-03-28 | Uab Research Foundation | immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA) |
JP3507486B2 (ja) * | 1991-03-15 | 2004-03-15 | アムジエン・インコーポレーテツド | 顆粒球コロニー刺激因子の肺内投与 |
US5683985A (en) | 1991-04-18 | 1997-11-04 | The Salk Institute For Biological Studies | Oligonucleotide decoys and methods relating thereto |
US5498410A (en) * | 1991-04-22 | 1996-03-12 | Gleich; Gerald J. | Method for the treatment of eosinophil-associated conditions with anionic polymers |
US5681555A (en) | 1991-04-22 | 1997-10-28 | Gleich; Gerald J. | Method for the treatment of bronchial asthma by parenteral administration of anionic polymers |
WO1994008003A1 (en) | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
CA2110040A1 (en) | 1991-05-31 | 1992-12-10 | Lyle J. Arnold, Jr. | Compositions and delivery systems for transdermal administration of neutral oligomers |
US5582986A (en) | 1991-06-14 | 1996-12-10 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of the ras gene |
US6030954A (en) * | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
US5576302A (en) | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
CA2123611A1 (en) | 1991-11-15 | 1993-05-27 | Alan M. Gewirtz | Treatment of melanoma with antisense oligonucleotides to c-myb proto-oncogene |
WO1993010138A1 (en) | 1991-11-18 | 1993-05-27 | Tanox Biosystems, Inc. | Anti-sense oligonucleotides for isotype-specific suppression of immunoglobulin production |
US5858784A (en) * | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
WO1993015207A2 (en) | 1992-02-04 | 1993-08-05 | Viagene, Inc. | Hepatitis therapeutics |
US5643578A (en) * | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US6498147B2 (en) | 1992-05-22 | 2002-12-24 | The Scripps Research Institute | Suppression of nuclear factor-κb dependent processes using oligonucleotides |
IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
US5726518A (en) * | 1992-07-22 | 1998-03-10 | Nikon Corporation | Supporting device of relative moving element of vibration actuator or vibration motor |
US5585479A (en) | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
DE69316369D1 (en) | 1992-07-27 | 1998-02-19 | Hybridon Inc | Oligonukleotid alkylphosphonothiate |
US6107062A (en) * | 1992-07-30 | 2000-08-22 | Inpax, Inc. | Antisense viruses and antisense-ribozyme viruses |
WO1994004196A1 (en) | 1992-08-14 | 1994-03-03 | Imperial Cancer Research Technology Limited | Tumour therapy |
US5429199A (en) * | 1992-08-26 | 1995-07-04 | Kennametal Inc. | Cutting bit and cutting insert |
HUT72400A (en) | 1992-10-05 | 1996-04-29 | Hybridon Inc | Therapeutic anti-hiv oligonucleotide, pharmaceutical compositions containing them and methods for use of compositions |
US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
EP0692972B2 (en) * | 1993-04-02 | 2012-03-21 | AntiCancer, Inc. | Method for delivering beneficial compositions to hair follicles |
US5567604A (en) * | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
SG54115A1 (en) * | 1993-04-27 | 1998-11-16 | Gerber Scient Products Inc | Thermal printing apparatus with improved power supply |
WO1994029461A1 (en) | 1993-06-11 | 1994-12-22 | Commonwealth Scientific And Industrial Research Organisation | Method for specific silencing of genes by dna methylation |
WO1995000638A2 (en) * | 1993-06-23 | 1995-01-05 | Genesys Pharma Inc. | Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection |
CA2166889C (en) | 1993-07-19 | 2001-09-11 | Todd C. Peterson | Oligonucleotides with activity against human immunodeficiency virus |
US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
US6605708B1 (en) | 1993-07-28 | 2003-08-12 | Hybridon, Inc. | Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom |
US5849719A (en) | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US20030109469A1 (en) | 1993-08-26 | 2003-06-12 | Carson Dennis A. | Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen |
AU705889B2 (en) | 1993-08-26 | 1999-06-03 | Regents Of The University Of California, The | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides |
US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
US5985847A (en) | 1993-08-26 | 1999-11-16 | The Regents Of The University Of California | Devices for administration of naked polynucleotides which encode biologically active peptides |
FR2711670B1 (fr) * | 1993-10-22 | 1996-01-12 | Pasteur Institut | Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite. |
DE4338704A1 (de) * | 1993-11-12 | 1995-05-18 | Hoechst Ag | Stabilisierte Oligonucleotide und deren Verwendung |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
EP0736093B1 (en) | 1993-12-23 | 2003-03-19 | BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH | ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB-2 PLAYS A ROLL |
US5712384A (en) | 1994-01-05 | 1998-01-27 | Gene Shears Pty Ltd. | Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
US5728518A (en) * | 1994-01-12 | 1998-03-17 | The Immune Response Corporation | Antiviral poly-and oligonucleotides |
US5646126A (en) | 1994-02-28 | 1997-07-08 | Epoch Pharmaceuticals | Sterol modified oligonucleotide duplexes having anticancer activity |
CA2190121A1 (en) | 1994-03-15 | 1995-09-21 | Edith Mathiowitz | Polymeric gene delivery system |
US5596091A (en) * | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
US5696248A (en) | 1994-06-15 | 1997-12-09 | Hoechst Aktiengesellschaft | 3'-modified oligonucleotide derivatives |
US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7935675B1 (en) * | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030050263A1 (en) * | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
EP1167378B1 (en) * | 1994-07-15 | 2011-05-11 | University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
JPH10502820A (ja) | 1994-07-18 | 1998-03-17 | ユニバーシティ・オブ・ノース・カロライナ・アット・チャペル・ヒル | 腫瘍増殖、浸潤および転移を阻害するためのオリゴヌクレオシド化合物および方法 |
US5646262A (en) * | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
ATE219660T1 (de) * | 1994-09-30 | 2002-07-15 | Inex Pharmaceuticals Corp | Mittel zum einbringen polyanionischer materialien in zellen |
US5753613A (en) * | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
US6027726A (en) * | 1994-09-30 | 2000-02-22 | Inex Phamaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
WO1996012008A1 (en) | 1994-10-13 | 1996-04-25 | Merck & Co., Inc. | Synthesis of methylase-resistant genes |
US6630455B1 (en) | 1995-01-13 | 2003-10-07 | Vanderbilt University | Methods for inducing mucosal immune responses |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5674483A (en) * | 1995-01-31 | 1997-10-07 | National Jewish Medical And Research Center | Treatment for diseases involving inflammation |
DE19502912A1 (de) | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilisierte Oligonucleotide |
WO1996024380A1 (en) | 1995-02-09 | 1996-08-15 | Icn Pharmaceuticals, Inc. | Methods and compositions for regulation of cd28 expression |
US5932556A (en) | 1995-09-17 | 1999-08-03 | Tam; Robert C | Methods and compositions for regulation of CD28 expression |
GB9505438D0 (en) | 1995-03-17 | 1995-05-03 | Sod Conseils Rech Applic | Antisense oligonucleotides |
US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
CA2192674C (en) | 1995-04-13 | 2001-02-13 | John Mcmichael | Methods for treating respiratory disease |
US6096721A (en) * | 1995-04-13 | 2000-08-01 | Milkhaus Laboratory, Inc. | Method for treating mucositis by sublingual administration of DNA |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5858987A (en) * | 1995-05-05 | 1999-01-12 | Mitotix, Inc. | E6AP antisense constructs and methods of use |
CA2220433C (en) | 1995-05-11 | 2010-02-16 | Applied Research Systems Ars Holding N.V. | Il-6 activity inhibitor |
US5955059A (en) * | 1995-06-06 | 1999-09-21 | Trustees Of Boston University | Use of locally applied DNA fragments |
US6025339A (en) * | 1995-06-07 | 2000-02-15 | East Carolina University | Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation |
US5830878A (en) | 1995-06-07 | 1998-11-03 | Megabios Corporation | Cationic lipid: DNA complexes for gene targeting |
US7034007B1 (en) * | 1995-06-07 | 2006-04-25 | East Carolina University | Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion |
US6040296A (en) * | 1995-06-07 | 2000-03-21 | East Carolina University | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation |
US5705385A (en) * | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
EP1489184A1 (en) | 1995-06-07 | 2004-12-22 | Inex Pharmaceutical Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5994315A (en) | 1995-06-07 | 1999-11-30 | East Carolina University | Low adenosine agent, composition, kit and method for treatment of airway disease |
WO1997000957A1 (en) | 1995-06-23 | 1997-01-09 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
CA2227287A1 (en) | 1995-07-21 | 1997-02-06 | Brown University Research Foundation | A method for gene therapy using nucleic acid loaded polymeric microparticles |
US6248720B1 (en) * | 1996-07-03 | 2001-06-19 | Brown University Research Foundation | Method for gene therapy using nucleic acid loaded polymeric microparticles |
US5968909A (en) | 1995-08-04 | 1999-10-19 | Hybridon, Inc. | Method of modulating gene expression with reduced immunostimulatory response |
US6667293B1 (en) * | 1995-09-12 | 2003-12-23 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
CZ97798A3 (cs) | 1995-10-04 | 1999-02-17 | Immunex Corporation | Použití ligandu flt3, adjuvants vakcíny, expanzní media, přípravek a populace buněk a způsob |
US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US5780448A (en) * | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
WO1997028259A1 (en) | 1996-01-30 | 1997-08-07 | The Regents Of The University Of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
US20030078223A1 (en) * | 1996-01-30 | 2003-04-24 | Eyal Raz | Compositions and methods for modulating an immune response |
SE9600647D0 (sv) | 1996-02-21 | 1996-02-21 | Bror Morein | Ny användning |
US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
SE9600648D0 (sv) * | 1996-02-21 | 1996-02-21 | Bror Morein | Receptorbimdande enhet |
US5843770A (en) | 1996-03-11 | 1998-12-01 | The Immune Response Corporation | Antisense constructs directed against viral post-transcriptional regulatory sequences |
US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
US6030955A (en) * | 1996-03-21 | 2000-02-29 | The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc. | Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof |
US6121247A (en) | 1996-03-29 | 2000-09-19 | The Johns Hopkins University | Therapy for allergic diseases |
US6184037B1 (en) | 1996-05-17 | 2001-02-06 | Genemedicine, Inc. | Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell |
JP2002514047A (ja) | 1996-07-10 | 2002-05-14 | イミュネックス・コーポレーション | 樹状細胞を活性化する方法 |
DE69736692T2 (de) | 1996-07-16 | 2007-06-14 | Archibald James Mixson | Kationisches Vehikel: DNS Komplexe und ihre Verwendung in Gentherapie |
US5854418A (en) | 1996-07-25 | 1998-12-29 | The Trustees Of Columbia University In The City Of New York | Kaposi's sarcoma-associated herpesvirus (KSHV) viral macrophage inflammatory protein-1α II (vMIP-1α II) and uses thereof |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
DE19637223A1 (de) * | 1996-09-13 | 1998-04-09 | Beiersdorf Ag | Wiederlösbare, selbstklebende Vorrichtung |
ES2241042T3 (es) * | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora. |
US6562345B1 (en) * | 1996-11-12 | 2003-05-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
US6797276B1 (en) * | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
US20060002949A1 (en) * | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
US20060002959A1 (en) * | 1996-11-14 | 2006-01-05 | Government Of The United States | Skin-sctive adjuvants for transcutaneous immuization |
SE9604296D0 (sv) | 1996-11-22 | 1996-11-22 | Astra Ab | New pharmaceutical formulation of polypeptides |
HU0000769A (en) | 1996-12-27 | 2000-07-28 | G-rich oligo aptamers and methods of modulating an immune response | |
FR2757876B1 (fr) | 1996-12-27 | 1999-04-09 | Biovector Therapeutics Sa | Conjuges d'un vecteur particulaire et d'oligonucleotides, leur procede de preparation et les compositions pharmaceutiques les contenant |
EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
US20030064945A1 (en) * | 1997-01-31 | 2003-04-03 | Saghir Akhtar | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
GB9702021D0 (en) | 1997-01-31 | 1997-03-19 | Imperial College | Medicaments |
US7517952B1 (en) * | 1997-02-25 | 2009-04-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US6214806B1 (en) * | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
CA2283557A1 (en) * | 1997-03-10 | 1998-09-17 | Heather L. Davis | Use of nucleic acids containing unmethylated cpg dinucleotide as an adjuvant |
US5965542A (en) | 1997-03-18 | 1999-10-12 | Inex Pharmaceuticals Corp. | Use of temperature to control the size of cationic liposome/plasmid DNA complexes |
US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
US6835395B1 (en) | 1997-05-14 | 2004-12-28 | The University Of British Columbia | Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles |
US20030104044A1 (en) * | 1997-05-14 | 2003-06-05 | Semple Sean C. | Compositions for stimulating cytokine secretion and inducing an immune response |
DE69841002D1 (de) * | 1997-05-14 | 2009-09-03 | Univ British Columbia | Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln |
JP2001526688A (ja) | 1997-05-19 | 2001-12-18 | メルク エンド カンパニー インコーポレーテッド | オリゴヌクレオチドアジュバント |
WO1998052581A1 (en) | 1997-05-20 | 1998-11-26 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
US20040006034A1 (en) * | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
DE69840850D1 (de) * | 1997-06-06 | 2009-07-09 | Dynavax Tech Corp | Inhibitoren von immunstimulatorischen dna sequenz aktivität |
EP1009440B1 (en) * | 1997-07-03 | 2008-09-17 | MacFarlane, Donald E. | Method for inhibiting immunostimulatory dna associated responses |
AU8428998A (en) | 1997-07-24 | 1999-02-16 | Inex Pharmaceuticals Corporation | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method |
US5877309A (en) * | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
WO1999009154A2 (en) | 1997-08-19 | 1999-02-25 | Hybridon, Inc. | Novel hiv-specific synthetic oligonucleotides and methods of their use |
AU757175B2 (en) | 1997-09-05 | 2003-02-06 | Regents Of The University Of California, The | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
US6749856B1 (en) | 1997-09-11 | 2004-06-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Mucosal cytotoxic T lymphocyte responses |
NZ504894A (en) * | 1997-12-02 | 2002-12-20 | Powderject Vaccines Inc | Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique |
AU1656799A (en) | 1997-12-12 | 1999-07-05 | Inex Pharmaceuticals Corp. | Cationic drugs encapsulated in anionic liposomes |
US7393630B2 (en) * | 1997-12-16 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Use of microparticles combined with submicron oil-in-water emulsions |
DE69834133D1 (de) | 1997-12-23 | 2006-05-18 | Inex Pharmaceuticals Corp | Polyamid-oligomere |
US20050031638A1 (en) * | 1997-12-24 | 2005-02-10 | Smithkline Beecham Biologicals S.A. | Vaccine |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
JPH11209289A (ja) * | 1998-01-22 | 1999-08-03 | Taisho Pharmaceut Co Ltd | 粘膜免疫誘起剤 |
BR9908278A (pt) | 1998-02-25 | 2002-01-02 | Iomai Corp | Uso de agentes de melhoria de penetração e de rompimento de barreiras da pele, melhorar a resposta transcutânea imune induzida pela etoxina de ribosilatação de adp |
CN1159348C (zh) * | 1998-03-12 | 2004-07-28 | 卢西特国际英国有限公司 | 聚合物组合物 |
AU760549B2 (en) * | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
NZ506603A (en) | 1998-04-09 | 2002-10-25 | Smithkline Beecham Biolog S | Adjuvant compositions comprising polyoxyethylene ether or polyoxyethylene ester |
DE69932164D1 (de) | 1998-04-28 | 2006-08-10 | Inex Pharmaceuticals Corp | Polyanionische polymere mit verbesserter fusogenfähigkeit |
JP2002513763A (ja) | 1998-05-06 | 2002-05-14 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Cpgオリゴヌクレオチドを使用して寄生生物感染および関連する疾患を予防および処置するための方法 |
CA2328406A1 (en) | 1998-05-14 | 1999-11-18 | Hermann Wagner | Methods for regulating hematopoiesis using cpg-oligonucleotides |
DK1077722T3 (da) | 1998-05-22 | 2006-11-27 | Ottawa Health Research Inst | Fremgangsmåder og produkter til induktion af mukosaimmunitet |
US6881561B1 (en) | 1998-05-27 | 2005-04-19 | Cheil Jedang Corporation | Endonuclease of immune cell, process for producing the same and immune adjuvant using the same |
US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
JP4627369B2 (ja) | 1998-06-10 | 2011-02-09 | バイオグノスティック ゲゼルシャフト フュア バイオモレキュラー ダイアグノスティック ミット ベシュレンクテル ハフツング | 免疫系を刺激する方法 |
WO1999066947A1 (en) * | 1998-06-23 | 1999-12-29 | The Board Of Trustees Of The Leland Stanford Junior University | Adjuvant therapy |
US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US20030022854A1 (en) * | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
ATE237312T1 (de) | 1998-07-20 | 2003-05-15 | Protiva Biotherapeutics Inc | In liposomen verkapselte nukleinsäurekomplexe |
EP1100807A1 (en) | 1998-07-27 | 2001-05-23 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
EP0979869A1 (en) | 1998-08-07 | 2000-02-16 | Hoechst Marion Roussel Deutschland GmbH | Short oligonucleotides for the inhibition of VEGF expression |
US20010034330A1 (en) | 1998-08-10 | 2001-10-25 | Charlotte Kensil | Innate immunity-stimulating compositions of CpG and saponin and methods thereof |
ATE315405T1 (de) | 1998-08-10 | 2006-02-15 | Antigenics Inc | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung |
DE69943392D1 (de) * | 1998-08-20 | 2011-06-09 | Du Pont | Gene für fettsäuremodfizierende enzyme von planzen und damit verbundene bildung von konjugierten doppelbindungen |
EP1108017A2 (en) | 1998-09-03 | 2001-06-20 | Coley Pharmaceutical GmbH | G-motif oligonucleotides and uses thereof |
US20020065236A1 (en) | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
FR2783170B1 (fr) * | 1998-09-11 | 2004-07-16 | Pasteur Merieux Serums Vacc | Emulsion immunostimulante |
ATE326239T1 (de) | 1998-09-18 | 2006-06-15 | Dynavax Tech Corp | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren |
EP1671646A3 (en) | 1998-09-18 | 2007-08-29 | Dynavax Technologies Corporation | Methods of treating IgE-associated disorders and compositions for use therein |
WO2000020039A1 (en) | 1998-10-05 | 2000-04-13 | The Regents Of The University Of California | Methods and adjuvants for stimulating mucosal immunity |
AU6425999A (en) | 1998-10-09 | 2000-05-01 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
DE69935606T9 (de) | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | Adjuvanzsysteme und impfstoffe |
AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
EP1165773A4 (en) | 1999-02-02 | 2005-01-05 | Biocache Pharmaceuticals Inc | IMPROVED PLATFORM FOR PRESENTING ANTIGENS |
US6887464B1 (en) | 1999-02-02 | 2005-05-03 | Biocache Pharmaceuticals, Inc. | Advanced antigen presentation platform |
WO2000045849A2 (en) | 1999-02-05 | 2000-08-10 | Genzyme Corporation | Use of cationic lipids to generate anti-tumor immunity |
US6207819B1 (en) | 1999-02-12 | 2001-03-27 | Isis Pharmaceuticals, Inc. | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds |
AU3760100A (en) * | 1999-03-16 | 2000-10-04 | Panacea Pharmaceuticals, Llc | Immunostimulatory nucleic acids and antigens |
FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
NZ513841A (en) | 1999-03-19 | 2001-09-28 | Smithkline Beecham Biolog S | Vaccine against Streptococcus pneumoniae |
US6625426B2 (en) * | 1999-03-22 | 2003-09-23 | Ronald Baratono | Combined rear view mirror and telephone |
US6977245B2 (en) * | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
WO2000061151A2 (en) | 1999-04-12 | 2000-10-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
AU4642600A (en) | 1999-04-15 | 2000-11-02 | Regents Of The University Of California, The | Methods and compositions for use in potentiating antigen presentation by antigenpresenting cells |
US6558670B1 (en) * | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
HU229255B1 (en) | 1999-04-19 | 2013-10-28 | Smithkline Beecham Biolog | Vaccines |
WO2000067023A1 (en) | 1999-04-29 | 2000-11-09 | Coley Pharmaceutical Gmbh | Screening for immunostimulatory dna functional modifyers |
US6737066B1 (en) * | 1999-05-06 | 2004-05-18 | The Immune Response Corporation | HIV immunogenic compositions and methods |
CA2372960C (en) | 1999-05-06 | 2006-03-28 | The Immune Response Corporation | Hiv immunogenic compositions and methods |
CA2376634A1 (en) | 1999-06-08 | 2000-12-14 | Aventis Pasteur | Immunostimulant oligonucleotide |
CA2412345A1 (en) | 1999-06-16 | 2000-12-21 | University Of Iowa Research Foundation | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
GB9915204D0 (en) | 1999-06-29 | 1999-09-01 | Smithkline Beecham Biolog | Vaccine |
US20050002958A1 (en) * | 1999-06-29 | 2005-01-06 | Smithkline Beecham Biologicals Sa | Vaccines |
WO2001000232A2 (en) | 1999-06-29 | 2001-01-04 | Smithkline Beecham Biologicals S.A. | Use of cpg as an adjuvant for hiv vaccine |
US6514948B1 (en) * | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
FR2795963A1 (fr) * | 1999-07-08 | 2001-01-12 | Pasteur Merieux Serums Vacc | Polynucleotide immunostimulant |
DE19935756A1 (de) * | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation |
PT1200580E (pt) | 1999-08-13 | 2005-03-31 | Hybridon Inc | Modulacao da estimulacao imunitaria mediada por oligonucleotidos cpg atraves de modificacao posicional de nucleosidos |
ATE419869T1 (de) | 1999-08-19 | 2009-01-15 | Dynavax Tech Corp | Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür |
US20050249794A1 (en) | 1999-08-27 | 2005-11-10 | Semple Sean C | Compositions for stimulating cytokine secretion and inducing an immune response |
US6395678B1 (en) * | 1999-09-01 | 2002-05-28 | Aero-Terra-Aqua Technologies Corporation | Bead and process for removing dissolved metal contaminants |
GB9921147D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9921146D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
DK1221955T3 (da) | 1999-09-25 | 2006-01-30 | Univ Iowa Res Found | Immunstimulerende nukleinsyre |
IL148844A0 (en) * | 1999-09-27 | 2002-09-12 | Coley Pharm Group Inc | Methods related to immunostimulatory nucleic acid-induced interferon |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
JP2003512826A (ja) * | 1999-10-27 | 2003-04-08 | カイロン コーポレイション | Hcv特異的t細胞の活性化 |
US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
WO2001037869A1 (en) | 1999-11-19 | 2001-05-31 | Csl Limited | Vaccine compositions |
AU4139801A (en) * | 1999-12-06 | 2001-06-12 | Board Of Trustees Of The University Of Arkansas, The | Controlled delivery of antigens |
AU2593701A (en) | 1999-12-21 | 2001-07-03 | Regents Of The University Of California, The | Method for preventing an anaphylactic reaction |
WO2001051083A2 (en) | 2000-01-13 | 2001-07-19 | Antigenics Inc. | Innate immunity-stimulating compositions of cpg and saponin and methods thereof |
ATE378348T1 (de) * | 2000-01-14 | 2007-11-15 | Us Health | Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion |
AU3108001A (en) * | 2000-01-20 | 2001-12-24 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing a th2 immune response |
US6852705B2 (en) * | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
WO2001055370A2 (en) | 2000-01-26 | 2001-08-02 | Hybridon, Inc. | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
AT409085B (de) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
WO2001055341A2 (en) | 2000-01-31 | 2001-08-02 | The Regents Of The University Of California | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
KR100808348B1 (ko) | 2000-01-31 | 2008-02-27 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Hiv에 대한 예방 또는 치료용 면역화를 위한 백신 |
US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
FR2805265B1 (fr) | 2000-02-18 | 2002-04-12 | Aventis Pasteur | Oligonucleotides immunostimulants |
US20030130217A1 (en) * | 2000-02-23 | 2003-07-10 | Eyal Raz | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
CA2399550A1 (en) | 2000-02-23 | 2001-08-30 | The Regents Of The University Of California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
WO2001062275A1 (en) | 2000-02-24 | 2001-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Adjuvant treatment by in vivo activation of dendritic cells |
US20020156033A1 (en) * | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
US20020028784A1 (en) * | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
US6851845B2 (en) * | 2000-03-10 | 2005-02-08 | The Maitland Company, Inc. | Method and apparatus for processing waste material |
US7157437B2 (en) * | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
US20030129251A1 (en) * | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US20010046967A1 (en) | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
US7129222B2 (en) * | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US20020107212A1 (en) | 2000-03-10 | 2002-08-08 | Nest Gary Van | Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences |
CA2404041A1 (en) | 2000-03-28 | 2001-10-04 | The Regents Of The University Of California | Methods for increasing a cytotoxic t lymphocyte response in vivo |
US8246945B2 (en) * | 2000-04-06 | 2012-08-21 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
US20020142978A1 (en) | 2000-04-07 | 2002-10-03 | Eyal Raz | Synergistic improvements to polynucleotide vaccines |
US7524826B2 (en) | 2000-04-14 | 2009-04-28 | Mcmaster University And Hamilton Health Sciences Corporation | Method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque |
US6321873B1 (en) * | 2000-04-21 | 2001-11-27 | Tra-Lor-Mate, Inc. | Ladder mounting system |
EP1278761B1 (en) | 2000-05-01 | 2005-04-06 | Hybridon, Inc. | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
US6893821B2 (en) * | 2000-05-05 | 2005-05-17 | The Regents Of The University Of California | Agents that modulate DNA-PK activity and methods of use thereof |
WO2001085751A1 (en) | 2000-05-09 | 2001-11-15 | Reliable Biopharmaceutical, Inc. | Polymeric compounds useful as prodrugs |
EP1280521B1 (en) | 2000-05-12 | 2005-07-20 | Pharmacia & Upjohn Company LLC | Vaccine composition, method of preparing the same, and method of vaccinating vertebrates |
US6339630B1 (en) * | 2000-05-18 | 2002-01-15 | The United States Of America As Represented By The United States Department Of Energy | Sealed drive screw operator |
GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
EP1292331A2 (en) | 2000-06-07 | 2003-03-19 | Biosynexus Incorporated | Immunostimulatory rna/dna hybrid molecules |
AU7013401A (en) * | 2000-06-22 | 2002-01-02 | Univ Iowa Res Found | Methods for enhancing antibody-induced cell lysis and treating cancer |
US20020165178A1 (en) * | 2000-06-28 | 2002-11-07 | Christian Schetter | Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia |
JP5511117B2 (ja) | 2000-07-27 | 2014-06-04 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | 髄膜炎菌に起因する疾患に対する広域防御のためのワクチン |
WO2002009748A1 (en) | 2000-07-31 | 2002-02-07 | Yale University | Innate immune system-directed vaccines |
US20020198165A1 (en) * | 2000-08-01 | 2002-12-26 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of gastric ulcers |
ES2299520T3 (es) | 2000-09-01 | 2008-06-01 | Epigenomics Ag | Procedimiento para la determinacion del grado de metilacion de determinadas citosinas en dna genomico en el contexto secuencial 5'-cpg-3'. |
WO2002018631A2 (de) * | 2000-09-01 | 2002-03-07 | Epigenomics Ag | Diagnose von bestehenden erkrankungen oder der prädisposition für bestimmte erkrankungen |
US20020091097A1 (en) * | 2000-09-07 | 2002-07-11 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of sexually transmitted diseases |
EP1366077B1 (en) * | 2000-09-15 | 2011-05-25 | Coley Pharmaceutical GmbH | PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST |
GB0023008D0 (en) | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
US6787524B2 (en) * | 2000-09-22 | 2004-09-07 | Tanox, Inc. | CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies |
AU9475001A (en) | 2000-09-26 | 2002-04-08 | Hybridon Inc | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
SE0003538D0 (sv) * | 2000-09-29 | 2000-09-29 | Isconova Ab | New immunogenic complex |
US7537772B1 (en) * | 2000-10-02 | 2009-05-26 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, gene sequence and the uses thereof |
FR2814958B1 (fr) | 2000-10-06 | 2003-03-07 | Aventis Pasteur | Composition vaccinale |
GB0025577D0 (en) * | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
ES2377077T3 (es) * | 2000-10-18 | 2012-03-22 | Glaxosmithkline Biologicals S.A. | Vacunas que comprenden al antígeno MAGE unido a un fragmento de proteína D |
JP2004512383A (ja) | 2000-11-02 | 2004-04-22 | アイネックス ファーマシューティカルズ コーポレイション | 毒性の減少した治療用オリゴヌクレオチド |
US20020110840A1 (en) * | 2000-12-08 | 2002-08-15 | 3M Innovative Properties Company | Screening method for identifying compounds that selectively induce interferon alpha |
ES2307568T3 (es) * | 2000-12-08 | 2008-12-01 | Coley Pharmaceutical Gmbh | Acidos nucleicos de tipo cpg y metodos de uso de los mismos. |
US20030055014A1 (en) * | 2000-12-14 | 2003-03-20 | Bratzler Robert L. | Inhibition of angiogenesis by nucleic acids |
WO2002052002A2 (en) * | 2000-12-27 | 2002-07-04 | Dynavax Technologies Corporation | Immunomodulatory polynucleotides and methods of using the same |
US7337306B2 (en) * | 2000-12-29 | 2008-02-26 | Stmicroelectronics, Inc. | Executing conditional branch instructions in a data processor having a clustered architecture |
US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
US7713942B2 (en) | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
US7176296B2 (en) | 2001-04-30 | 2007-02-13 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
US7105495B2 (en) | 2001-04-30 | 2006-09-12 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
US20030129605A1 (en) | 2001-05-04 | 2003-07-10 | Dong Yu | Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosophonate linkages |
WO2004030608A2 (en) * | 2001-06-05 | 2004-04-15 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
JP2005509591A (ja) | 2001-06-15 | 2005-04-14 | リバファーム・インコーポレイテッド | ヌクレオシドワクチンアジュバント |
ES2487645T3 (es) | 2001-06-21 | 2014-08-22 | Dynavax Technologies Corporation | Compuestos inmunomoduladores quiméricos y métodos de uso de los mismos |
US7785610B2 (en) | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
US20040132677A1 (en) | 2001-06-21 | 2004-07-08 | Fearon Karen L. | Chimeric immunomodulatory compounds and methods of using the same-IV |
WO2003000232A2 (en) | 2001-06-25 | 2003-01-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides |
US20030003970A1 (en) | 2001-06-28 | 2003-01-02 | Alan Johnson | Portable communications device |
US20030138458A1 (en) | 2001-06-29 | 2003-07-24 | Michael Houghton | HCV E1E2 vaccine compositions |
US6982033B2 (en) * | 2001-07-13 | 2006-01-03 | Donald Hubbard H | Aerobic treatment plant with filter pipe |
WO2003040308A2 (en) | 2001-07-27 | 2003-05-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
US20030148316A1 (en) * | 2001-08-01 | 2003-08-07 | Lipford Grayson B. | Methods and compositions relating to plasmacytoid dendritic cells |
EP1420829A4 (en) * | 2001-08-07 | 2006-05-17 | Dynavax Tech Corp | IMMUNOMODULATING COMPOSITIONS, FORMULATIONS AND METHOD FOR THEIR USE |
JP2005510462A (ja) | 2001-08-10 | 2005-04-21 | ダイナバックス テクノロジーズ コーポレイション | 免疫調節オリゴヌクレオチドの生成及びその使用方法 |
WO2003020884A2 (en) * | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
DE60229422D1 (de) * | 2001-08-17 | 2008-11-27 | Coley Pharm Gmbh | Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung |
WO2003020889A2 (en) | 2001-08-30 | 2003-03-13 | 3M Innovative Properties Company | Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
WO2003027313A2 (en) * | 2001-09-24 | 2003-04-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE |
US20030119774A1 (en) * | 2001-09-25 | 2003-06-26 | Marianna Foldvari | Compositions and methods for stimulating an immune response |
DE60234782D1 (de) | 2001-09-28 | 2010-01-28 | Purdue Research Foundation | Behandlungsverfahren mit liganden-immunogenkonjugaten |
EP1451581A4 (en) * | 2001-10-05 | 2006-01-11 | Coley Pharm Gmbh | AGONISTS AND ANTAGONISTS OF THE SIGNALING OF THE GREAT-SIMILAR RECEPTOR 3 |
WO2003030656A2 (en) | 2001-10-06 | 2003-04-17 | Merial Limited | Methods and compositions for promoting growth and innate immunity in young animals |
US20050238660A1 (en) | 2001-10-06 | 2005-10-27 | Babiuk Lorne A | Cpg formulations and related methods |
WO2003094836A2 (en) * | 2001-10-12 | 2003-11-20 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
WO2003039595A2 (en) | 2001-11-07 | 2003-05-15 | Inex Pharmaceuticals Corporation | Mucosal adjuvants comprising an oligonucleotide and a cationic lipid |
US20040014779A1 (en) | 2001-11-16 | 2004-01-22 | 3M Innovative Properties Company | Methods and compositions related to IRM compounds and toll-like recptor pathways |
TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
EP1455833A1 (en) * | 2001-12-04 | 2004-09-15 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES | Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
DE10161755B4 (de) * | 2001-12-15 | 2005-12-15 | Infineon Technologies Ag | Kontaktstift zum Testen mikroelektronischer Bauteile mit kugelförmigen Kontakten |
US7615227B2 (en) * | 2001-12-20 | 2009-11-10 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce angiogenesis |
US8466116B2 (en) * | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
CA2471092A1 (en) | 2001-12-21 | 2003-07-10 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
JP2005526497A (ja) | 2002-02-04 | 2005-09-08 | ビオミラ,インコーポレーテッド | 免疫刺激性、共有結合性脂質化オリゴヌクレオチド |
US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
US20030232443A1 (en) | 2002-06-18 | 2003-12-18 | Isis Pharmaceuticals Inc. | Antisense modulation of centromere protein B expression |
WO2003086280A2 (en) * | 2002-04-04 | 2003-10-23 | Coley Pharmaceutical Gmbh | Immunostimulatory g,u-containing oligoribonucleotides |
EP1496925A4 (en) * | 2002-04-11 | 2007-05-30 | Zymogenetics Inc | USE OF INTERLEUKIN-24 FOR THE TREATMENT OF OVARIAL CARCINOMA |
JP2006515266A (ja) * | 2002-04-22 | 2006-05-25 | バイオニケ ライフ サイエンシーズ インコーポレイテッド | オリゴヌクレオチド組成物および免疫応答の調節のためのそれらの使用 |
US6948271B2 (en) * | 2002-05-06 | 2005-09-27 | Innovative Supply, Inc. | Identification and tracking system for deceased bodies |
EP1502012A4 (en) * | 2002-05-08 | 2009-07-01 | Btu Int | EXHAUST GAS TREATMENT OF A PLASMA ASSISTED ENGINE |
JP2005525414A (ja) | 2002-05-10 | 2005-08-25 | イネックス ファーマシューティカルズ コーポレイション | 病原体ワクチン及びその使用方法 |
WO2003094963A2 (en) | 2002-05-10 | 2003-11-20 | Inex Pharmaceuticals Corporation | Methylated immunostimulatory oligonucleotides and methods of using the same |
US20040009944A1 (en) | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Methylated immunostimulatory oligonucleotides and methods of using the same |
EP1507850A1 (en) | 2002-05-28 | 2005-02-23 | MERCK PATENT GmbH | A method for generating antigen-presenting cells |
CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
US20040009949A1 (en) * | 2002-06-05 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids |
US7807803B2 (en) * | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040053880A1 (en) * | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) * | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
AU2003267986A1 (en) * | 2002-07-03 | 2004-01-23 | Depuy Mitek, Inc. | Vaccines to induce mucosal immunity |
US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
AU2003255969A1 (en) | 2002-07-17 | 2004-02-02 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
CN1468957A (zh) | 2002-07-19 | 2004-01-21 | 中国人民解放军第二军医大学 | 一种用作人用治疗性疫苗佐剂的质粒 |
US20050209183A1 (en) | 2002-07-25 | 2005-09-22 | Phenion Gmbh & Co. Kg | Cosmetic or pharmaceutical preparations comprising nucleic acids based on non-methylated CPG motifs |
EP1393745A1 (en) | 2002-07-29 | 2004-03-03 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends |
EP1575504A4 (en) * | 2002-08-01 | 2009-11-04 | Us Gov Health & Human Serv | METHOD FOR THE TREATMENT OF INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF THE CPG OLIGONUCLEOTIDES |
EP1551376A4 (en) | 2002-08-12 | 2010-10-06 | Dynavax Tech Corp | IMMUNOMODULATORY COMPOSITIONS, THEIR METHODS OF PREPARATION AND USE |
AR040996A1 (es) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
US6928476B2 (en) * | 2002-08-23 | 2005-08-09 | Mirra, Inc. | Peer to peer remote data storage and collaboration |
US6744084B2 (en) * | 2002-08-29 | 2004-06-01 | Micro Technology, Inc. | Two-transistor pixel with buried reset channel and method of formation |
CN100536853C (zh) * | 2002-09-13 | 2009-09-09 | 艾登尼科斯(开曼)有限公司 | β-L-2′-脱氧核苷用于治疗抗性HBV株以及联合治疗 |
US6994870B2 (en) * | 2002-09-18 | 2006-02-07 | Jaw-Ji Tsai | Local nasal immunotherapy with allergen strip for allergic rhinitis |
US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
WO2004026888A2 (en) | 2002-09-19 | 2004-04-01 | Coley Pharmaceutical Gmbh | Toll-like receptor 9 (tlr9) from various mammalian species |
US6988995B2 (en) * | 2002-09-30 | 2006-01-24 | Carl Zeiss Meditec, Inc. | Method and system for detecting the effects of Alzheimer's disease in the human retina |
US8043622B2 (en) * | 2002-10-08 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
CN1753687A (zh) | 2002-10-29 | 2006-03-29 | 科勒制药集团股份有限公司 | Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用 |
WO2004041183A2 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of California | Methods of treating pulmonary fibrotic disorders |
AU2003304107B2 (en) * | 2002-11-01 | 2008-05-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides |
JP2006512927A (ja) * | 2002-12-11 | 2006-04-20 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 5’cpg核酸およびその使用方法 |
KR100525321B1 (ko) | 2002-12-13 | 2005-11-02 | 안웅식 | 파필로마바이러스 항원 단백질 및CpG-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물 |
AU2003302743B2 (en) | 2002-12-23 | 2008-09-04 | Dynavax Technologies Corporation | Branched immunomodulatory compounds and methods of using the same |
ATE544772T1 (de) * | 2002-12-23 | 2012-02-15 | Dynavax Tech Corp | Immunstimulierende sequenz-oligonukleotide und verwendungsverfahren dafür |
EP1601789A4 (en) | 2003-01-16 | 2007-10-31 | Idera Pharmaceuticals Inc | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS USING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES |
US7189781B2 (en) * | 2003-03-13 | 2007-03-13 | H.B. Fuller Licensing & Finance Inc. | Moisture curable, radiation curable sealant composition |
US20070041998A1 (en) | 2003-03-24 | 2007-02-22 | Intercell Ag | Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses |
AU2004224761A1 (en) | 2003-03-26 | 2004-10-07 | Cytos Biotechnology Ag | HIV-peptide-carrier-conjugates |
AU2004226605A1 (en) | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
WO2005016235A2 (en) * | 2003-04-14 | 2005-02-24 | The Regents Of The University Of California | Combined use of impdh inhibitors with toll-like receptor agonists |
WO2004094671A2 (en) | 2003-04-22 | 2004-11-04 | Coley Pharmaceutical Gmbh | Methods and products for identification and assessment of tlr ligands |
JP3887346B2 (ja) * | 2003-04-28 | 2007-02-28 | 株式会社東芝 | 映像信号処理装置及び映像信号処理方法、映像表示装置 |
MXPA05012421A (es) | 2003-05-16 | 2006-02-22 | Hybridon Inc | Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos. |
EP1484336A1 (en) * | 2003-06-02 | 2004-12-08 | Pevion Biotech Ltd. | Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines |
ES2569927T3 (es) | 2003-06-11 | 2016-05-13 | Idera Pharmaceuticals, Inc. | Oligonucleótidos inmunomoduladores estabilizados |
WO2004110489A1 (ja) * | 2003-06-13 | 2004-12-23 | Daiichi Asubio Pharma Co., Ltd. | Th1型免疫疾患予防又は治療用医薬組成物 |
EP2356999A1 (en) * | 2003-06-17 | 2011-08-17 | Mannkind Corporation | Compositions to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes |
US7410975B2 (en) * | 2003-06-20 | 2008-08-12 | Coley Pharmaceutical Group, Inc. | Small molecule toll-like receptor (TLR) antagonists |
US20040265833A1 (en) | 2003-06-23 | 2004-12-30 | Cathy Lofton-Day | Methods and nucleic acids for the analysis of colorectal cell proliferative disorders |
KR20060031607A (ko) | 2003-07-10 | 2006-04-12 | 사이토스 바이오테크놀로지 아게 | 패킹된 바이러스-양 입자 |
JP4734241B2 (ja) | 2003-07-11 | 2011-07-27 | インターツェル・アクチェンゲゼルシャフト | Hcvワクチン |
US20050013812A1 (en) | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
WO2005009355A2 (en) | 2003-07-15 | 2005-02-03 | Hybridon, Inc. | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
EP1646427A1 (en) * | 2003-07-22 | 2006-04-19 | Cytos Biotechnology AG | Cpg-packaged liposomes |
AU2004269379A1 (en) | 2003-08-28 | 2005-03-10 | The Immune Response Corporation | Immunogenic HIV compositions and related methods |
DE602004026891D1 (de) * | 2003-09-05 | 2010-06-10 | Anadys Pharmaceuticals Inc | Tlr7-liganden zur behandlung von hepatitis c |
US20070110714A1 (en) | 2003-09-08 | 2007-05-17 | Norio Hayashi | Medicinal composition for treatment of chronic hepatitis c |
GB0321615D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
WO2005027920A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | 2-alkylidene-19-nor-vitamin d derivatives for the treatment of rickets or vitamin d deficiency |
CA2536139A1 (en) * | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
WO2005034979A2 (en) | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
US20050087538A1 (en) * | 2003-10-23 | 2005-04-28 | Wolfe Darrell R. | Iceless multiple can cooler |
US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
UA88457C2 (ru) | 2003-10-30 | 2009-10-26 | Коли Фармасьютикал Гмбх | Иммуностимулирующая нуклеиновая кислота с улучшенной иммуностимулирующей эффективностью |
US20050239733A1 (en) | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
US20050100983A1 (en) * | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
JP4088246B2 (ja) * | 2003-12-05 | 2008-05-21 | 富士通株式会社 | リングネットワークのマスタ設定方法及び装置 |
CN101094594B (zh) | 2003-12-08 | 2012-08-15 | 海布里顿公司 | 通过基于小寡核苷酸的化合物调节免疫刺激性质 |
US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
US20070172315A1 (en) * | 2003-12-18 | 2007-07-26 | Barrett Robert K | Method and Apparatus for Creating Soil or Rock Subsurface Support |
EP1550458A1 (en) | 2003-12-23 | 2005-07-06 | Vectron Therapeutics AG | Synergistic liposomal adjuvants |
KR100558851B1 (ko) | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | 면역조절능력이 증가된 CpG 올리고데옥시뉴클레오티드변형체 |
AU2005213460A1 (en) * | 2004-02-06 | 2005-08-25 | Mayo Foundation For Medical Education And Research | Complexed polypeptide and adjuvant for improved vaccines |
US20050181035A1 (en) | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
TW200533750A (en) | 2004-02-19 | 2005-10-16 | Coley Pharm Group Inc | Immunostimulatory viral RNA oligonucleotides |
WO2005080567A1 (de) | 2004-02-20 | 2005-09-01 | Mologen Ag | Substituiertes, nicht-kodierendes nukleinsäuremolekül zur therapeutischen und prophylaktischen immunstimulation in menschen und höheren tieren |
US20050266015A1 (en) | 2004-03-12 | 2005-12-01 | Hybridon, Inc. | Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide |
JP2007531746A (ja) * | 2004-04-02 | 2007-11-08 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Il−10応答を誘導するための免疫活性化核酸 |
US7303881B2 (en) * | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
WO2005115449A1 (en) * | 2004-05-28 | 2005-12-08 | Alk-Abelló A/S | Method of treating allergy and infection by eliciting an iga antibody response |
US8399025B2 (en) * | 2004-06-04 | 2013-03-19 | Board Of Regents, The University Of Texas System | Polyamine modified particles |
AU2005326144A1 (en) | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
US7756043B1 (en) * | 2004-06-09 | 2010-07-13 | Sprint Communications Company L.P. | Method for identifying high traffic origin-destination node pairs in a packet based network |
US7498425B2 (en) | 2004-06-15 | 2009-03-03 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
CA2570786C (en) | 2004-06-15 | 2013-05-28 | Idera Pharmaceuticals, Inc. | Modified cpg-containing oligonucleotide multimers in immune stimulation |
EP1766610A1 (en) * | 2004-06-25 | 2007-03-28 | TC Electronic A/S | Method of evaluating perception intensity of an audio signal and a method of controlling an input audio signal on the basis of the evaluation |
US7534449B2 (en) * | 2004-07-01 | 2009-05-19 | Yale University | Targeted and high density drug loaded polymeric materials |
AU2005333126A1 (en) * | 2004-07-18 | 2006-12-21 | Csl Limited | Methods and compositions for inducing innate immune responses |
JP2008506789A (ja) | 2004-07-18 | 2008-03-06 | シーエスエル、リミテッド | インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物 |
WO2006015560A1 (de) | 2004-08-09 | 2006-02-16 | Mologen Ag | Immunmodulierendes mittel in verbindung mit chemotherapeutischen massnahmen |
US20060058261A1 (en) * | 2004-09-15 | 2006-03-16 | Andre Aube | Chitin derivatives for hyperlipidemia |
MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
KR100721928B1 (ko) * | 2004-11-05 | 2007-05-28 | 주식회사 바이오씨에스 | CpG 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물 |
US20060105979A1 (en) | 2004-11-08 | 2006-05-18 | Hybridon, Inc. | Synergistic inhibition of VEGF and modulation of the immune response |
CA2594382A1 (en) | 2005-01-07 | 2006-07-13 | Alk-Abello A/S | Method of preventive treatment of allergy by oromucosal administration of an allergy vaccine |
BRPI0617254A2 (pt) * | 2005-01-12 | 2011-07-19 | Cancer Rec Tech Ltd | "oligonucleotìdeo de filamento único, composição farmacêutica, métodos para estimular a atividade de tlr7 em uma célula que expressa tlr7, para estimular a atividade de tlr8 em uma célula que expressa tlr8, e, para estimular uma resposta imune em um paciente |
JP2008531018A (ja) * | 2005-02-24 | 2008-08-14 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 免疫刺激性オリゴヌクレオチド |
SG161260A1 (en) | 2005-04-08 | 2010-05-27 | Coley Pharm Group Inc | Methods for treating infectious disease exacerbated asthma |
US20060241076A1 (en) | 2005-04-26 | 2006-10-26 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
US7325152B2 (en) * | 2005-06-30 | 2008-01-29 | Infineon Technologies Ag | Synchronous signal generator |
US20090117132A1 (en) * | 2005-07-07 | 2009-05-07 | Pfizer, Inc. | Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment |
WO2007027718A1 (en) * | 2005-08-31 | 2007-03-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods of altering an immune response induced by cpg oligodeoxynucleotides |
BRPI0616235A2 (pt) | 2005-09-16 | 2011-06-14 | Coley Pharm Gmbh | acido ribonuclÉico monofilamentado imunoestimulante com cadeia principal de fosfodiÉster |
KR20080047463A (ko) | 2005-09-16 | 2008-05-28 | 콜리 파마슈티칼 게엠베하 | 뉴클레오티드 변형에 의한 짧은 간섭 리보핵산(sirna)의 면역자극 특성의 조절 |
WO2007038720A2 (en) | 2005-09-27 | 2007-04-05 | Coley Pharmaceutical Gmbh | Modulation of tlr-mediated immune responses using adaptor oligonucleotides |
US20070093439A1 (en) | 2005-10-25 | 2007-04-26 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
CA2625969A1 (en) * | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
US20070243209A1 (en) * | 2005-10-28 | 2007-10-18 | Health Research, Inc. | Compositions and methods for prevention and treatment of fungal diseases |
AU2006310339B2 (en) | 2005-11-04 | 2013-01-10 | Novartis Ag | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
CN102755645A (zh) | 2005-11-04 | 2012-10-31 | 诺华疫苗和诊断有限公司 | 佐剂配制的包含细胞因子诱导剂的流感疫苗 |
US7470674B2 (en) | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
US7776834B2 (en) | 2005-11-07 | 2010-08-17 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
MX2008006004A (es) | 2005-11-07 | 2008-10-01 | Idera Pharmaceuticals Inc | Propiedades inmunoestimuladoras de compuestos a base de oligonucleotidos que comprenden dinucleotidos inmunoestimuladores modificados. |
CA2628306C (en) | 2005-11-07 | 2014-06-17 | Sudhir Agrawal | Immunostimulatory oligonucleotide-based compounds with glycerol-linked dinucleotides and modified guanosines at cpg and uses thereof |
AU2006318464B2 (en) * | 2005-11-25 | 2011-02-17 | Zoetis Belgium Sa | Immunostimulatory oligoribonucleotides |
JP2009521218A (ja) | 2005-12-20 | 2009-06-04 | イデラ ファーマシューティカルズ インコーポレイテッド | 異なる長さのパリンドロームセグメントを含むパリンドローム免疫調節オリゴヌクレオチド(imo(tm))の免疫賦活作用 |
EP2405002B1 (en) * | 2006-02-15 | 2014-09-24 | AdiuTide Pharmaceuticals GmbH | Compositions and methods for oligonucleotide formulations |
DE102006007433A1 (de) | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure |
WO2008019018A2 (en) * | 2006-08-03 | 2008-02-14 | William Soo Hoo | Bioactive molecular matrix and methods of use in the treatment of disease |
US20080124366A1 (en) * | 2006-08-06 | 2008-05-29 | Ohlfest John R | Methods and Compositions for Treating Tumors |
WO2008019486A1 (en) * | 2006-08-16 | 2008-02-21 | Protiva Biotherapeutics, Inc. | Nucleic acid modulation of toll-like receptor-mediated immune stimulation |
US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
WO2008033432A2 (en) | 2006-09-12 | 2008-03-20 | Coley Pharmaceutical Group, Inc. | Immune modulation by chemically modified ribonucleosides and oligoribonucleotides |
CN101516396B (zh) * | 2006-09-26 | 2013-10-09 | 传染性疾病研究院 | 包含合成佐剂的疫苗组合物 |
US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
PT2078080E (pt) | 2006-09-27 | 2015-09-18 | Coley Pharm Gmbh | Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada |
EP2068912A2 (en) | 2006-09-27 | 2009-06-17 | Coley Pharmaceutical Group, Inc. | Compositions of tlr ligands and antivirals |
US20100144846A1 (en) * | 2006-10-26 | 2010-06-10 | Coley Pharmaceutical Gmbh | Oligoribonucleotides and uses thereof |
WO2008057529A2 (en) * | 2006-11-06 | 2008-05-15 | Coley Pharmaceutical Group, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp) |
KR20090095626A (ko) * | 2006-12-04 | 2009-09-09 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | 쿠프레독신과 CpG 리치 DNA를 이용한 조성물 및 암 치료 방법 |
US8057804B2 (en) * | 2006-12-28 | 2011-11-15 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
EP2591800A1 (en) * | 2006-12-28 | 2013-05-15 | The Trustees of The University of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
AR066405A1 (es) * | 2007-04-20 | 2009-08-19 | Glaxosmithkline Biolog Sa | Vacuna |
MX2009012482A (es) | 2007-05-17 | 2009-12-02 | Coley Pharm Group Inc | Oligonucleotidos de clase a con potencia inmunoestimuladora. |
JP2010536335A (ja) * | 2007-08-13 | 2010-12-02 | ファイザー・インク | 活性が改善した組合せモチーフ免疫賦活性オリゴヌクレオチド |
CN101835487A (zh) * | 2007-08-21 | 2010-09-15 | 戴纳瓦克斯技术公司 | 制备和使用流感蛋白质的组合物和方法 |
EP2185160B1 (en) * | 2007-08-31 | 2019-02-13 | Neurimmune Holding AG | Method of providing patient specific immune response in amyloidoses and protein aggregation disorders |
US7892567B2 (en) * | 2007-10-01 | 2011-02-22 | Board Of Regents, The University Of Texas System | Methods and compositions for immunization against chlamydial infection and disease |
CN101820908A (zh) | 2007-10-09 | 2010-09-01 | 科利制药公司 | 包含改性糖部分的免疫刺激寡核苷酸类似物 |
TW200932274A (en) * | 2007-12-18 | 2009-08-01 | Alcon Res Ltd | Interfering RNA delivery system and uses thereof |
US7720322B2 (en) * | 2008-06-30 | 2010-05-18 | Intuitive Surgical, Inc. | Fiber optic shape sensor |
TWI351288B (en) * | 2008-07-04 | 2011-11-01 | Univ Nat Pingtung Sci & Tech | Cpg dna adjuvant in avian vaccines |
US20100166782A1 (en) * | 2008-07-25 | 2010-07-01 | Martha Karen Newell | Clip inhibitors and methods of modulating immune function |
US8053422B2 (en) * | 2008-12-04 | 2011-11-08 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-cancer oligodeoxynucleotides |
-
1996
- 1996-10-30 US US08/738,652 patent/US6207646B1/en not_active Expired - Lifetime
-
1997
- 1997-10-30 WO PCT/US1997/019791 patent/WO1998018810A1/en active IP Right Grant
- 1997-10-30 DE DE69736331T patent/DE69736331T2/de not_active Revoked
- 1997-10-30 EP EP10186177.1A patent/EP2360252B8/en not_active Expired - Lifetime
- 1997-10-30 EP EP97947311A patent/EP0948510B1/en not_active Revoked
- 1997-10-30 AU AU52424/98A patent/AU5242498A/en not_active Abandoned
- 1997-10-30 NZ NZ335397A patent/NZ335397A/xx not_active IP Right Cessation
- 1997-10-30 PT PT97947311T patent/PT948510E/pt unknown
- 1997-10-30 CN CNA2007101300520A patent/CN101265285A/zh active Pending
- 1997-10-30 CN CNB971993521A patent/CN100338086C/zh not_active Expired - Lifetime
- 1997-10-30 ES ES10186177.1T patent/ES2624859T3/es not_active Expired - Lifetime
- 1997-10-30 CA CA2270345A patent/CA2270345C/en not_active Expired - Lifetime
- 1997-10-30 EP EP06115792A patent/EP1714969A3/en not_active Withdrawn
- 1997-10-30 EP EP06115801A patent/EP1746159A3/en not_active Withdrawn
- 1997-10-30 EP EP10186108A patent/EP2322615A1/en not_active Withdrawn
- 1997-10-30 JP JP52078498A patent/JP2001503267A/ja active Pending
- 1997-10-30 AT AT97947311T patent/ATE332966T1/de active
- 1997-10-30 DK DK97947311T patent/DK0948510T3/da active
- 1997-10-30 ES ES97947311T patent/ES2268736T3/es not_active Expired - Lifetime
- 1997-10-30 KR KR1019997003873A patent/KR100689942B1/ko not_active IP Right Cessation
-
2001
- 2001-03-27 US US09/818,918 patent/US20030050261A1/en not_active Abandoned
- 2001-12-14 AU AU97249/01A patent/AU775185B2/en not_active Expired
-
2003
- 2003-03-03 JP JP2003056446A patent/JP2003286174A/ja not_active Withdrawn
- 2003-05-09 US US10/435,656 patent/US20050277604A1/en not_active Abandoned
- 2003-07-03 US US10/613,916 patent/US20050070491A1/en not_active Abandoned
- 2003-09-10 JP JP2003319045A patent/JP2004041224A/ja not_active Withdrawn
- 2003-10-03 US US10/679,710 patent/US20040147468A1/en not_active Abandoned
- 2003-12-22 US US10/743,625 patent/US20040132685A1/en not_active Abandoned
-
2004
- 2004-01-30 US US10/769,282 patent/US7674777B2/en not_active Expired - Fee Related
- 2004-04-02 US US10/817,165 patent/US20040198688A1/en not_active Abandoned
- 2004-04-23 US US10/831,647 patent/US7402572B2/en not_active Expired - Fee Related
- 2004-05-17 US US10/847,642 patent/US20050004061A1/en not_active Abandoned
- 2004-06-24 US US10/877,407 patent/US20040229835A1/en not_active Abandoned
- 2004-07-02 US US10/884,852 patent/US20050059625A1/en not_active Abandoned
- 2004-07-09 US US10/888,449 patent/US20050049215A1/en not_active Abandoned
- 2004-07-09 US US10/888,785 patent/US7517861B2/en not_active Expired - Fee Related
- 2004-07-16 US US10/894,657 patent/US20050054602A1/en not_active Abandoned
- 2004-07-16 US US10/894,862 patent/US8058249B2/en not_active Expired - Fee Related
- 2004-08-26 US US10/928,762 patent/US20050123523A1/en not_active Abandoned
- 2004-10-01 US US10/956,494 patent/US7879810B2/en not_active Expired - Fee Related
- 2004-10-01 US US10/956,745 patent/US20050239732A1/en not_active Abandoned
- 2004-10-13 AU AU2004218696A patent/AU2004218696B2/en not_active Expired
- 2004-10-22 US US10/972,301 patent/US20050215500A1/en not_active Abandoned
- 2004-11-12 US US10/987,146 patent/US20050148537A1/en not_active Abandoned
-
2005
- 2005-01-07 US US11/031,460 patent/US8158592B2/en not_active Expired - Fee Related
- 2005-01-14 US US11/036,527 patent/US7723022B2/en not_active Expired - Fee Related
- 2005-02-25 US US11/067,587 patent/US8129351B2/en not_active Expired - Fee Related
- 2005-05-23 US US11/134,918 patent/US20050267064A1/en not_active Abandoned
- 2005-12-07 US US11/296,572 patent/US20060089326A1/en not_active Abandoned
-
2006
- 2006-08-11 US US11/503,483 patent/US7723500B2/en not_active Expired - Fee Related
- 2006-09-22 US US11/526,197 patent/US20070078104A1/en not_active Abandoned
- 2006-11-10 US US11/598,207 patent/US8258106B2/en not_active Expired - Fee Related
-
2007
- 2007-06-05 US US11/810,353 patent/US20080026011A1/en not_active Abandoned
-
2008
- 2008-07-25 JP JP2008192729A patent/JP5082063B2/ja not_active Expired - Lifetime
- 2008-10-09 US US12/248,493 patent/US20090202575A1/en not_active Abandoned
-
2009
- 2009-03-25 US US12/383,824 patent/US7888327B2/en not_active Expired - Fee Related
-
2010
- 2010-03-10 JP JP2010053784A patent/JP2010150280A/ja active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107513533A (zh) * | 2011-05-26 | 2017-12-26 | 英特维特国际股份有限公司 | 免疫刺激性寡脱氧核苷酸 |
CN112263675A (zh) * | 2013-07-19 | 2021-01-26 | 财团法人卫生研究院 | CpG寡脱氧核苷酸、包含其的免疫组合物及制备组合物并通过其刺激免疫反应的方法 |
CN112263675B (zh) * | 2013-07-19 | 2024-02-27 | 财团法人卫生研究院 | CpG寡脱氧核苷酸、包含其的免疫组合物及制备组合物并通过其刺激免疫反应的方法 |
CN112118847A (zh) * | 2018-03-02 | 2020-12-22 | 伊莱西奥治疗有限公司 | 包含突变kras序列和脂质的化合物及其用途 |
WO2020228606A1 (en) * | 2019-05-10 | 2020-11-19 | Microbio (Shanghai) Co., Ltd. | Dimeric cpg oligonucleotides for use in modulating immune responses |
CN114072506A (zh) * | 2019-05-10 | 2022-02-18 | 中天(上海)生物科技有限公司 | 用于调节免疫应答的二聚CpG寡核苷酸 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101265285A (zh) | 免疫刺激性核酸分子 | |
US6653292B1 (en) | Method of treating cancer using immunostimulatory oligonucleotides | |
US20110081366A1 (en) | Immunostimulatory nucleic acid molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1122042 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080917 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1122042 Country of ref document: HK |